{"PMC7129368": [["S6 The critical concentration is important ::: Surveillance of resistance in M. tuberculosis and potential impact of epidemiological cut-off values", [["tuberculosis", "DISEASE", 80, 92], ["M. tuberculosis", "ORGANISM", 77, 92], ["S6", "PROTEIN", 0, 2], ["M. tuberculosis", "SPECIES", 77, 92], ["M. tuberculosis", "SPECIES", 77, 92], ["M. tuberculosis", "PROBLEM", 77, 92], ["epidemiological cut", "TEST", 117, 136], ["resistance", "OBSERVATION_MODIFIER", 63, 73], ["M. tuberculosis", "OBSERVATION", 77, 92]]]], "806479c51dcccea20825446a2dee8b09033f3389": [["IntroductionThe novel infection of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in December 2019 in China and is now widely spread worldwide.", [["infection", "DISEASE", 22, 31], ["coronavirus disease", "DISEASE", 35, 54], ["COVID-19", "CHEMICAL", 61, 69], ["acute respiratory syndrome coronavirus", "DISEASE", 88, 126], ["coronavirus", "ORGANISM", 35, 46], ["COVID-19", "ORGANISM", 61, 69], ["SARS-CoV-2", "ORGANISM", 130, 140], ["coronavirus disease 2019 (COVID-19", "SPECIES", 35, 69], ["severe acute respiratory syndrome coronavirus", "SPECIES", 81, 126], ["SARS-CoV-2", "SPECIES", 130, 140], ["The novel infection of coronavirus disease", "PROBLEM", 12, 54], ["COVID", "TEST", 61, 66], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 81, 126], ["CoV", "TEST", 135, 138], ["infection", "OBSERVATION", 22, 31], ["coronavirus disease", "OBSERVATION", 35, 54], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory syndrome", "OBSERVATION", 94, 114], ["widely", "OBSERVATION_MODIFIER", 185, 191], ["spread", "OBSERVATION", 192, 198]]], ["COVID-19 commonly presents with respiratory symptoms including cough and dyspnea.", [["respiratory", "ANATOMY", 32, 43], ["respiratory symptoms", "DISEASE", 32, 52], ["cough", "DISEASE", 63, 68], ["dyspnea", "DISEASE", 73, 80], ["COVID", "TEST", 0, 5], ["respiratory symptoms", "PROBLEM", 32, 52], ["cough", "PROBLEM", 63, 68], ["dyspnea", "PROBLEM", 73, 80], ["cough", "OBSERVATION", 63, 68]]], ["However, the neuroinvasive propensity through the angiotensin-converting enzyme 2 (ACE2) receptor [1] , which is expressed in glial cells and neurons as well, and the cerebrovascular complication because of the hypercoagulable state are also reported as a feature of COVID-19 [2] .", [["glial cells", "ANATOMY", 126, 137], ["neurons", "ANATOMY", 142, 149], ["cerebrovascular", "ANATOMY", 167, 182], ["angiotensin", "CHEMICAL", 50, 61], ["cerebrovascular complication", "DISEASE", 167, 195], ["COVID-19", "CHEMICAL", 267, 275], ["angiotensin-converting enzyme 2 (ACE2) receptor [1", "GENE_OR_GENE_PRODUCT", 50, 100], ["glial cells", "CELL", 126, 137], ["neurons", "CELL", 142, 149], ["cerebrovascular", "ANATOMICAL_SYSTEM", 167, 182], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 50, 97], ["glial cells", "CELL_TYPE", 126, 137], ["the angiotensin-converting enzyme", "TEST", 46, 79], ["the cerebrovascular complication", "PROBLEM", 163, 195], ["the hypercoagulable state", "PROBLEM", 207, 232], ["COVID", "TEST", 267, 272], ["glial cells", "OBSERVATION", 126, 137], ["cerebrovascular", "ANATOMY", 167, 182], ["complication", "OBSERVATION", 183, 195], ["hypercoagulable", "OBSERVATION", 211, 226]]], ["An immediate neurological care is important to minimize the mortality and morbidity of patients with convulsion and other neurological emergencies.", [["neurological", "ANATOMY", 13, 25], ["neurological", "ANATOMY", 122, 134], ["convulsion", "DISEASE", 101, 111], ["neurological emergencies", "DISEASE", 122, 146], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["An immediate neurological care", "TREATMENT", 0, 30], ["convulsion", "PROBLEM", 101, 111], ["other neurological emergencies", "PROBLEM", 116, 146]]], ["An understanding of potential neurological manifestations in COVID-19 cases is crucial to care for patients and the protection of medical workers appropriately.", [["neurological", "ANATOMY", 30, 42], ["COVID", "DISEASE", 61, 66], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["potential neurological manifestations", "PROBLEM", 20, 57]]], ["We report a case of a patient presenting an acute symptomatic seizure with a recurrence of severe brain edema post cerebral venous thrombosis who was later found to have a COVID-19 infection.IntroductionJ o u r n a l P r e -p r o o fCase PresentationIn April 2020, a 44-year-old man was transferred to our emergency room for an intermittent twitch on the left hand and face.", [["brain", "ANATOMY", 98, 103], ["cerebral venous", "ANATOMY", 115, 130], ["left hand", "ANATOMY", 355, 364], ["seizure", "DISEASE", 62, 69], ["brain edema", "DISEASE", 98, 109], ["cerebral venous thrombosis", "DISEASE", 115, 141], ["infection", "DISEASE", 181, 190], ["patient", "ORGANISM", 22, 29], ["brain edema", "PATHOLOGICAL_FORMATION", 98, 109], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 115, 130], ["man", "ORGANISM", 279, 282], ["hand", "ORGANISM_SUBDIVISION", 360, 364], ["patient", "SPECIES", 22, 29], ["man", "SPECIES", 279, 282], ["an acute symptomatic seizure", "PROBLEM", 41, 69], ["severe brain edema", "PROBLEM", 91, 109], ["cerebral venous thrombosis", "PROBLEM", 115, 141], ["a COVID-19 infection", "PROBLEM", 170, 190], ["an intermittent twitch on the left hand and face", "PROBLEM", 325, 373], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["symptomatic", "OBSERVATION_MODIFIER", 50, 61], ["seizure", "OBSERVATION", 62, 69], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["brain", "ANATOMY", 98, 103], ["edema", "OBSERVATION", 104, 109], ["cerebral venous", "ANATOMY", 115, 130], ["thrombosis", "OBSERVATION", 131, 141], ["infection", "OBSERVATION", 181, 190], ["intermittent", "OBSERVATION_MODIFIER", 328, 340], ["twitch", "OBSERVATION", 341, 347], ["left", "ANATOMY_MODIFIER", 355, 359], ["hand", "ANATOMY", 360, 364], ["face", "ANATOMY", 369, 373]]], ["Six months ago, he had symptomatic epilepsy following cerebral venous thrombosis with acute hemorrhagic infarction because of nephrosis.", [["cerebral venous", "ANATOMY", 54, 69], ["epilepsy", "DISEASE", 35, 43], ["cerebral venous thrombosis", "DISEASE", 54, 80], ["hemorrhagic infarction", "DISEASE", 92, 114], ["nephrosis", "DISEASE", 126, 135], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 54, 69], ["symptomatic epilepsy", "PROBLEM", 23, 43], ["cerebral venous thrombosis", "PROBLEM", 54, 80], ["acute hemorrhagic infarction", "PROBLEM", 86, 114], ["nephrosis", "PROBLEM", 126, 135], ["symptomatic", "OBSERVATION_MODIFIER", 23, 34], ["epilepsy", "OBSERVATION", 35, 43], ["cerebral venous", "ANATOMY", 54, 69], ["thrombosis", "OBSERVATION", 70, 80], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["hemorrhagic", "OBSERVATION_MODIFIER", 92, 103], ["infarction", "OBSERVATION", 104, 114], ["nephrosis", "OBSERVATION", 126, 135]]], ["The venous thrombosis was involved the right sphenoparietal sinus and a right front-temporal decompression surgery was performed.", [["venous", "ANATOMY", 4, 10], ["right sphenoparietal sinus", "ANATOMY", 39, 65], ["right front", "ANATOMY", 72, 83], ["venous thrombosis", "DISEASE", 4, 21], ["venous", "MULTI-TISSUE_STRUCTURE", 4, 10], ["sphenoparietal sinus", "MULTI-TISSUE_STRUCTURE", 45, 65], ["The venous thrombosis", "PROBLEM", 0, 21], ["a right front-temporal decompression surgery", "TREATMENT", 70, 114], ["venous", "ANATOMY", 4, 10], ["thrombosis", "OBSERVATION", 11, 21], ["right", "ANATOMY_MODIFIER", 39, 44], ["sphenoparietal sinus", "ANATOMY", 45, 65], ["right", "ANATOMY_MODIFIER", 72, 77], ["temporal", "OBSERVATION_MODIFIER", 84, 92], ["decompression", "OBSERVATION", 93, 106], ["surgery", "OBSERVATION", 107, 114]]], ["After surgery, he was seizure-free with 1500 mg/day levetiracetam for five months.", [["seizure", "DISEASE", 22, 29], ["levetiracetam", "CHEMICAL", 52, 65], ["levetiracetam", "CHEMICAL", 52, 65], ["levetiracetam", "SIMPLE_CHEMICAL", 52, 65], ["surgery", "TREATMENT", 6, 13], ["seizure", "PROBLEM", 22, 29], ["levetiracetam", "TREATMENT", 52, 65]]], ["He also received anticoagulation therapy with warfarin (international normalized ratio [INR] range: 2.0-3.0) and a maintenance dose of 20 mg/day prednisone for nephrosis.", [["warfarin", "CHEMICAL", 46, 54], ["prednisone", "CHEMICAL", 145, 155], ["nephrosis", "DISEASE", 160, 169], ["warfarin", "CHEMICAL", 46, 54], ["prednisone", "CHEMICAL", 145, 155], ["warfarin", "SIMPLE_CHEMICAL", 46, 54], ["prednisone", "SIMPLE_CHEMICAL", 145, 155], ["anticoagulation therapy", "TREATMENT", 17, 40], ["warfarin", "TREATMENT", 46, 54], ["international normalized ratio", "TEST", 56, 86], ["INR", "TEST", 88, 91], ["prednisone", "TREATMENT", 145, 155], ["nephrosis", "PROBLEM", 160, 169], ["nephrosis", "OBSERVATION", 160, 169]]], ["Before admission, the last INR was 2.3.", [["the last INR", "TEST", 18, 30]]], ["A week before admission, he felt bulging of a scalp flap.", [["scalp", "ANATOMY", 46, 51], ["scalp", "ORGAN", 46, 51], ["bulging", "PROBLEM", 33, 40], ["a scalp flap", "TREATMENT", 44, 56], ["bulging", "OBSERVATION", 33, 40], ["scalp", "ANATOMY", 46, 51], ["flap", "OBSERVATION", 52, 56]]], ["Two days before admission, he noticed the loss of smell.", [["loss of smell", "DISEASE", 42, 55], ["the loss of smell", "PROBLEM", 38, 55]]], ["On the morning of the admission day, he had numbness in his left hand and face and called the ambulance.", [["left hand", "ANATOMY", 60, 69], ["numbness", "DISEASE", 44, 52], ["hand", "ORGANISM_SUBDIVISION", 65, 69], ["numbness in his left hand and face", "PROBLEM", 44, 78], ["numbness", "OBSERVATION", 44, 52], ["left", "ANATOMY_MODIFIER", 60, 64], ["hand", "ANATOMY", 65, 69], ["face", "ANATOMY", 74, 78]]], ["In the ambulance, his oxygen saturation was 97%, and his body temperature was 37.5 \u00b0C. Just after arrival, he had a seizure, starting from jerking of his left hand and then the entire body.", [["body", "ANATOMY", 57, 61], ["left hand", "ANATOMY", 154, 163], ["body", "ANATOMY", 184, 188], ["oxygen", "CHEMICAL", 22, 28], ["seizure", "DISEASE", 116, 123], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "SIMPLE_CHEMICAL", 22, 28], ["body", "ORGANISM_SUBDIVISION", 57, 61], ["hand", "ORGANISM_SUBDIVISION", 159, 163], ["body", "ORGANISM_SUBDIVISION", 184, 188], ["his oxygen saturation", "TEST", 18, 39], ["his body temperature", "TEST", 53, 73], ["a seizure", "PROBLEM", 114, 123], ["seizure", "OBSERVATION", 116, 123], ["left", "ANATOMY_MODIFIER", 154, 158], ["hand", "ANATOMY", 159, 163], ["entire", "ANATOMY_MODIFIER", 177, 183], ["body", "ANATOMY", 184, 188]]], ["The focal aware seizure lasted for a few minutes before the administration of 7.5 mg diazepam.", [["seizure", "DISEASE", 16, 23], ["diazepam", "CHEMICAL", 85, 93], ["diazepam", "CHEMICAL", 85, 93], ["diazepam", "SIMPLE_CHEMICAL", 85, 93], ["The focal aware seizure", "PROBLEM", 0, 23], ["7.5 mg diazepam", "TREATMENT", 78, 93], ["focal", "OBSERVATION_MODIFIER", 4, 9]]], ["A head computed tomography (CT) showed severe brain swelling of the right J o u r n a l P r e -p r o o f temporal lobe, which was injured by the previous hemorrhagic infarction, compared to the last CT ( Fig. 1A and B ).", [["head", "ANATOMY", 2, 6], ["brain", "ANATOMY", 46, 51], ["temporal lobe", "ANATOMY", 105, 118], ["brain swelling", "DISEASE", 46, 60], ["hemorrhagic infarction", "DISEASE", 154, 176], ["head", "ORGAN", 2, 6], ["brain", "ORGAN", 46, 51], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 105, 118], ["A head computed tomography (CT)", "TEST", 0, 31], ["severe brain swelling", "PROBLEM", 39, 60], ["temporal lobe", "PROBLEM", 105, 118], ["the previous hemorrhagic infarction", "PROBLEM", 141, 176], ["the last CT", "TEST", 190, 201], ["head", "ANATOMY", 2, 6], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["brain", "ANATOMY", 46, 51], ["swelling", "OBSERVATION", 52, 60], ["right", "ANATOMY_MODIFIER", 68, 73], ["l", "ANATOMY_MODIFIER", 86, 87], ["f temporal lobe", "ANATOMY", 103, 118], ["hemorrhagic", "OBSERVATION_MODIFIER", 154, 165], ["infarction", "OBSERVATION", 166, 176]]], ["Brain magnetic resonance images did not show any acute cerebral infarction or any new vessel obstruction (Fig. 1D, E, prevented a seizure recurrence.", [["cerebral", "ANATOMY", 55, 63], ["vessel", "ANATOMY", 86, 92], ["cerebral infarction", "DISEASE", 55, 74], ["vessel obstruction", "DISEASE", 86, 104], ["seizure", "DISEASE", 130, 137], ["cerebral", "ORGAN", 55, 63], ["vessel obstruction", "PATHOLOGICAL_FORMATION", 86, 104], ["Brain magnetic resonance images", "TEST", 0, 31], ["any acute cerebral infarction", "PROBLEM", 45, 74], ["any new vessel obstruction", "PROBLEM", 78, 104], ["a seizure recurrence", "PROBLEM", 128, 148], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["cerebral", "ANATOMY", 55, 63], ["infarction", "OBSERVATION", 64, 74], ["new", "OBSERVATION_MODIFIER", 82, 85], ["vessel", "ANATOMY", 86, 92], ["obstruction", "OBSERVATION", 93, 104], ["Fig", "OBSERVATION_MODIFIER", 106, 109]]], ["On hospital day 13, a negative report of RT-PCR for SARS-CoV-2 was obtained twice, then he was discharged.", [["SARS", "DISEASE", 52, 56], ["SARS-CoV-2", "ORGANISM", 52, 62], ["SARS-CoV", "SPECIES", 52, 60], ["RT-PCR", "TEST", 41, 47], ["SARS", "PROBLEM", 52, 56], ["CoV", "TEST", 57, 60]]], ["At discharge, the D-dimer level was normal, and INR was 4.1.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 18, 25], ["INR", "PROTEIN", 48, 51], ["the D-dimer level", "TEST", 14, 31], ["INR", "TEST", 48, 51]]], ["The head CT two weeks after discharge showed improvement in the brain swelling (Fig. 1C ).DiscussionCOVID-19 is a novel infection that became pandemic but the pathophysiology has been uncertain.", [["head", "ANATOMY", 4, 8], ["brain", "ANATOMY", 64, 69], ["brain swelling", "DISEASE", 64, 78], ["infection", "DISEASE", 120, 129], ["head", "ORGAN", 4, 8], ["brain", "ORGAN", 64, 69], ["The head CT", "TEST", 0, 11], ["the brain swelling", "PROBLEM", 60, 78], ["a novel infection", "PROBLEM", 112, 129], ["pandemic", "PROBLEM", 142, 150], ["head", "ANATOMY", 4, 8], ["improvement", "OBSERVATION_MODIFIER", 45, 56], ["brain", "ANATOMY", 64, 69], ["swelling", "OBSERVATION", 70, 78], ["infection", "OBSERVATION", 120, 129]]], ["Coronaviruses commonly have the pathogenic mechanisms of neuroinvasion through ACE2 receptor [1] , which may be applicable for SARS-CoV-2.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 79, 92], ["SARS-CoV-2", "ORGANISM", 127, 137], ["ACE2 receptor", "PROTEIN", 79, 92], ["SARS-CoV", "SPECIES", 127, 135], ["Coronaviruses", "PROBLEM", 0, 13], ["neuroinvasion through ACE2 receptor", "TREATMENT", 57, 92], ["SARS", "PROBLEM", 127, 131], ["CoV", "TEST", 132, 135]]], ["This may explain anosmia in COVID-19 [3] .", [["anosmia", "DISEASE", 17, 24], ["anosmia", "PROBLEM", 17, 24], ["COVID", "TEST", 28, 33]]], ["Furthermore, COVID-19 may predispose the patient to a hypercoagulable state.", [["COVID-19", "CHEMICAL", 13, 21], ["COVID-19", "GENE_OR_GENE_PRODUCT", 13, 21], ["patient", "ORGANISM", 41, 48], ["COVID-19", "DNA", 13, 21], ["patient", "SPECIES", 41, 48], ["COVID", "TEST", 13, 18], ["a hypercoagulable state", "PROBLEM", 52, 75], ["hypercoagulable", "OBSERVATION", 54, 69]]], ["In a study of Italy, although patients received standard J o u r n a l P r e -p r o o f thromboprophylaxis, the cumulative rate of venous thromboembolism was 21% in 388 patients with COVID-19 [2] .", [["venous", "ANATOMY", 131, 137], ["venous thromboembolism", "DISEASE", 131, 153], ["COVID-19", "CHEMICAL", 183, 191], ["patients", "ORGANISM", 30, 38], ["venous", "MULTI-TISSUE_STRUCTURE", 131, 137], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 169, 177], ["a study", "TEST", 3, 10], ["standard J o u r n", "TREATMENT", 48, 66], ["a l P r e -p", "TREATMENT", 67, 79], ["thromboprophylaxis", "TREATMENT", 88, 106], ["venous thromboembolism", "PROBLEM", 131, 153], ["COVID", "TEST", 183, 188], ["thromboprophylaxis", "OBSERVATION", 88, 106], ["venous", "ANATOMY", 131, 137], ["thromboembolism", "OBSERVATION", 138, 153]]], ["Although we lack data on the cerebrospinal fluid of the patient, the anosmia and transient brain edema indicate a neurological invasion of COVID-19.", [["cerebrospinal fluid", "ANATOMY", 29, 48], ["brain edema", "ANATOMY", 91, 102], ["neurological", "ANATOMY", 114, 126], ["anosmia", "DISEASE", 69, 76], ["brain edema", "DISEASE", 91, 102], ["COVID-19", "CHEMICAL", 139, 147], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 29, 48], ["patient", "ORGANISM", 56, 63], ["brain edema", "PATHOLOGICAL_FORMATION", 91, 102], ["patient", "SPECIES", 56, 63], ["the cerebrospinal fluid", "TEST", 25, 48], ["the anosmia", "PROBLEM", 65, 76], ["transient brain edema", "PROBLEM", 81, 102], ["a neurological invasion", "PROBLEM", 112, 135], ["COVID", "TEST", 139, 144], ["transient", "OBSERVATION_MODIFIER", 81, 90], ["brain", "ANATOMY", 91, 96], ["edema", "OBSERVATION", 97, 102], ["neurological", "OBSERVATION_MODIFIER", 114, 126], ["invasion", "OBSERVATION", 127, 135]]], ["A cerebrovascular event because of the hypercoagulable state of COVID-19 may also cause the recurrence of brain edema.", [["cerebrovascular", "ANATOMY", 2, 17], ["brain", "ANATOMY", 106, 111], ["COVID-19", "CHEMICAL", 64, 72], ["brain edema", "DISEASE", 106, 117], ["COVID-19", "CHEMICAL", 64, 72], ["COVID-19", "SIMPLE_CHEMICAL", 64, 72], ["brain edema", "PATHOLOGICAL_FORMATION", 106, 117], ["A cerebrovascular event", "PROBLEM", 0, 23], ["the hypercoagulable state", "PROBLEM", 35, 60], ["COVID", "TEST", 64, 69], ["brain edema", "PROBLEM", 106, 117], ["cerebrovascular", "ANATOMY", 2, 17], ["hypercoagulable", "OBSERVATION", 39, 54], ["recurrence", "OBSERVATION_MODIFIER", 92, 102], ["brain", "ANATOMY", 106, 111], ["edema", "OBSERVATION", 112, 117]]], ["Cerebral angiography and perfusion study were not performed; however, the magnetic resonance results do not show major vessel thrombosis.", [["Cerebral", "ANATOMY", 0, 8], ["vessel", "ANATOMY", 119, 125], ["vessel thrombosis", "DISEASE", 119, 136], ["Cerebral", "MULTI-TISSUE_STRUCTURE", 0, 8], ["vessel", "MULTI-TISSUE_STRUCTURE", 119, 125], ["Cerebral angiography", "TEST", 0, 20], ["perfusion study", "TEST", 25, 40], ["the magnetic resonance", "TEST", 70, 92], ["major vessel thrombosis", "PROBLEM", 113, 136], ["vessel", "ANATOMY", 119, 125], ["thrombosis", "OBSERVATION", 126, 136]]], ["In this case, microcirculation might be disturbed in COVID-19 infection that could develop edema and lead to the seizure.", [["edema", "ANATOMY", 91, 96], ["infection", "DISEASE", 62, 71], ["edema", "DISEASE", 91, 96], ["seizure", "DISEASE", 113, 120], ["COVID-19", "CELL", 53, 61], ["edema", "PATHOLOGICAL_FORMATION", 91, 96], ["COVID-19", "SPECIES", 53, 61], ["COVID-19 infection", "PROBLEM", 53, 71], ["edema", "PROBLEM", 91, 96], ["the seizure", "PROBLEM", 109, 120], ["infection", "OBSERVATION", 62, 71], ["edema", "OBSERVATION", 91, 96]]], ["Although data are lacking to verify the hypothesis, another case of COVID-19 presenting a post-encephalitic status epilepticus [4] and previous reports on the hypercoagulable and neuroinvasive features of COVID-19 support this.", [["status epilepticus", "DISEASE", 108, 126], ["COVID", "TEST", 68, 73], ["a post-encephalitic status epilepticus", "PROBLEM", 88, 126], ["the hypercoagulable", "PROBLEM", 155, 174], ["COVID", "TEST", 205, 210], ["hypercoagulable", "OBSERVATION", 159, 174]]], ["However, we believe that COVID-19 infection has a potential to develop brain edema and lead to the seizure in patients with post-stroke symptomatic epilepsy.", [["brain", "ANATOMY", 71, 76], ["COVID-19", "CHEMICAL", 25, 33], ["infection", "DISEASE", 34, 43], ["brain edema", "DISEASE", 71, 82], ["seizure", "DISEASE", 99, 106], ["stroke", "DISEASE", 129, 135], ["epilepsy", "DISEASE", 148, 156], ["COVID-19", "ORGANISM", 25, 33], ["brain", "ORGAN", 71, 76], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["COVID-19", "SPECIES", 25, 33], ["COVID-19 infection", "PROBLEM", 25, 43], ["brain edema", "PROBLEM", 71, 82], ["the seizure", "PROBLEM", 95, 106], ["post-stroke symptomatic epilepsy", "PROBLEM", 124, 156], ["infection", "OBSERVATION", 34, 43], ["brain", "ANATOMY", 71, 76], ["edema", "OBSERVATION", 77, 82], ["symptomatic", "OBSERVATION_MODIFIER", 136, 147], ["epilepsy", "OBSERVATION", 148, 156]]], ["Thus, we hope that this case report will increase the awareness of neurologists about epilepsy during a COVID-19 infection in emergent medicine and help in providing appropriate care to the patients.", [["epilepsy", "DISEASE", 86, 94], ["infection", "DISEASE", 113, 122], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["epilepsy", "PROBLEM", 86, 94], ["a COVID-19 infection", "PROBLEM", 102, 122], ["emergent medicine", "TREATMENT", 126, 143], ["infection", "OBSERVATION", 113, 122]]]], "78fc7ceee1744a948a23c30f993cb9ccbe650a30": [["Most workers in these sectors have a higher dependence on public transport (Rachele et al. 2015) to reach their work site and allegedly sub-standard access to Personal protective equipment (PPE).", [["Personal protective equipment", "TREATMENT", 159, 188], ["higher dependence", "OBSERVATION_MODIFIER", 37, 54]]]], "27b6060c0b758e847c99465c5e21f971db346ad0": [["The random physical screening (PS) of compound collections, that is the in-house database of a pharmaceutical company, or the catalogs of various chemicals' vendors, represented a long-range strategy and was regarded as a substitute for serendipity [1] .", [["The random physical screening", "TEST", 0, 29], ["compound collections", "PROBLEM", 38, 58], ["a long-range strategy", "TREATMENT", 178, 199]]]], "PMC7295548": [["To the EditorSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) has reached a pandemic level.", [["acute respiratory syndrome coronavirus", "DISEASE", 20, 58], ["coronavirus disease", "DISEASE", 88, 107], ["COVID-19", "CHEMICAL", 114, 122], ["EditorSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 7, 60], ["SARS-CoV-2", "ORGANISM", 62, 72], ["EditorSevere acute respiratory syndrome coronavirus", "SPECIES", 7, 58], ["SARS-CoV-2", "SPECIES", 62, 72], ["the EditorSevere acute respiratory syndrome coronavirus", "PROBLEM", 3, 58], ["SARS-CoV", "TEST", 62, 70], ["coronavirus disease", "PROBLEM", 88, 107], ["COVID", "TEST", 114, 119], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory syndrome", "OBSERVATION", 26, 46], ["coronavirus disease", "OBSERVATION", 88, 107]]], ["In a recent retrospective cohort study of COVID-19, comorbidities such as diabetes and hypertension were present in nearly half of patients [1].", [["diabetes", "DISEASE", 74, 82], ["hypertension", "DISEASE", 87, 99], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["COVID", "TEST", 42, 47], ["comorbidities", "PROBLEM", 52, 65], ["diabetes", "PROBLEM", 74, 82], ["hypertension", "PROBLEM", 87, 99], ["diabetes", "OBSERVATION", 74, 82], ["hypertension", "OBSERVATION", 87, 99]]], ["The odds of in-hospital death were significantly higher in patients with diabetes (2.85) and hypertension (3.05) [1].To the EditorIt remains unknown why the prevalence of diabetes and hypertension is high in COVID-19 patients and why such diseases can be risk for severe COVID-19 including death.To the EditorTo elucidate such clinical questions, I searched the prevalence of diabetes and hypertension and the controlling status of such diseases in all COVID-19 patients, severe and non-severe COVID-19 patients using PubMed.", [["death", "DISEASE", 24, 29], ["diabetes", "DISEASE", 73, 81], ["hypertension", "DISEASE", 93, 105], ["diabetes", "DISEASE", 171, 179], ["hypertension", "DISEASE", 184, 196], ["COVID", "DISEASE", 271, 276], ["death", "DISEASE", 290, 295], ["diabetes", "DISEASE", 376, 384], ["hypertension", "DISEASE", 389, 401], ["COVID", "DISEASE", 494, 499], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 217, 225], ["patients", "ORGANISM", 462, 470], ["patients", "ORGANISM", 503, 511], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 217, 225], ["patients", "SPECIES", 462, 470], ["patients", "SPECIES", 503, 511], ["diabetes", "PROBLEM", 73, 81], ["hypertension", "PROBLEM", 93, 105], ["diabetes", "PROBLEM", 171, 179], ["hypertension", "PROBLEM", 184, 196], ["such diseases", "PROBLEM", 234, 247], ["severe COVID", "PROBLEM", 264, 276], ["death", "PROBLEM", 290, 295], ["diabetes", "PROBLEM", 376, 384], ["hypertension", "PROBLEM", 389, 401], ["such diseases", "PROBLEM", 432, 445], ["all COVID", "TEST", 449, 458], ["severe and non-severe COVID", "PROBLEM", 472, 499], ["hypertension", "OBSERVATION", 93, 105], ["diabetes", "OBSERVATION", 171, 179], ["hypertension", "OBSERVATION", 184, 196], ["high", "OBSERVATION_MODIFIER", 200, 204], ["diabetes", "OBSERVATION", 376, 384], ["hypertension", "OBSERVATION", 389, 401]]], ["The prevalence of each disease in severe and non-severe COVID-19 patients was meta-analyzed by Peto\u2019s exact method, and odds ratio (OR) with 95% confidence interval (CI) was shown.To the EditorThe prevalence of diabetes in all COVID-19 patients, severe and non-severe COVID-19 patients were shown in Table 1 [1-12].", [["COVID", "DISEASE", 56, 61], ["diabetes", "DISEASE", 211, 219], ["COVID", "DISEASE", 268, 273], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 236, 244], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 277, 285], ["each disease in severe and non-severe COVID", "PROBLEM", 18, 61], ["CI", "TEST", 166, 168], ["diabetes", "PROBLEM", 211, 219], ["all COVID", "TEST", 223, 232], ["severe and non-severe COVID", "PROBLEM", 246, 273], ["disease", "OBSERVATION", 23, 30], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["non-severe", "OBSERVATION_MODIFIER", 45, 55], ["diabetes", "OBSERVATION", 211, 219], ["severe", "OBSERVATION_MODIFIER", 246, 252]]], ["Half of studies showed a statistically significantly higher prevalence of diabetes in severe patients than in non-severe patients.", [["diabetes", "DISEASE", 74, 82], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 121, 129], ["studies", "TEST", 8, 15], ["diabetes", "PROBLEM", 74, 82], ["diabetes", "OBSERVATION", 74, 82], ["severe", "OBSERVATION_MODIFIER", 86, 92]]], ["In the meta-analysis, the prevalence of diabetes in severe patients was significantly higher than that in non-severe patients (OR: 3.52, 95% CI: 2.65 - 4.67).", [["diabetes", "DISEASE", 40, 48], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 117, 125], ["diabetes", "PROBLEM", 40, 48], ["CI", "TEST", 141, 143], ["diabetes", "OBSERVATION", 40, 48], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["higher", "OBSERVATION_MODIFIER", 86, 92]]], ["Unfortunately, only three studies were available to analyze the controlling status of diabetes.", [["diabetes", "DISEASE", 86, 94], ["three studies", "TEST", 20, 33], ["diabetes", "PROBLEM", 86, 94], ["diabetes", "OBSERVATION", 86, 94]]], ["All three studies showed that plasma glucose levels in severe patients were significantly higher than those in non-severe patients.", [["plasma", "ANATOMY", 30, 36], ["glucose", "CHEMICAL", 37, 44], ["glucose", "CHEMICAL", 37, 44], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["glucose", "SIMPLE_CHEMICAL", 37, 44], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 122, 130], ["All three studies", "TEST", 0, 17], ["plasma glucose levels", "TEST", 30, 51], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["significantly", "OBSERVATION_MODIFIER", 76, 89], ["higher", "OBSERVATION_MODIFIER", 90, 96]]], ["Although such data did not present sufficient evidence, elevation of plasma glucose is likely to be associated with severity of COVID-19.", [["plasma", "ANATOMY", 69, 75], ["glucose", "CHEMICAL", 76, 83], ["glucose", "CHEMICAL", 76, 83], ["COVID-19", "CHEMICAL", 128, 136], ["plasma", "ORGANISM_SUBSTANCE", 69, 75], ["glucose", "SIMPLE_CHEMICAL", 76, 83], ["elevation of plasma glucose", "PROBLEM", 56, 83], ["COVID", "TEST", 128, 133], ["elevation", "OBSERVATION_MODIFIER", 56, 65]]], ["Zhu et al performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing type 2 diabetes [13].", [["type 2 diabetes", "DISEASE", 144, 159], ["multi-centered study", "TEST", 37, 57], ["COVID", "TEST", 76, 81], ["pre-existing type 2 diabetes", "PROBLEM", 131, 159]]], ["They found that subjects with type 2 diabetes required more medical interventions, and had a significantly higher mortality (7.8% vs. 2.7%) and multiple organ injury than the non-diabetic individuals.", [["organ", "ANATOMY", 153, 158], ["type 2 diabetes", "DISEASE", 30, 45], ["organ injury", "DISEASE", 153, 165], ["non-diabetic", "DISEASE", 175, 187], ["organ", "ORGAN", 153, 158], ["type 2 diabetes", "PROBLEM", 30, 45], ["medical interventions", "TREATMENT", 60, 81], ["a significantly higher mortality", "PROBLEM", 91, 123], ["multiple organ injury", "PROBLEM", 144, 165], ["the non-diabetic individuals", "PROBLEM", 171, 199], ["multiple", "OBSERVATION_MODIFIER", 144, 152], ["organ", "ANATOMY", 153, 158], ["injury", "OBSERVATION", 159, 165]]], ["Further, well-controlled blood glucose was associated with markedly lower mortality compared to individuals with poorly controlled blood glucose, supporting a significance of hyperglycemia in severe COVID-19.To the EditorThe prevalence of hypertension in all COVID-19 patients, severe and non-severe COVID-19 patients was shown in Table 2 [1-12].", [["blood", "ANATOMY", 25, 30], ["blood", "ANATOMY", 131, 136], ["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 137, 144], ["hyperglycemia", "DISEASE", 175, 188], ["hypertension", "DISEASE", 239, 251], ["COVID", "DISEASE", 300, 305], ["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 137, 144], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["glucose", "SIMPLE_CHEMICAL", 31, 38], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["glucose", "SIMPLE_CHEMICAL", 137, 144], ["patients", "ORGANISM", 268, 276], ["patients", "ORGANISM", 309, 317], ["patients", "SPECIES", 268, 276], ["patients", "SPECIES", 309, 317], ["blood glucose", "TEST", 25, 38], ["markedly lower mortality", "PROBLEM", 59, 83], ["poorly controlled blood glucose", "PROBLEM", 113, 144], ["hyperglycemia", "PROBLEM", 175, 188], ["severe COVID", "PROBLEM", 192, 204], ["hypertension", "PROBLEM", 239, 251], ["all COVID", "TEST", 255, 264], ["severe and non-severe COVID", "PROBLEM", 278, 305], ["hyperglycemia", "OBSERVATION", 175, 188], ["severe", "OBSERVATION_MODIFIER", 192, 198], ["hypertension", "OBSERVATION", 239, 251], ["severe", "OBSERVATION_MODIFIER", 278, 284]]], ["Five of 12 studies showed a statistically significantly higher prevalence of hypertension in severe patients than in non-severe patients.", [["hypertension", "DISEASE", 77, 89], ["patients", "ORGANISM", 100, 108], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 128, 136], ["12 studies", "TEST", 8, 18], ["hypertension", "PROBLEM", 77, 89], ["hypertension", "OBSERVATION", 77, 89], ["severe", "OBSERVATION_MODIFIER", 93, 99]]], ["In the meta-analysis, the prevalence of hypertension in severe patients was significantly higher than that in non-severe patients (OR: 2.69, 95% CI: 2.16 - 3.34).", [["hypertension", "DISEASE", 40, 52], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 121, 129], ["hypertension", "PROBLEM", 40, 52], ["CI", "TEST", 145, 147], ["hypertension", "OBSERVATION", 40, 52], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["significantly", "OBSERVATION_MODIFIER", 76, 89], ["higher", "OBSERVATION_MODIFIER", 90, 96]]], ["Seven studies were available to analyze the controlling status of hypertension.", [["hypertension", "DISEASE", 66, 78], ["Seven studies", "TEST", 0, 13], ["hypertension", "PROBLEM", 66, 78], ["hypertension", "OBSERVATION", 66, 78]]], ["Five studies did not show any difference in blood pressure between severe and non-severe patients.", [["blood", "ANATOMY", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Five studies", "TEST", 0, 12], ["blood pressure", "TEST", 44, 58], ["severe and non-severe patients", "PROBLEM", 67, 97], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["non-severe", "OBSERVATION_MODIFIER", 78, 88]]], ["Huang et al showed that systolic blood pressure was significantly higher in severe patients than in non-severe patients [2].", [["blood", "ANATOMY", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 111, 119], ["systolic blood pressure", "TEST", 24, 47], ["significantly", "OBSERVATION_MODIFIER", 52, 65], ["higher", "OBSERVATION_MODIFIER", 66, 72], ["severe", "OBSERVATION_MODIFIER", 76, 82]]], ["Itelman et al showed that minimal systolic blood pressure was significantly lower in severe patients than in non-severe patients, and maximal systolic blood pressure was significantly higher in severe patients than in non-severe patients [11].", [["blood", "ANATOMY", 43, 48], ["blood", "ANATOMY", 151, 156], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 120, 128], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 229, 237], ["minimal systolic blood pressure", "TEST", 26, 57], ["maximal systolic blood pressure", "TEST", 134, 165], ["minimal", "OBSERVATION_MODIFIER", 26, 33], ["systolic", "OBSERVATION_MODIFIER", 34, 42], ["blood pressure", "OBSERVATION", 43, 57], ["significantly", "OBSERVATION_MODIFIER", 62, 75], ["lower", "OBSERVATION_MODIFIER", 76, 81], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["higher", "OBSERVATION_MODIFIER", 184, 190], ["severe", "OBSERVATION_MODIFIER", 194, 200]]], ["Blood pressure itself is unlikely to be associated with severity of COVID-19.", [["Blood", "ANATOMY", 0, 5], ["COVID-19", "CHEMICAL", 68, 76], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["COVID", "TEST", 68, 73], ["pressure", "OBSERVATION_MODIFIER", 6, 14], ["unlikely to be", "UNCERTAINTY", 25, 39]]], ["Since hypertension is one of the most significant risk factors for severe disease and mortality in COVID-19, and angiotensin-converting enzyme (ACE) 2 is the entry receptor of SARS-CoV-2 [14, 15], the effects of ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in COVID-19 patients have received much focus.", [["hypertension", "DISEASE", 6, 18], ["angiotensin", "CHEMICAL", 113, 124], ["ACE inhibitors", "CHEMICAL", 212, 226], ["ACEIs", "CHEMICAL", 228, 233], ["angiotensin", "CHEMICAL", 239, 250], ["angiotensin-converting enzyme (ACE) 2", "GENE_OR_GENE_PRODUCT", 113, 150], ["ACE", "GENE_OR_GENE_PRODUCT", 212, 215], ["ACEIs", "SIMPLE_CHEMICAL", 228, 233], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 239, 268], ["ARBs", "SIMPLE_CHEMICAL", 270, 274], ["patients", "ORGANISM", 288, 296], ["angiotensin-converting enzyme (ACE) 2", "PROTEIN", 113, 150], ["patients", "SPECIES", 288, 296], ["hypertension", "PROBLEM", 6, 18], ["severe disease", "PROBLEM", 67, 81], ["COVID", "TEST", 99, 104], ["angiotensin-converting enzyme (ACE)", "TREATMENT", 113, 148], ["SARS", "TEST", 176, 180], ["CoV", "TEST", 181, 184], ["ACE inhibitors", "TREATMENT", 212, 226], ["ACEIs", "TREATMENT", 228, 233], ["angiotensin receptor blockers", "TREATMENT", 239, 268], ["ARBs", "TREATMENT", 270, 274], ["hypertension", "OBSERVATION", 6, 18], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["disease", "OBSERVATION", 74, 81]]], ["A recent study has shown the protective effects of ACEIs/ARBs against mortality in COVID-19 [16], challenging the association between ACEIs/ARBs use and severe COVID-19.To the EditorWhy is hypertension one of the most significant risk factors for severe disease and mortality in COVID-19?", [["ACEIs", "CHEMICAL", 51, 56], ["ARBs", "CHEMICAL", 57, 61], ["ACEIs", "CHEMICAL", 134, 139], ["ARBs", "CHEMICAL", 140, 144], ["hypertension", "DISEASE", 189, 201], ["COVID-19", "CHEMICAL", 160, 168], ["ACEIs", "SIMPLE_CHEMICAL", 51, 56], ["ARBs", "SIMPLE_CHEMICAL", 57, 61], ["ACEIs", "SIMPLE_CHEMICAL", 134, 139], ["A recent study", "TEST", 0, 14], ["ACEIs", "TREATMENT", 51, 56], ["ARBs", "TREATMENT", 57, 61], ["COVID", "TEST", 83, 88], ["ACEIs", "TREATMENT", 134, 139], ["ARBs", "TREATMENT", 140, 144], ["severe COVID", "PROBLEM", 153, 165], ["hypertension", "PROBLEM", 189, 201], ["severe disease", "PROBLEM", 247, 261], ["COVID", "TEST", 279, 284], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["hypertension", "OBSERVATION", 189, 201], ["severe", "OBSERVATION_MODIFIER", 247, 253], ["disease", "OBSERVATION", 254, 261]]], ["Diabetes and hypertension are crucial coronary risk factors, and diabetes and hypertension are closely interlinked because of similar risk factors, such as endothelial dysfunction, vascular inflammation, arterial re-modelling, atherosclerosis, dyslipidemia, and obesity [17].", [["coronary", "ANATOMY", 38, 46], ["endothelial", "ANATOMY", 156, 167], ["vascular", "ANATOMY", 181, 189], ["arterial", "ANATOMY", 204, 212], ["Diabetes", "DISEASE", 0, 8], ["hypertension", "DISEASE", 13, 25], ["diabetes", "DISEASE", 65, 73], ["hypertension", "DISEASE", 78, 90], ["endothelial dysfunction", "DISEASE", 156, 179], ["vascular inflammation", "DISEASE", 181, 202], ["atherosclerosis", "DISEASE", 227, 242], ["dyslipidemia", "DISEASE", 244, 256], ["obesity", "DISEASE", 262, 269], ["coronary", "MULTI-TISSUE_STRUCTURE", 38, 46], ["endothelial", "CELL", 156, 167], ["vascular", "MULTI-TISSUE_STRUCTURE", 181, 189], ["arterial", "MULTI-TISSUE_STRUCTURE", 204, 212], ["Diabetes", "PROBLEM", 0, 8], ["hypertension", "PROBLEM", 13, 25], ["crucial coronary risk factors", "PROBLEM", 30, 59], ["diabetes", "PROBLEM", 65, 73], ["hypertension", "PROBLEM", 78, 90], ["similar risk factors", "PROBLEM", 126, 146], ["endothelial dysfunction", "PROBLEM", 156, 179], ["vascular inflammation", "PROBLEM", 181, 202], ["arterial re-modelling", "PROBLEM", 204, 225], ["atherosclerosis", "PROBLEM", 227, 242], ["dyslipidemia", "PROBLEM", 244, 256], ["obesity", "PROBLEM", 262, 269], ["hypertension", "OBSERVATION", 13, 25], ["coronary", "ANATOMY", 38, 46], ["diabetes", "OBSERVATION", 65, 73], ["hypertension", "OBSERVATION", 78, 90], ["endothelial dysfunction", "OBSERVATION", 156, 179], ["vascular", "ANATOMY", 181, 189], ["inflammation", "OBSERVATION", 190, 202], ["arterial", "ANATOMY", 204, 212], ["atherosclerosis", "OBSERVATION", 227, 242], ["dyslipidemia", "OBSERVATION", 244, 256]]], ["Common mechanisms, such as upregulation of the renin-angiotensin-aldosterone system, oxidative stress, inflammation, and activation of the immune system likely contribute to the close relationship between diabetes and hypertension [17].", [["immune system", "ANATOMY", 139, 152], ["angiotensin", "CHEMICAL", 53, 64], ["aldosterone", "CHEMICAL", 65, 76], ["inflammation", "DISEASE", 103, 115], ["diabetes", "DISEASE", 205, 213], ["hypertension", "DISEASE", 218, 230], ["aldosterone", "CHEMICAL", 65, 76], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 47, 76], ["renin", "PROTEIN", 47, 52], ["Common mechanisms", "PROBLEM", 0, 17], ["the renin", "TEST", 43, 52], ["angiotensin-aldosterone system", "TREATMENT", 53, 83], ["oxidative stress", "PROBLEM", 85, 101], ["inflammation", "PROBLEM", 103, 115], ["activation of the immune system", "PROBLEM", 121, 152], ["diabetes", "PROBLEM", 205, 213], ["hypertension", "PROBLEM", 218, 230], ["inflammation", "OBSERVATION", 103, 115], ["hypertension", "OBSERVATION", 218, 230]]], ["High prevalence of diabetes and hypertension in severe COVID-19 patients can be explained by such vascular damage.", [["vascular", "ANATOMY", 98, 106], ["diabetes", "DISEASE", 19, 27], ["hypertension", "DISEASE", 32, 44], ["COVID", "DISEASE", 55, 60], ["vascular damage", "DISEASE", 98, 113], ["patients", "ORGANISM", 64, 72], ["vascular", "MULTI-TISSUE_STRUCTURE", 98, 106], ["patients", "SPECIES", 64, 72], ["diabetes", "PROBLEM", 19, 27], ["hypertension", "PROBLEM", 32, 44], ["severe COVID", "PROBLEM", 48, 60], ["such vascular damage", "PROBLEM", 93, 113], ["diabetes", "OBSERVATION", 19, 27], ["hypertension", "OBSERVATION", 32, 44], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["vascular", "ANATOMY", 98, 106], ["damage", "OBSERVATION", 107, 113]]], ["The prevalence of cardiovascular disease (CVD) in all COVID-19 patients, severe and non-severe COVID-19 patients was shown in Table 3 [1-8, 10-12].", [["cardiovascular", "ANATOMY", 18, 32], ["cardiovascular disease", "DISEASE", 18, 40], ["CVD", "DISEASE", 42, 45], ["COVID", "DISEASE", 95, 100], ["cardiovascular", "ANATOMICAL_SYSTEM", 18, 32], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 104, 112], ["cardiovascular disease", "PROBLEM", 18, 40], ["CVD", "PROBLEM", 42, 45], ["all COVID", "TEST", 50, 59], ["severe and non-severe COVID", "PROBLEM", 73, 100], ["cardiovascular", "ANATOMY", 18, 32], ["disease", "OBSERVATION", 33, 40], ["severe", "OBSERVATION_MODIFIER", 73, 79]]], ["Four of 11 studies showed a statistically significantly higher prevalence of CVD in severe patients than in non-severe patients.", [["CVD", "DISEASE", 77, 80], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 119, 127], ["11 studies", "TEST", 8, 18], ["CVD", "PROBLEM", 77, 80], ["severe", "OBSERVATION_MODIFIER", 84, 90]]], ["In the meta-analysis, the prevalence of CVD in severe patients was significantly higher than that in non-severe patients (OR: 5.37, 95% CI: 3.73 - 7.74).", [["CVD", "DISEASE", 40, 43], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 112, 120], ["CVD", "PROBLEM", 40, 43], ["CI", "TEST", 136, 138], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["significantly", "OBSERVATION_MODIFIER", 67, 80], ["higher", "OBSERVATION_MODIFIER", 81, 87]]], ["Further, CVD was significantly associated with increased odds of death (OR: 21.4) [1], supporting a significant association between vascular damage and severity of COVID-19.To the EditorD-dimer is detected in injured vascular endothelium [18], and von Willebrand factor is produced by endothelial cells in response to injury, and high von Willebrand factor level has been observed in systemic vasculitis [19].", [["vascular", "ANATOMY", 132, 140], ["vascular endothelium", "ANATOMY", 217, 237], ["endothelial cells", "ANATOMY", 285, 302], ["CVD", "DISEASE", 9, 12], ["death", "DISEASE", 65, 70], ["vascular damage", "DISEASE", 132, 147], ["vasculitis", "DISEASE", 393, 403], ["COVID-19", "CHEMICAL", 164, 172], ["vascular", "MULTI-TISSUE_STRUCTURE", 132, 140], ["EditorD-dimer", "GENE_OR_GENE_PRODUCT", 180, 193], ["vascular endothelium", "TISSUE", 217, 237], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 248, 269], ["endothelial cells", "CELL", 285, 302], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 335, 356], ["EditorD", "PROTEIN", 180, 187], ["dimer", "PROTEIN", 188, 193], ["von Willebrand factor", "PROTEIN", 248, 269], ["endothelial cells", "CELL_TYPE", 285, 302], ["von Willebrand factor", "PROTEIN", 335, 356], ["CVD", "PROBLEM", 9, 12], ["death", "PROBLEM", 65, 70], ["a significant association between vascular damage", "PROBLEM", 98, 147], ["COVID", "TEST", 164, 169], ["injury", "PROBLEM", 318, 324], ["high von Willebrand factor level", "PROBLEM", 330, 362], ["systemic vasculitis", "PROBLEM", 384, 403], ["vascular", "ANATOMY", 132, 140], ["damage", "OBSERVATION", 141, 147], ["injured", "OBSERVATION", 209, 216], ["vascular endothelium", "ANATOMY", 217, 237], ["endothelial cells", "OBSERVATION", 285, 302], ["injury", "OBSERVATION", 318, 324], ["systemic", "ANATOMY", 384, 392], ["vasculitis", "OBSERVATION", 393, 403]]], ["Multivariable regression showed increasing odds of in-hospital death associated with D-dimer greater than 1 \u00b5g/mL (OR: 18.42, 95% CI: 2.64 - 128.55; P = 0.0033) on admission [1].", [["death", "DISEASE", 63, 68], ["D-dimer", "GENE_OR_GENE_PRODUCT", 85, 92], ["Multivariable regression", "TEST", 0, 24], ["in-hospital death", "PROBLEM", 51, 68], ["D-dimer", "TEST", 85, 92], ["CI", "TEST", 130, 132], ["P", "TEST", 149, 150], ["increasing", "OBSERVATION_MODIFIER", 32, 42]]], ["Elevated von Willebrand factor levels were observed in COVID-19 patients in the intensive care unit [20].", [["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 9, 30], ["patients", "ORGANISM", 64, 72], ["von Willebrand factor", "PROTEIN", 9, 30], ["patients", "SPECIES", 64, 72], ["Elevated von Willebrand factor levels", "PROBLEM", 0, 37], ["von", "OBSERVATION", 9, 12]]], ["D-dimer was also reported to be significantly increased in Kawasaki disease with coronary artery lesions, and to be the independent risk for coronary artery lesions in Kawasaki disease [21].", [["coronary artery lesions", "ANATOMY", 81, 104], ["coronary artery lesions", "ANATOMY", 141, 164], ["Kawasaki disease", "DISEASE", 59, 75], ["coronary artery lesions", "DISEASE", 81, 104], ["coronary artery lesions", "DISEASE", 141, 164], ["Kawasaki disease", "DISEASE", 168, 184], ["D-dimer", "GENE_OR_GENE_PRODUCT", 0, 7], ["coronary artery lesions", "PATHOLOGICAL_FORMATION", 81, 104], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 141, 156], ["lesions", "PATHOLOGICAL_FORMATION", 157, 164], ["D-dimer", "PROTEIN", 0, 7], ["D-dimer", "TEST", 0, 7], ["Kawasaki disease", "PROBLEM", 59, 75], ["coronary artery lesions", "PROBLEM", 81, 104], ["coronary artery lesions", "PROBLEM", 141, 164], ["Kawasaki disease", "PROBLEM", 168, 184], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["Kawasaki disease", "OBSERVATION", 59, 75], ["coronary artery", "ANATOMY", 81, 96], ["lesions", "OBSERVATION", 97, 104], ["coronary artery", "ANATOMY", 141, 156], ["lesions", "OBSERVATION", 157, 164]]], ["Von Willebrand factor parameters were reported to represent potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease [22].", [["coronary artery lesion", "ANATOMY", 106, 128], ["coronary artery lesion", "DISEASE", 106, 128], ["Kawasaki disease", "DISEASE", 146, 162], ["Von Willebrand factor", "GENE_OR_GENE_PRODUCT", 0, 21], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 106, 121], ["patients", "ORGANISM", 132, 140], ["Von Willebrand factor", "PROTEIN", 0, 21], ["patients", "SPECIES", 132, 140], ["Von Willebrand factor parameters", "TEST", 0, 32], ["disease activity", "PROBLEM", 85, 101], ["coronary artery lesion", "PROBLEM", 106, 128], ["Kawasaki disease", "PROBLEM", 146, 162], ["coronary artery", "ANATOMY", 106, 121], ["lesion", "OBSERVATION", 122, 128]]], ["A very recent article reported the development of Kawasaki disease in COVID-19 patient [23], supporting an association between endothelial injury and severe COVID-19.To the EditorIn conclusion, endothelial injury may be associated with severity of COVID-19, which can partially explain high prevalence of diabetes and hypertension in severe COVID-19.", [["endothelial", "ANATOMY", 127, 138], ["endothelial", "ANATOMY", 194, 205], ["Kawasaki disease", "DISEASE", 50, 66], ["endothelial injury", "DISEASE", 127, 145], ["endothelial injury", "DISEASE", 194, 212], ["diabetes", "DISEASE", 305, 313], ["hypertension", "DISEASE", 318, 330], ["COVID-19", "CHEMICAL", 157, 165], ["Kawasaki disease", "CANCER", 50, 66], ["patient", "ORGANISM", 79, 86], ["endothelial", "TISSUE", 127, 138], ["endothelial", "TISSUE", 194, 205], ["patient", "SPECIES", 79, 86], ["Kawasaki disease", "PROBLEM", 50, 66], ["COVID", "TEST", 70, 75], ["endothelial injury", "PROBLEM", 127, 145], ["severe COVID", "PROBLEM", 150, 162], ["endothelial injury", "PROBLEM", 194, 212], ["COVID", "TEST", 248, 253], ["diabetes", "PROBLEM", 305, 313], ["hypertension", "PROBLEM", 318, 330], ["severe COVID", "PROBLEM", 334, 346], ["Kawasaki disease", "OBSERVATION", 50, 66], ["endothelial", "ANATOMY", 127, 138], ["injury", "OBSERVATION", 139, 145], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["endothelial", "ANATOMY", 194, 205], ["injury", "OBSERVATION", 206, 212], ["diabetes", "OBSERVATION", 305, 313], ["hypertension", "OBSERVATION", 318, 330], ["severe", "OBSERVATION_MODIFIER", 334, 340]]]], "9c80c57936a548404844aa756a359217f47d71cf": [["COVID-19 es la infecci\u00f3n respiratoria aguda con m\u00e1s impacto y da\u00f1o internacional en las \u00faltimas d\u00e9cadas.", [["COVID", "TEST", 0, 5]]], ["3 La mejor estrategia de manejo, seg\u00fan los Centros de Control y Prevenci\u00f3n de Enfermedades (CDC), es evitar la exposici\u00f3n al virus.", [["La mejor estrategia", "PROBLEM", 2, 21]]], ["Pero \u00bfpor qu\u00e9 COVID-19 ha generado tanto impacto en algunas poblaciones?", [["COVID", "TEST", 14, 19], ["ha generado tanto impacto", "TREATMENT", 23, 48]]], ["El brote de COVID-19 ha demostrado la importancia de la prevenci\u00f3n y control de infecciones.", [["ha demostrado la importancia", "TREATMENT", 21, 49]]], ["1 Seg\u00fan numerosas organizaciones internacionales la estrategia de mayor eficacia contin\u00faa siendo la cuarentena.", [["la estrategia", "PROBLEM", 49, 62]]], ["1 Si logramos la prevenci\u00f3n no tendremos que llegar al manejo de la enfermedad en los centros hospitalarios y de esta forma no colapsar los sistemas de salud, ya debilitados en nuestros pa\u00edses.", [["Si", "CHEMICAL", 2, 4]]]], "PMC5580485": [], "170f0a7070650e42066d011135cc9e9d9f931223": [["were administered due to exposure in enzootic areas).", [["exposure in enzootic areas", "PROBLEM", 25, 51], ["enzootic", "OBSERVATION_MODIFIER", 37, 45]]], ["The majority of animals known to be involved in exposures in Alaska were dogs [1] .", [["animals", "ORGANISM", 16, 23], ["dogs", "SPECIES", 73, 77]]], ["Rates of serious dog bites to humans (those requiring hospitalization) are significantly higher in Alaska than the national average.", [["dog bites", "DISEASE", 17, 26], ["dog", "ORGANISM", 17, 20], ["humans", "ORGANISM", 30, 36], ["dog", "SPECIES", 17, 20], ["humans", "SPECIES", 30, 36], ["humans", "SPECIES", 30, 36], ["serious", "OBSERVATION_MODIFIER", 9, 16], ["higher", "OBSERVATION_MODIFIER", 89, 95]]], ["The high rate of those severe dog bite injuries are concentrated in the same regions as reported cases of animal rabies on a per capita basis [3] This highlights the importance of rabies to human health in Alaska, especially in those regions with enzootic rabies activity that are characterized by significant healthcare disparities and limited access to both veterinary and human medical services [4] .", [["dog bite injuries", "DISEASE", 30, 47], ["rabies", "DISEASE", 113, 119], ["rabies", "DISEASE", 256, 262], ["dog", "ORGANISM", 30, 33], ["rabies", "ORGANISM", 180, 186], ["human", "ORGANISM", 190, 195], ["human", "ORGANISM", 375, 380], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 375, 380], ["rabies", "SPECIES", 180, 186], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 375, 380], ["those severe dog bite injuries", "PROBLEM", 17, 47], ["enzootic rabies activity", "PROBLEM", 247, 271], ["high", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["enzootic", "OBSERVATION_MODIFIER", 247, 255], ["rabies activity", "OBSERVATION", 256, 271], ["significant", "OBSERVATION_MODIFIER", 298, 309]]]], "43011ed3031efad98fb37d92e22f2f2155ff2238": [["StatisticsFor all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.n/a ConfirmedThe exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedlyn/a ConfirmedThe statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.n/a ConfirmedA description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)n/a ConfirmedFor null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value notedn/a ConfirmedGive P values as exact values whenever suitable.For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settingsFor hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.Software and codePolicy information about availability of computer code Data collection Excel Data analysis Prism, Igor, R, Excel , SAS, MATLAB For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers.", [["sample", "ANATOMY", 174, 180], ["samples", "ANATOMY", 341, 348], ["all statistical analyses", "TEST", 14, 38], ["Methods section", "TREATMENT", 135, 150], ["The statistical test", "TEST", 412, 432], ["central tendency", "PROBLEM", 816, 832], ["variation (e.g. standard deviation)", "PROBLEM", 905, 940], ["null hypothesis testing", "TEST", 1024, 1047], ["the test statistic", "TEST", 1049, 1067], ["freedom", "PROBLEM", 1135, 1142], ["P value", "TEST", 1147, 1154], ["a ConfirmedGive P values", "TEST", 1162, 1186], ["Bayesian analysis", "TEST", 1225, 1242], ["hierarchical and complex designs", "PROBLEM", 1321, 1353], ["tests", "TEST", 1399, 1404], ["effect sizes", "PROBLEM", 1449, 1461], ["Prism", "TEST", 1731, 1736], ["Igor", "TEST", 1738, 1742], ["custom algorithms", "TREATMENT", 1793, 1810], ["size", "OBSERVATION_MODIFIER", 181, 185], ["sizes", "OBSERVATION_MODIFIER", 1117, 1122], ["complex", "OBSERVATION_MODIFIER", 1338, 1345], ["designs", "OBSERVATION", 1346, 1353]]], ["This statement should provide the following information, where applicable:Data-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availabilityDataThe main data supporting the results in this study are available within the paper and its Supplementary Information.", [["this study", "TEST", 309, 319], ["main", "OBSERVATION_MODIFIER", 273, 277]]], ["All data generated in this study, including source data and the data used to make the figures, are available in Mendeley data with the identifier http://dx.doi.org/10.17632/2f73pzdkr4.1.Field-specific reportingPlease select the one below that is the best fit for your research.", [["All data", "TEST", 0, 8], ["this study", "TEST", 22, 32], ["source data", "TEST", 44, 55], ["the data", "TEST", 60, 68]]], ["If you are not sure, read the appropriate sections before making your selection.", [["sections", "ANATOMY", 42, 50]]], ["Data exclusions 1 data point from the model-building cohort was excluded from the model because it was not measured by the instrument due to a mechanical failure (only 1/12 of assays had a missing value that it did not allow for modelling).", [["the model", "TEST", 34, 43], ["a mechanical failure", "PROBLEM", 141, 161], ["mechanical", "OBSERVATION_MODIFIER", 143, 153], ["failure", "OBSERVATION", 154, 161]]], ["Additionally, the immunocompromised patients were not included in modelling.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["immunocompromised", "OBSERVATION", 18, 35]]]], "ba107b533a1bf5feaed346f290a1e96a0bade93c": [["INTRODUCTIONCOVID-19 is a disease caused by a new human coronavirus (SARS-CoV-2) that emerged in Wuhan, China, in late 2019 1 .", [["human coronavirus", "DISEASE", 50, 67], ["SARS", "DISEASE", 69, 73], ["human", "ORGANISM", 50, 55], ["coronavirus", "ORGANISM", 56, 67], ["SARS-CoV-2", "ORGANISM", 69, 79], ["human", "SPECIES", 50, 55], ["coronavirus", "SPECIES", 56, 67], ["human coronavirus", "SPECIES", 50, 67], ["a disease", "PROBLEM", 24, 33], ["a new human coronavirus", "PROBLEM", 44, 67]]], ["In Spain, the first case of SARS-CoV-2 was identified on January 31 st imported from Germany.", [["SARS", "DISEASE", 28, 32], ["SARS-CoV-2", "ORGANISM", 28, 38], ["SARS-CoV", "SPECIES", 28, 36], ["SARS", "PROBLEM", 28, 32]]], ["Since that time, a sharp increase in the number of cases has pushed the capacity of healthcare system in Madrid beyond the limit 2 .", [["a sharp increase", "PROBLEM", 17, 33], ["sharp", "OBSERVATION_MODIFIER", 19, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["More than 60.000 patients were attended in Madrid`s hospitals during March and April 2020 2 .", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["As the pandemic accelerated, access to personal protective equipment (PPE) for health workers was a key concern, moreover because of PPE shortages 4 .INTRODUCTIONHealth-care workers (HCW) are at increased risk for infection, and specific requirements for their protection are advisable to ensure the functioning of the healthcare system 5 .", [["infection", "DISEASE", 214, 223], ["personal protective equipment", "TREATMENT", 39, 68], ["infection", "PROBLEM", 214, 223], ["their protection", "TREATMENT", 255, 271], ["infection", "OBSERVATION", 214, 223]]], ["Alongside concerns for the healthcare workers personal safety, anxiety about transmitting the infection to their relatives and patients adds another stress to HCW.INTRODUCTIONAt this time, it is known that SARS-CoV-2 human to human transmission occurs during the presymptomatic stage through droplets or direct contact [6] [7] [8] .", [["anxiety", "DISEASE", 63, 70], ["infection", "DISEASE", 94, 103], ["SARS", "DISEASE", 206, 210], ["patients", "ORGANISM", 127, 135], ["SARS-CoV-2", "ORGANISM", 206, 216], ["human", "ORGANISM", 217, 222], ["human", "ORGANISM", 226, 231], ["patients", "SPECIES", 127, 135], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 226, 231], ["anxiety", "PROBLEM", 63, 70], ["the infection", "PROBLEM", 90, 103], ["SARS", "PROBLEM", 206, 210], ["the presymptomatic stage through droplets", "PROBLEM", 259, 300]]], ["The possibility of presymptomatic transmission increases the challenges of containment measures [9] [10] [11] .", [["presymptomatic transmission", "PROBLEM", 19, 46], ["containment measures", "TREATMENT", 75, 95], ["possibility of", "UNCERTAINTY", 4, 18], ["presymptomatic", "OBSERVATION_MODIFIER", 19, 33]]], ["Moreover, according to two studies, presumed hospital-related transmission of SARS-CoV-2 was suspected in 41% and 35% of patients 10, 12, 13 .", [["SARS", "DISEASE", 78, 82], ["SARS-CoV-2", "ORGANISM", 78, 88], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["SARS-CoV", "SPECIES", 78, 86], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86]]], ["Nosocomial transmission may originate from patients (where protective measures are usually strict), but also from asymptomatic HCW (where protective measures may be more relaxed or simply non-existing).INTRODUCTIONLittle is known about hospital HCW seroprevalence for SARS-CoV-2.", [["SARS", "DISEASE", 268, 272], ["patients", "ORGANISM", 43, 51], ["SARS-CoV-2", "ORGANISM", 268, 278], ["patients", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 268, 276], ["Nosocomial transmission", "PROBLEM", 0, 23], ["protective measures", "TREATMENT", 59, 78], ["protective measures", "TREATMENT", 138, 157]]], ["Rates from other coronavirus epidemic such as MERS and SARS range between 2.3% and 20% of subclinical infection [14] [15] [16] .", [["SARS", "DISEASE", 55, 59], ["infection", "DISEASE", 102, 111], ["other coronavirus epidemic", "PROBLEM", 11, 37], ["SARS range", "TEST", 55, 65], ["subclinical infection", "PROBLEM", 90, 111]]], ["Nosocomial transmission has been recognized as an important amplifier in epidemics of both SARS and Middle East respiratory syndrome [17] [18] [19] .INTRODUCTIONSerological surveillance of exposed individuals allows to estimate the individual risk.INTRODUCTIONThis approach is essential since the safety of health-care workers must be ensured.INTRODUCTIONScreening all health-care workers for SARS-CoV-2 in the hospital would be helpful to maintain the welfare of the staff and to enable identification of infected health-care workers.INTRODUCTIONOur objective was to evaluate the prevalence of immunoglobulin G (IgG) against SARS-CoV-2 among all the employees of a second level teaching hospital in the south of Madrid.INTRODUCTION. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020 .", [["SARS", "DISEASE", 91, 95], ["Middle East respiratory syndrome", "DISEASE", 100, 132], ["SARS", "DISEASE", 393, 397], ["CC", "CHEMICAL", 734, 736], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 595, 611], ["IgG", "GENE_OR_GENE_PRODUCT", 613, 616], ["SARS-CoV-2", "ORGANISM", 626, 636], ["immunoglobulin G", "PROTEIN", 595, 611], ["IgG", "PROTEIN", 613, 616], ["SARS-CoV", "SPECIES", 626, 634], ["Nosocomial transmission", "PROBLEM", 0, 23], ["both SARS and Middle East respiratory syndrome", "PROBLEM", 86, 132], ["immunoglobulin G (IgG", "TREATMENT", 595, 616], ["SARS", "PROBLEM", 626, 630], ["CC", "TEST", 734, 736], ["ND", "PROBLEM", 743, 745], ["Middle", "ANATOMY_MODIFIER", 100, 106], ["NC", "ANATOMY", 740, 742], ["med", "ANATOMY", 839, 842]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020Laboratory proceduresWe measured serum IgG antibody by an enzyme-linked immunosorbent assay (ELISA) IgG2 using a SARS-CoV-2 S spike and Nucleocapsid recombinant antigens (Diapro (Palex), Italy), to screen for the presence of human anti-SARS-CoV-2 IgG.", [["serum", "ANATOMY", 346, 351], ["CC", "CHEMICAL", 0, 2], ["serum", "ORGANISM_SUBSTANCE", 346, 351], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 352, 364], ["IgG2", "GENE_OR_GENE_PRODUCT", 413, 417], ["human", "ORGANISM", 538, 543], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 544, 563], ["serum IgG antibody", "PROTEIN", 346, 364], ["IgG2", "PROTEIN", 413, 417], ["SARS-CoV-2 S spike and Nucleocapsid recombinant antigens", "PROTEIN", 426, 482], ["Palex", "PROTEIN", 492, 497], ["human anti-SARS-CoV-2 IgG", "PROTEIN", 538, 563], ["human", "SPECIES", 538, 543], ["human", "SPECIES", 538, 543], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["Laboratory procedures", "TEST", 313, 334], ["serum IgG antibody", "TEST", 346, 364], ["an enzyme", "TEST", 368, 377], ["immunosorbent assay", "TEST", 385, 404], ["ELISA", "TEST", 406, 411], ["IgG2", "TEST", 413, 417], ["a SARS", "TEST", 424, 430], ["CoV", "TEST", 431, 434], ["spike", "PROBLEM", 439, 444], ["Nucleocapsid recombinant antigens (Diapro (Palex)", "TREATMENT", 449, 498], ["human anti-SARS", "TEST", 538, 553], ["CoV", "TEST", 554, 557], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["This assay (CE approved) was used according to the manufacturer's protocol.", [["This assay", "TEST", 0, 10], ["the manufacturer's protocol", "TREATMENT", 47, 74]]], ["Reported sensitivity of the assay by the manufacturer was 98% (Supplement 2)Laboratory procedures.", [["the assay", "TEST", 24, 33], ["Laboratory procedures", "TREATMENT", 76, 97]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["HCW with positive IgG and presence of symptoms older than 14 days were assumed to be infected but no longer contagious.", [["IgG", "GENE_OR_GENE_PRODUCT", 18, 21], ["positive IgG", "PROTEIN", 9, 21], ["positive IgG", "PROBLEM", 9, 21], ["symptoms", "PROBLEM", 38, 46], ["infected", "PROBLEM", 85, 93], ["positive IgG", "OBSERVATION_MODIFIER", 9, 21], ["infected", "OBSERVATION", 85, 93], ["no longer", "UNCERTAINTY", 98, 107]]], ["Those with positive IgG and symptoms in the past 14 days were considered as active infected and potential contagious and underwent PCR examination.", [["IgG", "GENE_OR_GENE_PRODUCT", 20, 23], ["IgG", "PROTEIN", 20, 23], ["positive IgG", "PROBLEM", 11, 23], ["symptoms", "PROBLEM", 28, 36], ["PCR examination", "TEST", 131, 146], ["positive", "OBSERVATION_MODIFIER", 11, 19], ["IgG", "OBSERVATION", 20, 23], ["active", "OBSERVATION_MODIFIER", 76, 82], ["infected", "OBSERVATION", 83, 91]]], ["If PCR results were positive, they were discharged.Laboratory proceduresHCW with IgG negative were considered susceptible to SARS-CoV-2 infection 21 .Laboratory proceduresAsymptomatic workers were not routinely tested with PCR, but such test was performed for persons with self-reported symptoms, and the report was voluntary.Statistical analysis.Data are reported as mean (\u00b1 SD), median (IQR) or percentage as appropriate.Statistical analysis.Categorical variables were compared using Pearson's X2 test or Fisher exact test.Statistical analysis.Continuous variables were analyzed using the Student t-test.Statistical analysis.A univariate analysis was carried out to find independently associated risk factors for positive IgG.", [["SARS", "DISEASE", 125, 129], ["infection", "DISEASE", 136, 145], ["IgG", "GENE_OR_GENE_PRODUCT", 81, 84], ["SARS-CoV-2", "ORGANISM", 125, 135], ["persons", "ORGANISM", 260, 267], ["IgG", "GENE_OR_GENE_PRODUCT", 724, 727], ["IgG", "PROTEIN", 81, 84], ["positive IgG", "PROTEIN", 715, 727], ["persons", "SPECIES", 260, 267], ["SARS-CoV-2", "SPECIES", 125, 135], ["PCR", "TEST", 3, 6], ["Laboratory proceduresHCW", "TEST", 51, 75], ["IgG", "TEST", 81, 84], ["SARS", "PROBLEM", 125, 129], ["CoV-2 infection", "PROBLEM", 130, 145], ["Laboratory procedures", "TEST", 150, 171], ["PCR", "TEST", 223, 226], ["such test", "TEST", 232, 241], ["self-reported symptoms", "PROBLEM", 273, 295], ["Statistical analysis", "TEST", 326, 346], ["Statistical analysis", "TEST", 423, 443], ["Categorical variables", "TEST", 444, 465], ["Pearson's X2 test", "TEST", 486, 503], ["Fisher exact test", "TEST", 507, 524], ["Statistical analysis", "TEST", 525, 545], ["the Student t-test", "TEST", 587, 605], ["Statistical analysis", "TEST", 606, 626], ["A univariate analysis", "TEST", 627, 648], ["positive IgG", "PROBLEM", 715, 727]]], ["A multivariate logistic regression model evaluated the association between risk factors and positive IgG was assessed by reference to odds ratio (OR).Statistical analysis.Statistical analysis was performed, with hypothesis testing based on a two-tailed test of significance and we considered statistical significance P<0.05 with the Statistical Package for Social Sciences (SPSSPC v 20 Illinois USA) Study approval / Ethics .", [["IgG", "GENE_OR_GENE_PRODUCT", 101, 104], ["positive IgG", "PROTEIN", 92, 104], ["A multivariate logistic regression model", "PROBLEM", 0, 40], ["positive IgG", "PROBLEM", 92, 104], ["Statistical analysis", "TEST", 150, 170], ["Statistical analysis", "TEST", 171, 191], ["hypothesis testing", "TEST", 212, 230]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint All participants enrolled into the study voluntarily, and written informed consent was required to use the data for analysis.", [["CC", "CHEMICAL", 0, 2], ["participants", "SPECIES", 346, 358], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 325, 332], ["analysis", "TEST", 458, 466], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Participation in the study or results were not reported to the employer.", [["the study", "TEST", 17, 26]]], ["The study protocol was approved by the HUFA independent ethics research committee (reference number 20/69).", [["The study protocol", "TEST", 0, 18]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprintGeneral descriptionAll 2,919 HCW HUFA were invited to participate in the study between April 14-27, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 325, 332], ["the study", "TEST", 410, 419], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In addition, 51 HCW (1.8%) refused consent to use their data for investigational purposes and were removed from the analysis.", [["investigational purposes", "TEST", 65, 89], ["the analysis", "TEST", 112, 124]]], ["Previous relevant clinical condition was present in 998 HCW (38.5%), distributed as follows: tobacco use 21%, chronic lung disease or asthma 8%, obesity 6.0%, high blood pressure 6.9%, diabetes mellitus 2.1% and other cardiovascular diseases 2.0% (Table 1) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020.", [["lung", "ANATOMY", 118, 122], ["blood", "ANATOMY", 164, 169], ["cardiovascular", "ANATOMY", 218, 232], ["chronic lung disease", "DISEASE", 110, 130], ["asthma", "DISEASE", 134, 140], ["obesity", "DISEASE", 145, 152], ["high blood pressure", "DISEASE", 159, 178], ["diabetes mellitus", "DISEASE", 185, 202], ["cardiovascular diseases", "DISEASE", 218, 241], ["tobacco", "ORGANISM", 93, 100], ["lung", "ORGAN", 118, 122], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["tobacco", "SPECIES", 93, 100], ["Previous relevant clinical condition", "PROBLEM", 0, 36], ["chronic lung disease", "PROBLEM", 110, 130], ["asthma", "PROBLEM", 134, 140], ["obesity", "PROBLEM", 145, 152], ["high blood pressure", "TEST", 159, 178], ["diabetes mellitus", "PROBLEM", 185, 202], ["other cardiovascular diseases", "PROBLEM", 212, 241], ["chronic", "OBSERVATION_MODIFIER", 110, 117], ["lung", "ANATOMY", 118, 122], ["disease", "OBSERVATION", 123, 130], ["asthma", "OBSERVATION", 134, 140], ["cardiovascular", "ANATOMY", 218, 232], ["diseases", "OBSERVATION", 233, 241], ["med", "ANATOMY", 295, 298]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint DISCUSSION This is the first study of the SARS-CoV-2 seroprevalence of all HCW, regardless whether they were or not direct employee of the hospital.", [["CC", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 384, 388], ["SARS-CoV", "SPECIES", 384, 392], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We found a relatively high proportion (30%) of HCW with a positive IgG for SARS-CoV-2.", [["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 75, 85], ["positive IgG", "PROTEIN", 58, 70], ["SARS-CoV", "SPECIES", 75, 83], ["a positive IgG", "PROBLEM", 56, 70], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["relatively", "OBSERVATION_MODIFIER", 11, 21], ["high", "OBSERVATION_MODIFIER", 22, 26]]], ["A recent study from Spanish population showed a national prevalence of 5%, but 11% in Madrid 23 .", [["A recent study", "TEST", 0, 14]]], ["A partial explanation for a higher prevalence at our hospital is the higher exposition to the virus in the city of Alcorc\u00f3n.", [["the virus", "PROBLEM", 90, 99], ["partial", "OBSERVATION_MODIFIER", 2, 9]]], ["Data from Madrid Regional Government shows that Alcorc\u00f3n had a slightly higher incidence of COVID-19 than the region of Madrid 24 .", [["COVID", "TEST", 92, 97]]], ["Furthermore, a recent study from a large hospital in Barcelona showed a prevalence in a sample of HCW of 11.6%, doubling the seroprevalence of the general population 25 , strengthening the notion of hospitals as a places of risk for SARS-Co2 infection among workers.", [["SARS-Co2 infection", "DISEASE", 233, 251], ["SARS-Co2", "SIMPLE_CHEMICAL", 233, 241], ["a recent study", "TEST", 13, 27], ["HCW", "TEST", 98, 101], ["SARS", "PROBLEM", 233, 237], ["Co2 infection", "PROBLEM", 238, 251]]], ["These data suggest a role for nosocomial transmission also for non-clinical workers 27, 28 Regarding clinical workers (all of them direct employees of the hospital), the rate of positive IgG was virtually identical among workers with direct contact with COVID-19-patients and those taking care of non-COVID-19 patients, as it has been reported in other settings 20 .", [["nosocomial transmission", "DISEASE", 30, 53], ["IgG", "GENE_OR_GENE_PRODUCT", 187, 190], ["patients", "ORGANISM", 263, 271], ["patients", "ORGANISM", 310, 318], ["positive IgG", "PROTEIN", 178, 190], ["patients", "SPECIES", 263, 271], ["patients", "SPECIES", 310, 318]]], ["Some have proposed that workers with no direct contact with COVID-19 could have been infected in the population (in a context in which the actual seroprevalence in the population was unknown) 20 .", [["COVID-19", "CHEMICAL", 60, 68], ["infected", "OBSERVATION", 85, 93]]], ["Our data argue against it: clinical worker in non-COVID areas become seropositive likely because of in-hospital contact, either from asymptomatic patients or colleagues.(which was not certified by peer review)These data suggest that the non-COVID-19 clinical areas are indeed an unrecognized potential source for COVID-19 infection among workers 27 .", [["infection", "DISEASE", 322, 331], ["patients", "ORGANISM", 146, 154], ["COVID-19", "ORGANISM", 313, 321], ["patients", "SPECIES", 146, 154], ["seropositive", "PROBLEM", 69, 81], ["These data", "TEST", 209, 219], ["the non-COVID-19 clinical areas", "PROBLEM", 233, 264], ["COVID", "TEST", 313, 318], ["seropositive", "OBSERVATION", 69, 81]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint analysis estimates that nosocomial transmission is the source of SARS-CoV-2 infection in about 44% of cases 29 .", [["CC", "CHEMICAL", 0, 2], ["nosocomial transmission", "DISEASE", 366, 389], ["SARS-CoV-2 infection", "DISEASE", 407, 427], ["SARS-CoV-2", "ORGANISM", 407, 417], ["CoV-2", "SPECIES", 412, 417], ["SARS-CoV-2", "SPECIES", 407, 417], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["nosocomial transmission", "PROBLEM", 366, 389], ["SARS", "PROBLEM", 407, 411], ["CoV", "TEST", 412, 415], ["2 infection", "PROBLEM", 416, 427], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["This estimation is further increased up to almost 90% of cases in a mathematical model.", [["This estimation", "TEST", 0, 15], ["increased", "OBSERVATION_MODIFIER", 27, 36]]], ["30 Since universal COVID-19 screening has not been a usual practice implemented it is conceivable that a substantial proportion of so-called non-COVID-19 patients may be actually subclinical or unnoticed COVID-19 cases 31,32 .", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["universal COVID", "TEST", 9, 24]]], ["These data emphasize the need for universal screening of all in-hospital patients as recommend World Health Organisation 34-36 and we are already implementing.(which was not certified by peer review)A similar proportion of seropositivity among clinicians taking direct care of COVID-19 patients suggest that the isolation protocols and PPE appear sufficient to prevent high levels of nosocomial transmission in our setting 13, 37 .", [["nosocomial transmission", "DISEASE", 384, 407], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 286, 294], ["universal screening", "TEST", 34, 53], ["the isolation protocols", "TREATMENT", 308, 331], ["PPE", "TREATMENT", 336, 339]]], ["Of note, critical care workers had one of the lowest seropositivity rates in our study.", [["our study", "TEST", 77, 86]]], ["Indeed, our hospital prioritized the use of the best available PPE for critical care units, where virtually all patients were COVID-19 at the peak of the epidemic 38 .(which was not certified by peer review)The clinical spectrum of COVID-19 in our workers resembles that described for the general population: about half of them are asymptomatic or paucisymptomatic [39] [40] [41] [42] [43] and less than 60% had fever (figure 3).", [["COVID-19", "CHEMICAL", 232, 240], ["fever", "DISEASE", 412, 417], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["COVID", "TEST", 126, 131], ["COVID", "TEST", 232, 237], ["asymptomatic", "PROBLEM", 332, 344], ["paucisymptomatic", "PROBLEM", 348, 364], ["fever", "PROBLEM", 412, 417]]], ["That means that most infected workers remain undetected unless there is a universal screening 44, 45 .", [["workers", "ORGANISM", 30, 37], ["a universal screening", "TEST", 72, 93]]], ["In retrospect, about 50% of seropositive workers attending to the serology study recalled minor symptoms that did not prompt a request for OHU evaluation.", [["workers", "ORGANISM", 41, 48], ["the serology study", "TEST", 62, 80], ["minor symptoms", "PROBLEM", 90, 104], ["OHU evaluation", "TEST", 139, 153]]], ["Thus, only about one fourth of IgG positive workers were fully asymptomatic, as reported in other studies 31, 33 .(which was not certified by peer review)Regarding workers with overt symptoms suggesting COVID-19 disease most of them (83%) had a mild disease that could be managed in the outpatient setting.", [["IgG", "GENE_OR_GENE_PRODUCT", 31, 34], ["IgG", "PROTEIN", 31, 34], ["overt symptoms", "PROBLEM", 177, 191], ["COVID-19 disease", "PROBLEM", 203, 219], ["a mild disease", "PROBLEM", 243, 257], ["mild", "OBSERVATION_MODIFIER", 245, 249], ["disease", "OBSERVATION", 250, 257]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint 6% required ER visit and 3% required hospital admission.", [["CC", "CHEMICAL", 0, 2], ["ER", "GENE_OR_GENE_PRODUCT", 354, 356], ["ER", "PROTEIN", 354, 356], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 325, 341], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["There were no deaths.", [["deaths", "DISEASE", 14, 20], ["deaths", "PROBLEM", 14, 20], ["no", "UNCERTAINTY", 11, 13]]], ["This is hardly surprisingly since there is no elder population among active workers 10 .(which was not certified by peer review)To prevent nosocomial transmission both patients and health care workers should be screened for SARS-CoV-2 infection regardless of the absence of typical symptoms for COVID-19 disease 45 as asymptomatic transmission is being increasing recognized as very relevant in SARS-CoV-2 spread.", [["SARS-CoV-2 infection", "DISEASE", 224, 244], ["SARS", "DISEASE", 395, 399], ["patients", "ORGANISM", 168, 176], ["SARS-CoV-2", "ORGANISM", 224, 234], ["SARS-CoV-2", "ORGANISM", 395, 405], ["patients", "SPECIES", 168, 176], ["SARS-CoV-2", "SPECIES", 224, 234], ["SARS-CoV", "SPECIES", 395, 403], ["SARS", "PROBLEM", 224, 228], ["CoV", "PROBLEM", 229, 232], ["2 infection", "PROBLEM", 233, 244], ["typical symptoms", "PROBLEM", 274, 290], ["COVID-19 disease", "PROBLEM", 295, 311], ["asymptomatic transmission", "PROBLEM", 318, 343], ["SARS", "PROBLEM", 395, 399], ["no", "UNCERTAINTY", 43, 45]]], ["9, 27, 46 .(which was not certified by peer review)Our study has some limitations that deserve consideration.", [["Our study", "TEST", 51, 60]]], ["First, we do not have data about Ig M or concurrent PCR.", [["Ig M", "GENE_OR_GENE_PRODUCT", 33, 37], ["Ig M", "TREATMENT", 33, 37], ["concurrent PCR", "PROBLEM", 41, 55]]], ["However, our study was designed to have a picture of past exposure to the virus in all our workers.", [["our study", "TEST", 9, 18], ["the virus", "PROBLEM", 70, 79]]], ["We did not pursue an evolutionary perspective of the disease.", [["the disease", "PROBLEM", 49, 60], ["disease", "OBSERVATION", 53, 60]]], ["Second, the samples were collected over two weeks, so the interpretation of the prevalence must be related to the average prevalence at that time.(which was not certified by peer review)Nonetheless, our work has several strengths.", [["samples", "ANATOMY", 12, 19], ["the samples", "TEST", 8, 19]]], ["First, the quality of the technology we had used seems to be one of the highest sensitivities available (ELISA) [47] [48] [49] .(which was not certified by peer review)Second, we had a virtually universal representation of all workers of the hospital (90%), including external employees, an evaluation hardly performed.", [["an evaluation", "TEST", 288, 301]]], ["Additionally, we identified the particular function of all employees in a time of changing roles for clinicians in the middle of the crisis.", [["crisis", "OBSERVATION", 133, 139]]], ["In addition, its close temporal vicinity with the serologic study in the Spanish population allows for a direct comparison.(which was not certified by peer review)In conclusion, seroprevalence unmasked a high rate of infection previously unnoticed in HCW.", [["infection", "DISEASE", 217, 226], ["the serologic study", "TEST", 46, 65], ["a direct comparison", "TEST", 103, 122], ["a high rate of infection", "PROBLEM", 202, 226], ["infection", "OBSERVATION", 217, 226]]], ["Clinical care of COVID-19 unscreened patients is associated with a similar prevalence of SARS-CoV-2 antibodies as the one found in COVID-19 facilities uncovering a relevant source for nosocomial SARS-CoV-2 transmission.", [["SARS", "DISEASE", 89, 93], ["SARS", "DISEASE", 195, 199], ["patients", "ORGANISM", 37, 45], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 89, 110], ["CoV-2", "ORGANISM", 200, 205], ["SARS-CoV-2 antibodies", "PROTEIN", 89, 110], ["patients", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 89, 97], ["COVID", "TEST", 17, 22], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["nosocomial SARS", "PROBLEM", 184, 199]]], ["In addition, apparently healthy HCW may also be another relevant source for SARS-CoV-2 transmission.", [["SARS", "DISEASE", 76, 80], ["HCW", "ORGANISM", 32, 35], ["CoV-2", "ORGANISM", 81, 86], ["SARS-CoV", "SPECIES", 76, 84], ["SARS", "PROBLEM", 76, 80]]], ["HCW testing could reduce in-hospital transmission 50 .", [["HCW testing", "TEST", 0, 11]]], ["Serosurveys in hospitals may be helpful to design strategies to control SARS-CoV-2 epidemic.(which was not certified by peer review).", [["SARS", "DISEASE", 72, 76], ["SARS-CoV-2", "ORGANISM", 72, 82], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["epidemic", "PROBLEM", 83, 91]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprintAcknowledgmentWe thank all workers of the Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, who bravely and generously faced the COVID-19 epidemic during the months of March and April for their everyday work and cooperation in this study.Acknowledgment.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["this study", "TEST", 561, 571], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint SUPPLEMENT 1(which was not certified by peer review)Previous health conditions: tobacco use, hypertension, obesity, cardiovascular disease, chronic liver disease, chronic lung disease or asthma, chronic renal failure, immunodeficiency, or pregnancy.(which was not certified by peer review)COVID-19 related symptoms: fever, myalgia, cough, sputum, dyspnea, rhinorrhea, sore throat, diarrhea, anosmia/hyposmia, ageusia/dysgeusia, asthenia, chest pain, headache, syncope, others), SARS-CoV-2 PCR test result as well as the severity of disease when appropriate (out-patient evaluation, ER consultation, hospital admission and clinical outcome.(which was not certified by peer review).", [["cardiovascular", "ANATOMY", 458, 472], ["liver", "ANATOMY", 490, 495], ["lung", "ANATOMY", 513, 517], ["renal", "ANATOMY", 545, 550], ["sputum", "ANATOMY", 681, 687], ["chest", "ANATOMY", 780, 785], ["CC", "CHEMICAL", 0, 2], ["hypertension", "DISEASE", 435, 447], ["obesity", "DISEASE", 449, 456], ["cardiovascular disease", "DISEASE", 458, 480], ["chronic liver disease", "DISEASE", 482, 503], ["chronic lung disease", "DISEASE", 505, 525], ["asthma", "DISEASE", 529, 535], ["chronic renal failure", "DISEASE", 537, 558], ["immunodeficiency", "DISEASE", 560, 576], ["fever", "DISEASE", 658, 663], ["myalgia", "DISEASE", 665, 672], ["cough", "DISEASE", 674, 679], ["dyspnea", "DISEASE", 689, 696], ["rhinorrhea", "DISEASE", 698, 708], ["sore throat", "DISEASE", 710, 721], ["diarrhea", "DISEASE", 723, 731], ["anosmia", "DISEASE", 733, 740], ["hyposmia", "DISEASE", 741, 749], ["ageusia", "DISEASE", 751, 758], ["dysgeusia", "DISEASE", 759, 768], ["asthenia", "DISEASE", 770, 778], ["chest pain", "DISEASE", 780, 790], ["headache", "DISEASE", 792, 800], ["syncope", "DISEASE", 802, 809], ["tobacco", "ORGANISM", 422, 429], ["liver", "ORGAN", 490, 495], ["lung", "ORGAN", 513, 517], ["renal", "ORGAN", 545, 550], ["patient", "ORGANISM", 904, 911], ["patient", "SPECIES", 904, 911], ["tobacco", "SPECIES", 422, 429], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint SUPPLEMENT", "TREATMENT", 325, 352], ["hypertension", "PROBLEM", 435, 447], ["obesity", "PROBLEM", 449, 456], ["cardiovascular disease", "PROBLEM", 458, 480], ["chronic liver disease", "PROBLEM", 482, 503], ["chronic lung disease", "PROBLEM", 505, 525], ["asthma", "PROBLEM", 529, 535], ["chronic renal failure", "PROBLEM", 537, 558], ["immunodeficiency", "PROBLEM", 560, 576], ["pregnancy", "PROBLEM", 581, 590], ["COVID", "TEST", 631, 636], ["symptoms", "PROBLEM", 648, 656], ["fever", "PROBLEM", 658, 663], ["myalgia", "PROBLEM", 665, 672], ["cough", "PROBLEM", 674, 679], ["sputum", "PROBLEM", 681, 687], ["dyspnea", "PROBLEM", 689, 696], ["rhinorrhea", "PROBLEM", 698, 708], ["sore throat", "PROBLEM", 710, 721], ["diarrhea", "PROBLEM", 723, 731], ["anosmia", "PROBLEM", 733, 740], ["hyposmia", "PROBLEM", 741, 749], ["ageusia", "PROBLEM", 751, 758], ["dysgeusia", "PROBLEM", 759, 768], ["asthenia", "PROBLEM", 770, 778], ["chest pain", "PROBLEM", 780, 790], ["headache", "PROBLEM", 792, 800], ["syncope", "PROBLEM", 802, 809], ["SARS", "PROBLEM", 820, 824], ["CoV-2 PCR test", "TEST", 825, 839], ["disease", "PROBLEM", 874, 881], ["patient evaluation", "TEST", 904, 922], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["hypertension", "OBSERVATION", 435, 447], ["obesity", "OBSERVATION", 449, 456], ["cardiovascular", "ANATOMY", 458, 472], ["disease", "OBSERVATION", 473, 480], ["chronic", "OBSERVATION_MODIFIER", 482, 489], ["liver", "ANATOMY", 490, 495], ["disease", "OBSERVATION", 496, 503], ["chronic", "OBSERVATION_MODIFIER", 505, 512], ["lung", "ANATOMY", 513, 517], ["disease", "OBSERVATION", 518, 525], ["asthma", "OBSERVATION", 529, 535], ["chronic", "OBSERVATION_MODIFIER", 537, 544], ["renal", "ANATOMY", 545, 550], ["failure", "OBSERVATION", 551, 558], ["immunodeficiency", "OBSERVATION", 560, 576], ["rhinorrhea", "OBSERVATION", 698, 708], ["sore throat", "ANATOMY", 710, 721], ["chest", "ANATOMY", 780, 785], ["disease", "OBSERVATION", 874, 881]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprintSUPPLEMENT 2We measured serum IgG antibody by an enzyme-linked immunosorbent assay (ELISA) IgG2 using a SARS-CoV-2 S spike and Nucleocapsid recombinant antigens (Diapro (Palex), Italy), to screen for the presence of human anti-SARS-CoV-2 IgG.SUPPLEMENT 2This assay (CE approved) was used according to the manufacturer's protocol.SUPPLEMENT 2Reported sensitivity of the assay by the manufacturer was 98%.SUPPLEMENT 2The results of the tested samples were determined by calculating the ratio of the optical density (OD) value of the sample to the OD value of the cut-off.", [["serum", "ANATOMY", 365, 370], ["samples", "ANATOMY", 782, 789], ["CC", "CHEMICAL", 0, 2], ["serum", "ORGANISM_SUBSTANCE", 365, 370], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 371, 383], ["IgG2", "GENE_OR_GENE_PRODUCT", 432, 436], ["human", "ORGANISM", 557, 562], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 563, 582], ["serum IgG antibody", "PROTEIN", 365, 383], ["IgG2", "PROTEIN", 432, 436], ["SARS-CoV-2 S spike and Nucleocapsid recombinant antigens", "PROTEIN", 445, 501], ["Palex", "PROTEIN", 511, 516], ["human anti-SARS-CoV-2 IgG", "PROTEIN", 557, 582], ["human", "SPECIES", 557, 562], ["human", "SPECIES", 557, 562], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprintSUPPLEMENT", "TREATMENT", 325, 351], ["serum IgG antibody", "TEST", 365, 383], ["an enzyme", "TEST", 387, 396], ["immunosorbent assay", "TEST", 404, 423], ["ELISA", "TEST", 425, 430], ["IgG2", "TEST", 432, 436], ["a SARS", "TEST", 443, 449], ["CoV", "TEST", 450, 453], ["spike", "PROBLEM", 458, 463], ["Nucleocapsid recombinant antigens (Diapro (Palex)", "TREATMENT", 468, 517], ["human anti-SARS", "TEST", 557, 572], ["CoV", "TEST", 573, 576], ["the manufacturer's protocol", "TREATMENT", 642, 669], ["the assay", "TEST", 706, 715], ["the tested samples", "TEST", 771, 789], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["optical density", "OBSERVATION", 838, 853]]], ["(Co) Ratios \u2265 1.1 were considered positive, ratios \u2265 0.9 to < 1.1 were considered borderline, and ratios < 0.9 were considered negative.", [["Co) Ratios \u2265", "TEST", 1, 13], ["ratios", "TEST", 44, 50], ["ratios", "TEST", 98, 104]]], ["All assays were run following manufacter\u00b4s instructions on the platforms DSX System ( Palex Medical SA) and Triturus ( Grifols Movaco SA).SUPPLEMENT 2Sensitivity of the assay using samples from 337 workers from our series with results previous positive PCR was 90.8% (manufacture shows 98%).", [["samples", "ANATOMY", 181, 188], ["All assays", "TEST", 0, 10], ["previous positive PCR", "TEST", 235, 256]]], ["Specificity manufacture's instructions shows that the assay was tested on hundreds of samples collected before the outbreak of COVID-19.", [["samples", "ANATOMY", 86, 93], ["the assay", "TEST", 50, 59], ["COVID", "TEST", 127, 132]]], ["A value of >90% was found.SUPPLEMENT 2Index values considered \"borderline\" were tested on Strips-module Enzyme Immunoassay for the confirmation of IgG antibodies to COVID-19-19 major antigens.SUPPLEMENT 2This assay detects IgG antibodies against the SARS-CoV-2: Spike glycoprotein 1, Spike glycoprotein 2 and nucleocapside proteins.", [["IgG antibodies", "GENE_OR_GENE_PRODUCT", 223, 237], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 250, 260], ["Spike glycoprotein 1", "GENE_OR_GENE_PRODUCT", 262, 282], ["Spike glycoprotein 2", "GENE_OR_GENE_PRODUCT", 284, 304], ["nucleocapside", "GENE_OR_GENE_PRODUCT", 309, 322], ["IgG antibodies", "PROTEIN", 147, 161], ["COVID-19-19 major antigens", "PROTEIN", 165, 191], ["IgG antibodies", "PROTEIN", 223, 237], ["SARS-CoV-2: Spike glycoprotein 1", "PROTEIN", 250, 282], ["Spike glycoprotein 2", "PROTEIN", 284, 304], ["nucleocapside proteins", "PROTEIN", 309, 331], ["SARS-CoV", "SPECIES", 250, 258], ["A value", "TEST", 0, 7], ["SUPPLEMENT 2Index values", "TEST", 26, 50], ["borderline\"", "PROBLEM", 63, 74], ["Strips", "TEST", 90, 96], ["module Enzyme Immunoassay", "TEST", 97, 122], ["the confirmation", "TEST", 127, 143], ["IgG antibodies", "TEST", 147, 161], ["COVID", "TEST", 165, 170], ["This assay", "TEST", 204, 214], ["IgG antibodies", "TEST", 223, 237], ["the SARS", "TEST", 246, 254], ["CoV", "TEST", 255, 258], ["Spike glycoprotein", "PROBLEM", 262, 280], ["Spike glycoprotein", "TEST", 284, 302], ["nucleocapside proteins", "TREATMENT", 309, 331]]], ["A sample is considered for a certain antibody negative S/Co<1, equivocal 1< S/Co<1.2, positive S/Co>1.2.", [["Co", "CHEMICAL", 97, 99], ["A sample", "TEST", 0, 8], ["a certain antibody", "TEST", 27, 45], ["S/Co", "TEST", 76, 80], ["Co", "TEST", 97, 99]]], ["These samples were run on the platform DSX System ( Palex Medical SA).", [["samples", "ANATOMY", 6, 13], ["These samples", "TEST", 0, 13]]], ["The manufacter\u00b4s instructions shows that the assay was tested on hundreds of samples collected before the outbreak of COVID- .", [["samples", "ANATOMY", 77, 84], ["the assay", "TEST", 41, 50]]], ["A value of >98% was found.", [["A value", "TEST", 0, 7]]], ["About 2% of the reactive \"normal\" population shows a reactivity to Nucleocapsid.", [["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 67, 79], ["Nucleocapsid", "PROTEIN", 67, 79], ["a reactivity to Nucleocapsid", "PROBLEM", 51, 79], ["reactive", "OBSERVATION_MODIFIER", 16, 24]]], ["A first minimum study carried .", [["A first minimum study", "TEST", 0, 21]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint Table 2 .(which was not certified by peer review)Univariate logistic regression Multivariate logistic regression (model 1)(which was not certified by peer review)Multivariate logistic regression (model 2) Figure 1 .(which was not certified by peer review).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 366, 382], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "CHEMICAL", 383, 385], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 488, 491]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.29.20116731 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 366, 373], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "52b6207a0e10220b8e47ec4d00fa5a711560ac68": [["Systematic testing for Bordetella pertussis in young infants with lower respiratory tract infections (LRTIs) has been suggested, because the early clinical characteristics are difficult to recognise and distinguish from viral infections (1) .", [["lower respiratory tract", "ANATOMY", 66, 89], ["Bordetella pertussis", "DISEASE", 23, 43], ["lower respiratory tract infections", "DISEASE", 66, 100], ["LRTIs", "DISEASE", 102, 107], ["viral infections", "DISEASE", 220, 236], ["Bordetella pertussis", "ORGANISM", 23, 43], ["infants", "ORGANISM", 53, 60], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 66, 89], ["Bordetella pertussis", "SPECIES", 23, 43], ["infants", "SPECIES", 53, 60], ["Bordetella pertussis", "SPECIES", 23, 43], ["Systematic testing", "TEST", 0, 18], ["Bordetella pertussis", "PROBLEM", 23, 43], ["lower respiratory tract infections", "PROBLEM", 66, 100], ["viral infections", "PROBLEM", 220, 236], ["lower", "ANATOMY_MODIFIER", 66, 71], ["respiratory tract", "ANATOMY", 72, 89], ["infections", "OBSERVATION", 90, 100], ["viral", "OBSERVATION_MODIFIER", 220, 225], ["infections", "OBSERVATION", 226, 236]]], ["Chlamydia trachomatis, a sexually transmitted disease passed on during birth, is also important (2, 3) .", [["Chlamydia trachomatis", "DISEASE", 0, 21], ["sexually transmitted disease", "DISEASE", 25, 53], ["Chlamydia trachomatis", "ORGANISM", 0, 21], ["Chlamydia trachomatis", "SPECIES", 0, 21], ["Chlamydia trachomatis", "SPECIES", 0, 21], ["Chlamydia trachomatis", "PROBLEM", 0, 21], ["a sexually transmitted disease", "PROBLEM", 23, 53], ["trachomatis", "OBSERVATION", 10, 21]]], ["Recently, multiplex polymerase chain reaction (PCR) panels that include other respiratory bacteria have been implemented in clinical practice.", [["multiplex polymerase chain reaction", "PROBLEM", 10, 45], ["PCR) panels", "TEST", 47, 58], ["other respiratory bacteria", "PROBLEM", 72, 98], ["respiratory bacteria", "OBSERVATION", 78, 98]]], ["Several studies have indicated that the atypical pathogens Mycoplasma pneumoniae and Chlamydia pneumoniae can cause community-acquired LRTIs in older children (4, 5) , but their role in young infants remains largely unknown.", [["Mycoplasma pneumoniae", "DISEASE", 59, 80], ["Chlamydia pneumoniae", "DISEASE", 85, 105], ["LRTIs", "DISEASE", 135, 140], ["Mycoplasma pneumoniae", "ORGANISM", 59, 80], ["Chlamydia pneumoniae", "ORGANISM", 85, 105], ["children", "ORGANISM", 150, 158], ["infants", "ORGANISM", 192, 199], ["Mycoplasma pneumoniae", "SPECIES", 59, 80], ["Chlamydia pneumoniae", "SPECIES", 85, 105], ["children", "SPECIES", 150, 158], ["infants", "SPECIES", 192, 199], ["Mycoplasma pneumoniae", "SPECIES", 59, 80], ["Chlamydia pneumoniae", "SPECIES", 85, 105], ["Several studies", "TEST", 0, 15], ["the atypical pathogens Mycoplasma pneumoniae", "PROBLEM", 36, 80], ["Chlamydia pneumoniae", "PROBLEM", 85, 105], ["atypical", "OBSERVATION_MODIFIER", 40, 48], ["pathogens", "OBSERVATION_MODIFIER", 49, 58], ["Mycoplasma pneumoniae", "OBSERVATION", 59, 80], ["LRTIs", "OBSERVATION", 135, 140]]]], "PMC7365411": [["In response to the protracted Ebola virus outbreak in the Democratic Republic of Congo, the international public health community called for increased attention, coordination, and resources to support the response.", [["Ebola virus", "DISEASE", 30, 41], ["Ebola virus", "ORGANISM", 30, 41], ["Ebola virus", "SPECIES", 30, 41], ["Ebola virus", "SPECIES", 30, 41], ["the protracted Ebola virus", "PROBLEM", 15, 41], ["protracted", "OBSERVATION_MODIFIER", 19, 29], ["Ebola virus", "OBSERVATION", 30, 41]]], ["Despite the informative role that infectious disease models played in the recent DRC outbreak [4\u20137], cross-talk within the infectious disease modeling community and between infectious disease modelers and model stakeholders, such as health agencies, may be limited.", [["infectious disease", "DISEASE", 34, 52], ["infectious disease", "DISEASE", 123, 141], ["infectious disease modelers", "DISEASE", 173, 200], ["infectious disease models", "PROBLEM", 34, 59], ["infectious disease modelers", "PROBLEM", 173, 200], ["infectious", "OBSERVATION", 34, 44], ["infectious", "OBSERVATION", 123, 133], ["infectious", "OBSERVATION_MODIFIER", 173, 183]]], ["Lack of communication can reduce the potential use of modeling capability to inform outbreak prevention and mitigation strategies.", [["modeling capability", "TREATMENT", 54, 73], ["outbreak prevention", "TREATMENT", 84, 103], ["mitigation strategies", "TREATMENT", 108, 129]]], ["For example, mathematical modelers may not be aware of questions that would be particularly useful for guiding the response, such as the location and staffing of Ebola treatment units.", [["Ebola", "DISEASE", 162, 167], ["Ebola", "ORGANISM", 162, 167], ["Ebola treatment units", "TREATMENT", 162, 183]]], ["On the other end, public health teams may not be aware of outbreak features that may signal improvement or worsening of incidence or increased potential for spatial spread.", [["spatial spread", "PROBLEM", 157, 171], ["worsening", "OBSERVATION_MODIFIER", 107, 116], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["spatial spread", "OBSERVATION", 157, 171]]]], "PMC7193021": [["IntroductionThe severe acute respiratory coronavirus disease 2019 (COVID-19) disease has been declared as the second pandemic disease of the twenty-century, after the A/H1N1 pandemic in 2009 (1).", [["acute respiratory coronavirus disease", "DISEASE", 23, 60], ["COVID-19) disease", "DISEASE", 67, 84], ["severe acute respiratory coronavirus disease 2019 (COVID-19", "SPECIES", 16, 75], ["A/H1N1 pandemic", "SPECIES", 167, 182], ["The severe acute respiratory coronavirus disease", "PROBLEM", 12, 60], ["COVID", "TEST", 67, 72], ["disease", "PROBLEM", 77, 84], ["the second pandemic disease", "PROBLEM", 106, 133], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory coronavirus disease", "OBSERVATION", 29, 60]]], ["COVID-19 is a complex human viral infectious disease caused by an RNA virus (genus Betacoronavirus), named SARS-CoV-2 due to its 82% similarity with the SARS coronavirus (SARS-CoV) (2, 3).", [["COVID-19", "CHEMICAL", 0, 8], ["viral infectious disease", "DISEASE", 28, 52], ["SARS coronavirus", "DISEASE", 153, 169], ["SARS", "DISEASE", 171, 175], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 22, 27], ["SARS-CoV-2", "ORGANISM", 107, 117], ["SARS coronavirus", "ORGANISM", 153, 169], ["SARS-CoV", "ORGANISM", 171, 179], ["human", "SPECIES", 22, 27], ["COVID-19", "SPECIES", 0, 8], ["human", "SPECIES", 22, 27], ["SARS-CoV", "SPECIES", 107, 115], ["SARS coronavirus", "SPECIES", 153, 169], ["SARS-CoV", "SPECIES", 171, 179], ["COVID", "TEST", 0, 5], ["a complex human viral infectious disease", "PROBLEM", 12, 52], ["an RNA virus", "PROBLEM", 63, 75], ["CoV", "TEST", 112, 115], ["the SARS coronavirus", "PROBLEM", 149, 169], ["viral", "OBSERVATION_MODIFIER", 28, 33], ["infectious", "OBSERVATION", 34, 44], ["RNA virus", "OBSERVATION", 66, 75]]], ["This severe acute respiratory syndrome's common symptoms include: fever, dyspnoea, fatigue, dry cough, and acute respiratory distress syndrome (4).", [["respiratory", "ANATOMY", 113, 124], ["acute respiratory syndrome", "DISEASE", 12, 38], ["fever", "DISEASE", 66, 71], ["dyspnoea", "DISEASE", 73, 81], ["fatigue", "DISEASE", 83, 90], ["dry cough", "DISEASE", 92, 101], ["acute respiratory distress syndrome", "DISEASE", 107, 142], ["This severe acute respiratory syndrome", "PROBLEM", 0, 38], ["common symptoms", "PROBLEM", 41, 56], ["fever", "PROBLEM", 66, 71], ["dyspnoea", "PROBLEM", 73, 81], ["fatigue", "PROBLEM", 83, 90], ["dry cough", "PROBLEM", 92, 101], ["acute respiratory distress syndrome", "PROBLEM", 107, 142], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["respiratory syndrome", "OBSERVATION", 18, 38], ["fever", "OBSERVATION", 66, 71], ["dry", "OBSERVATION_MODIFIER", 92, 95], ["cough", "OBSERVATION", 96, 101], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory distress", "OBSERVATION", 113, 133]]], ["The virus spreads mainly through person-to-person contact via respiratory droplets generated by coughing and sneezing, or even through contaminated surfaces (4, 5).", [["respiratory droplets", "ANATOMY", 62, 82], ["coughing", "DISEASE", 96, 104], ["sneezing", "DISEASE", 109, 117], ["person", "SPECIES", 33, 39], ["person", "SPECIES", 43, 49], ["The virus spreads", "PROBLEM", 0, 17], ["coughing", "PROBLEM", 96, 104], ["sneezing", "PROBLEM", 109, 117], ["virus", "OBSERVATION", 4, 9]]], ["Recent studies based on China showed an increased chance of in-hospital death associated with old age, male sex, and contemporary comorbidities (i.e., hypertension, diabetes, and coronary heart disease) (6\u20138).", [["coronary", "ANATOMY", 179, 187], ["heart", "ANATOMY", 188, 193], ["death", "DISEASE", 72, 77], ["hypertension", "DISEASE", 151, 163], ["diabetes", "DISEASE", 165, 173], ["coronary heart disease", "DISEASE", 179, 201], ["coronary", "MULTI-TISSUE_STRUCTURE", 179, 187], ["heart", "ORGAN", 188, 193], ["Recent studies", "TEST", 0, 14], ["in-hospital death", "PROBLEM", 60, 77], ["contemporary comorbidities", "PROBLEM", 117, 143], ["hypertension", "PROBLEM", 151, 163], ["diabetes", "PROBLEM", 165, 173], ["coronary heart disease)", "PROBLEM", 179, 202], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["hypertension", "OBSERVATION", 151, 163], ["diabetes", "OBSERVATION", 165, 173], ["coronary heart", "ANATOMY", 179, 193], ["disease", "OBSERVATION", 194, 201]]], ["Currently there is no available vaccine or a specific antiviral treatment recommended for COVID-19, so the early diagnosis is fundamental to promptly treat the symptoms (9).", [["available vaccine", "TREATMENT", 22, 39], ["a specific antiviral treatment", "TREATMENT", 43, 73], ["COVID", "TEST", 90, 95], ["the symptoms", "PROBLEM", 156, 168], ["no", "UNCERTAINTY", 19, 21]]], ["Furthermore, since infected patients with respiratory complications related to COVID-19 required hospitalizations in Intensive Care Units (ICU), this may be a crucial issue for the National Healthcare System's capacity (10).", [["respiratory", "ANATOMY", 42, 53], ["respiratory complications", "DISEASE", 42, 67], ["COVID", "DISEASE", 79, 84], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["respiratory complications", "PROBLEM", 42, 67], ["infected", "OBSERVATION_MODIFIER", 19, 27], ["respiratory complications", "OBSERVATION", 42, 67]]], ["The negative impact of this disease on the worldwide economy has been discussed and enormous socio-economic losses have been hypothesized, even more than the SARS epidemic (11).", [["SARS", "DISEASE", 158, 162], ["this disease", "PROBLEM", 23, 35], ["enormous socio-economic losses", "PROBLEM", 84, 114], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["impact", "OBSERVATION_MODIFIER", 13, 19], ["disease", "OBSERVATION", 28, 35], ["enormous", "OBSERVATION_MODIFIER", 84, 92]]], ["Nevertheless, specific economic impact estimation is highly uncertain and seems to be full of gaps, and an accurate estimation could be impossible.", [["specific economic impact estimation", "TEST", 14, 49], ["an accurate estimation", "TEST", 104, 126]]], ["A global macroeconomic analysis demonstrates that even a contained outbreak could significantly impact the economy and greater investment in public health systems will be the only way to avoid economic disasters (14).", [["A global macroeconomic analysis", "TEST", 0, 31], ["global", "OBSERVATION_MODIFIER", 2, 8], ["macroeconomic", "OBSERVATION", 9, 22], ["greater", "OBSERVATION_MODIFIER", 119, 126], ["investment", "OBSERVATION_MODIFIER", 127, 137]]], ["The dramatic evolution of COVID-19 resulted in a severe health scenario in China for the first 3 months of 2020 (15).", [["COVID-19", "CHEMICAL", 26, 34], ["COVID-19", "DNA", 26, 34], ["COVID", "TEST", 26, 31], ["a severe health scenario", "PROBLEM", 47, 71], ["dramatic", "OBSERVATION_MODIFIER", 4, 12], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["health scenario", "OBSERVATION", 56, 71]]], ["From 20th January the disease spread outside China with two cases in Thailand, one in Japan, and one in the Republic of Korea (16).", [["disease", "OBSERVATION", 22, 29]]], ["The first full-blown outbreak in Europe occurred on 22nd February in Italy (17, 18) and subsequently the disease spread all over the continent and worldwide with about one million cases as of 8th April, 2020 (19).", [["the disease spread", "PROBLEM", 101, 119], ["blown outbreak", "OBSERVATION", 15, 29], ["disease", "OBSERVATION", 105, 112], ["spread", "OBSERVATION_MODIFIER", 113, 119]]], ["The total number of cases in Italy continues to increase, exceeding 139,000 people, and the number of people killed by COVID-19 (17,669) outweighs the deaths recorded in China (3,259).", [["COVID-19", "CHEMICAL", 119, 127], ["deaths", "DISEASE", 151, 157], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 76, 82], ["people", "SPECIES", 102, 108], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["Using the same data, in Italy ~5,200 beds in ICU (10) are available and 3,693 patients are already admitted in ICU (18).", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86]]], ["The most affected Italian Region was Lombardy with 53,414 confirmed cases, 9,727 deaths, and 1,257 admitted in ICU (18).", [["deaths", "DISEASE", 81, 87]]], ["Recent studies tried to provide the number of COVID-19 case estimations in different world areas (20).", [["Recent studies", "TEST", 0, 14], ["COVID", "TEST", 46, 51]]], ["The first official predictive model for the Italian disease spread was published a few days after the first disease occurrence (10).", [["the Italian disease spread", "PROBLEM", 40, 66], ["the first disease occurrence", "PROBLEM", 98, 126]]], ["This study assimilates the number of Italian cases increment to an exponential trend and correctly predicted more than 30,000 infectious and 4,000 hospital beds needed during the first 2 weeks of March 2020.", [["This study", "TEST", 0, 10]]], ["The Italian Government put in place extraordinary measures, principally based on limiting contact to contain the virus spread, even before the WHO official declaration of pandemic status on 11th March 2020 (1).", [["extraordinary measures", "TREATMENT", 36, 58], ["the virus spread", "PROBLEM", 109, 125]]], ["Air and sea transport were subject to the same rule with specific involvement of Italian Islands Regions (Sardinia and Sicily).", [["sea transport", "TREATMENT", 8, 21]]], ["From 17th March, in order to strengthen the capacity of the Healthcare System to face the emergency, the Government identified funding to increase ICU beds and for the production of personal protective equipment.", [["ICU beds", "TREATMENT", 147, 155], ["personal protective equipment", "TREATMENT", 182, 211]]], ["In addition, the Italian Ministry of Defense has activated an extraordinary procedure for the recruitment of biologists, physicists, chemists, military doctors, physicians, and nurses (26).", [["an extraordinary procedure", "TREATMENT", 59, 85]]], ["Following the National regulations, considering the particular condition of Sardinian island and the several problems related to potential patients' transport toward other regions, from 14th March 2020 Sardinian Region ordered the closure of air and sea passenger transport (27).", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["Sardinian island", "PROBLEM", 76, 92], ["the closure of air", "TREATMENT", 227, 245], ["air", "OBSERVATION", 242, 245]]], ["Specific protocols have been put in place in the main Sardinian naval ports, aimed to control the COVID-19 spread (28).", [["Specific protocols", "TREATMENT", 0, 18], ["the COVID", "TEST", 94, 103]]], ["After the first SARS-CoV-2 case reported on the 2nd March in the metropolitan area of Cagliari, few cases have been reported all over the island.", [["Cagliari", "ANATOMY", 86, 94]]], ["The first declared outbreak in Sardinia dates back to 15th March in the north of the island (Sassari province) with 35 cases officially reported, when for the first time the intra-hospital contagion involved not only healthcare staff but also patients (28).", [["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 243, 251], ["outbreak", "OBSERVATION_MODIFIER", 19, 27], ["island", "ANATOMY_MODIFIER", 85, 91]]], ["From that time, the disease spread all over the region (29, 30).", [["the disease spread", "PROBLEM", 16, 34], ["disease", "OBSERVATION", 20, 27], ["spread", "OBSERVATION_MODIFIER", 28, 34], ["all", "OBSERVATION_MODIFIER", 35, 38], ["region", "ANATOMY_MODIFIER", 48, 54]]], ["This study aimed to investigate the current COVID-19 epidemiological situation in Sardinia based on official reported data.", [["This study", "TEST", 0, 10], ["the current COVID", "TEST", 32, 49]]], ["Furthermore, a stochastic model has been applied to estimate the transmission parameters and establish the number of SARS-CoV-2 positive, recovered, and deceased people expected.", [["SARS", "DISEASE", 117, 121], ["people", "ORGANISM", 162, 168], ["people", "SPECIES", 162, 168], ["SARS-CoV", "SPECIES", 117, 125], ["a stochastic model", "TREATMENT", 13, 31], ["the transmission parameters", "TEST", 61, 88], ["SARS", "TEST", 117, 121], ["CoV", "TEST", 122, 125]]], ["The present analysis aims to be a valid instrument to help political leaders and health authorities to manage the disease in an island where, if the most appropriate health measures are taken, the epidemic could be more rapidly controlled.Study Area ::: Materials and MethodsSardinia is an Italian island located in the middle of the Mediterranean Sea, with a total area of 24,100 km2, divided into four provinces [Cagliari (Metropolitan city and Sud Sardinia), Oristano, Sassari, and Nuoro], including 377 municipalities (31).", [["a valid instrument", "TREATMENT", 32, 50], ["the disease", "PROBLEM", 110, 121], ["MethodsSardinia", "TREATMENT", 268, 283], ["disease", "OBSERVATION", 114, 121], ["middle", "ANATOMY_MODIFIER", 320, 326], ["Mediterranean Sea", "ANATOMY", 334, 351], ["total", "OBSERVATION_MODIFIER", 360, 365]]], ["Despite being defined as the oldest civilization in Italy, in most of the Sardinian territory a modern and diversified economy coexists with a still intact natural ecosystem.", [["diversified", "OBSERVATION_MODIFIER", 107, 118], ["economy", "OBSERVATION", 119, 126], ["intact", "OBSERVATION", 149, 155], ["natural ecosystem", "OBSERVATION", 156, 173]]], ["Sardinia is one of the least populated regions of Italy (32) (69 inh./km2) and holds the record for the oldest population in Italy and one of the oldest all over the world (33).", [["one of", "OBSERVATION_MODIFIER", 12, 18], ["least", "OBSERVATION_MODIFIER", 23, 28], ["populated", "OBSERVATION", 29, 38]]], ["The last population census performed by Statistic National Italian Institute (ISTAT) showed that Sardinian people have an average age (46.3 years) older than Italy's national level (44.9 years), and an elderly rate of 212% with respect to the Italian rate of 173% (34).", [["people", "ORGANISM", 107, 113], ["people", "SPECIES", 107, 113], ["an elderly rate", "TEST", 199, 214], ["the Italian rate", "TEST", 239, 255]]], ["During the last year, a total of 389,614 people aged \u226565 years were living in Sardinia, over a total population of 1,639,591 inhabitants.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47]]], ["Most of the elderly population lives in Oristano province (elderly rate = 262%), while Sassari is the province with the lowest elderly rate in Sardinia (194.3%), however still higher than the national average (31).", [["higher", "OBSERVATION_MODIFIER", 176, 182]]], ["Cagliari is the most populated province with about 780,000 people (including Sud Sardinia), followed by Sassari (500,000), Nuoro (208,000), and Oristano (197,000).", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["Over the island, a total of 32 hospitals are present with a total of 486 ICU available for COVID-19 emergency (172 in the north and 314 in the south), as reported in the official Sardinian Region strategic plans against COVID-19 (35).Data Collection ::: Materials and MethodsFor the purpose of this work, an ad hoc case report based on Sardinian COVID-19 cases has been set up.", [["COVID-19", "CHEMICAL", 220, 228], ["COVID", "TEST", 91, 96], ["COVID", "TEST", 220, 225], ["Sardinian COVID", "TREATMENT", 336, 351]]], ["Considering a study period between 2nd and 15th March 2020 (1st period), data about province, city, date of reported infection (dd/mm/yyyy), sex (where available), hospitalization (yes/not), exposition, and contagion type (intra-hospital: yes/not), were collected from official sources (29, 30).", [["infection", "DISEASE", 117, 126], ["a study", "TEST", 12, 19], ["infection", "OBSERVATION", 117, 126]]], ["Patients reported as SARS-CoV-2 infected have been classified by way of exposure: \u201cFrom Italian Red Zone\u201d included subjects who arrived in Sardinia from high risk areas (North Italy); \u201c2nd contagious\u2014Red Zone\u201d included subjects living in Sardinia who developed COVID-19 after contact with subjects who arrived from the Italian Red Zone; \u201c2nd contagious\u201d included subjects infected not directly by the Red Zone.", [["SARS-CoV-2 infected", "DISEASE", 21, 40], ["COVID", "DISEASE", 261, 266], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["SARS", "PROBLEM", 21, 25], ["infected", "OBSERVATION", 372, 380]]], ["All Sardinian SARS-CoV-2 positives were laboratory-confirmed by regional accredited laboratories and Istituto Superiore di Sanit\u00e0 (ISS).Seasonal SIRD Model Formulation ::: Materials and MethodsIn order to pursue the main goal of this work, the baseline model used was a typical Susceptible-Infectious-Recovered-Dead (SIRD) model, largely used for the so-called \u201cimmunizing infections\u201d whose properties are well-understood as fitting well to Italian COVID-19 spread (36, 37).", [["SARS", "DISEASE", 14, 18], ["infections", "DISEASE", 373, 383], ["SARS-CoV-2", "ORGANISM", 14, 24], ["SARS-CoV", "SPECIES", 14, 22], ["All Sardinian SARS", "TEST", 0, 18], ["CoV", "TEST", 19, 22], ["Methods", "TREATMENT", 186, 193], ["the so-called \u201cimmunizing infections", "TREATMENT", 347, 383], ["Italian COVID", "TEST", 441, 454], ["Infectious", "OBSERVATION", 290, 300]]], ["Since no vaccine or population immunity is available, the model accounts for only two outcomes: death or recovery.", [["death", "DISEASE", 96, 101], ["vaccine", "TREATMENT", 9, 16], ["death", "PROBLEM", 96, 101]]], ["The all Sardinian population is assumed to be randomly distributed and closer; no births or unrelated deaths are considered.", [["deaths", "DISEASE", 102, 108], ["unrelated deaths", "PROBLEM", 92, 108], ["assumed to be", "UNCERTAINTY", 32, 45]]], ["Applying the SIRD model (Figure 1), at any time t \u2265 0, the susceptible people S(t) moved to the infectious I(t) compartment when they become infected.", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["the SIRD model", "TREATMENT", 9, 23], ["infected", "PROBLEM", 141, 149], ["infectious", "OBSERVATION", 96, 106], ["infected", "OBSERVATION", 141, 149]]], ["After an infectious period, the subjects entered in status of recovered R(t) (successfully immunized) or D(t) disease-induced death.", [["death", "DISEASE", 126, 131], ["D(t) disease", "PROBLEM", 105, 117], ["induced death", "PROBLEM", 118, 131], ["infectious", "OBSERVATION", 9, 19]]], ["At any time, the overall population (N) is described as S(t) + I(t) + R(t) + D(t) = N(t).", [["N", "CHEMICAL", 84, 85]]], ["The state variables change according to a system of differential equations:Seasonal SIRD Model Formulation ::: Materials and MethodsThe infection rate \u03b1 describes the translation from S to I, so the change in population is equal to -\u03b1SI and the transmission process for the non-linear term \u03b1SI is describes as:Seasonal SIRD Model Formulation ::: Materials and MethodsN is the population size, \u03b1N is the number of contacts by the infected per unit time, and the ration SN is the fraction of these contacts.", [["infection", "DISEASE", 136, 145], ["Methods", "TREATMENT", 125, 132], ["The infection rate", "PROBLEM", 132, 150], ["infection", "OBSERVATION", 136, 145], ["size", "OBSERVATION_MODIFIER", 387, 391]]], ["The infected people could die at rate \u03b4, or recover at rate \u03b2.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["infected", "OBSERVATION", 4, 12]]], ["In order to provide a useful instrument to stakeholders, given that the disease is particularly aggressive in elderly patients (38), the amount of the Sardinian population over 60 years who became infected with and died of COVID-19 has been estimated based on Sardinian SIRD models results and tajes into account the infectious rate and lethality by age-classes rate proposed by Istituto Superiore di Sanit\u00e0 (39).", [["COVID-19", "CHEMICAL", 223, 231], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["the disease", "PROBLEM", 68, 79], ["COVID", "TEST", 223, 228], ["lethality", "PROBLEM", 337, 346], ["disease", "OBSERVATION", 72, 79], ["aggressive", "OBSERVATION_MODIFIER", 96, 106], ["infectious", "OBSERVATION", 317, 327]]], ["The models were stochastically implemented in R-software (Version 3.6, R-Foundation for Statistical Computing, Vienna, Austria); \u201cdeSolve\u201d R package was used for implementation and solution of differential equations (40).Model Parameterization and Simulation ::: Materials and MethodsAs underlined by several studies, the main problem of these models is the approximation of the epidemiological parameters (i.e., \u03b1, \u03b2, \u03b4, and R0), since the actual number of infected I(t) people is underestimated or even unknown (20).", [["\u03b1", "GENE_OR_GENE_PRODUCT", 413, 414], ["\u03b2", "GENE_OR_GENE_PRODUCT", 416, 417], ["people", "ORGANISM", 472, 478], ["people", "SPECIES", 472, 478], ["Version", "TEST", 58, 65], ["deSolve\u201d R package", "TREATMENT", 130, 148], ["differential equations", "TEST", 193, 215], ["several studies", "TEST", 301, 316], ["the epidemiological parameters", "TEST", 375, 405], ["main", "OBSERVATION_MODIFIER", 322, 326], ["infected", "OBSERVATION", 458, 466]]], ["Furthermore, it is essential to consider the possible confounding role of different disease control strategies by country, which can make a substantial difference in identifying the real number of infected patients (41\u201344).", [["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["different disease control strategies", "TREATMENT", 74, 110], ["infected", "OBSERVATION_MODIFIER", 197, 205]]], ["In a specific population where all individuals are susceptible to infection, R0 represents the average number of secondary cases generated from the introduction of a single infectious case during the infectiousness period.", [["infection", "DISEASE", 66, 75], ["individuals", "ORGANISM", 35, 46], ["infection", "PROBLEM", 66, 75], ["infection", "OBSERVATION", 66, 75], ["average", "OBSERVATION_MODIFIER", 95, 102], ["number", "OBSERVATION_MODIFIER", 103, 109]]], ["In order to avoid the problem related to R0 classical definition, which strictly depends on \u03b1, \u03b2, \u03b4 rates, the calculation proposed by Anastassopoulou et al. (20), has been applied, considering Sardinian reported cases from 22nd to 29th March 2020.", [["\u03b4", "PROTEIN", 98, 99], ["the problem", "PROBLEM", 18, 29], ["R0 classical definition", "PROBLEM", 41, 64], ["the calculation", "TEST", 107, 122]]], ["Given the limited data on COVID-19 transmission parameters, and considering the recent incursion of the disease in Sardinia which does not allow for an accurate estimation of the recovered subjects (as the diagnostic assessment of the recovered people takes longer than the diagnostic assessment of infection), three methods have been compared to assess \u03b2 and \u03b4.", [["infection", "DISEASE", 299, 308], ["people", "ORGANISM", 245, 251], ["\u03b2", "GENE_OR_GENE_PRODUCT", 354, 355], ["people", "SPECIES", 245, 251], ["COVID", "TEST", 26, 31], ["transmission parameters", "TEST", 35, 58], ["the disease in Sardinia", "PROBLEM", 100, 123], ["the diagnostic assessment", "TEST", 202, 227], ["the diagnostic assessment", "TEST", 270, 295], ["infection", "PROBLEM", 299, 308], ["disease", "OBSERVATION", 104, 111], ["infection", "OBSERVATION", 299, 308]]], ["First, bibliographic research using PubMed database has been carried out.", [["PubMed database", "TEST", 36, 51]]], ["The key words used alone or in combination were \u201cCOVID-19,\u201d \u201cSARS-CoV-2,\u201d \u201ctransmission rate,\u201d \u201cmortality rate,\u201d and \u201cSIR model.\u201d", [["SARS", "DISEASE", 61, 65], ["COVID", "TEST", 49, 54], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["transmission rate", "TEST", 75, 92], ["mortality rate", "TEST", 96, 110]]], ["The beta-PERT distribution (45) has been used to generate the distribution that more closely resembles realistic probability distribution of \u03b2 and \u03b4.", [["beta-PERT", "GENE_OR_GENE_PRODUCT", 4, 13], ["\u03b2", "GENE_OR_GENE_PRODUCT", 141, 142], ["\u03b2", "PROTEIN", 141, 142], ["beta-PERT", "OBSERVATION_MODIFIER", 4, 13]]], ["Monte-Carlo simulation has been applied based beta-PERT parameter estimation, with 50,000 iterations after a burn-in for convergence of 10,000 iterations.", [["Monte-Carlo", "CHEMICAL", 0, 11], ["beta-PERT parameter estimation", "TREATMENT", 46, 76], ["a burn", "TREATMENT", 107, 113]]], ["Estimations proposed by this method were equal to 0.116 (min\u2013max = 0.089\u20130.230) and 0.0012 (min\u2013max = 0.0007\u20130.0015) for recovery and death rate, respectively.", [["death", "DISEASE", 134, 139], ["min\u2013max", "TEST", 92, 99], ["death rate", "TEST", 134, 144]]], ["Furthermore, the computation based on corresponding cumulative functions (20) have been applied for both parameters (\u03b2 = 0.164, 95% CI 0.041\u20130.187) and \u03b4 as 0.059 (95% CI 0.033\u20130.119).", [["CI", "TEST", 132, 134], ["CI", "TEST", 168, 170]]], ["Finally, the rate re-calculation proposed by Baud et al. (44) has been applied on date from the 15th March in Sardinia, showing a recovery rate of 0.154 (95% CI 0.117\u20130.191) and a death rate of 0.001 (95% CI 0.0008\u20130.0012).", [["death", "DISEASE", 180, 185], ["the rate re-calculation", "TEST", 9, 32], ["a recovery rate", "TEST", 128, 143], ["CI", "TEST", 158, 160], ["a death rate", "TEST", 178, 190], ["CI", "TEST", 205, 207]]], ["Two scenarios have been simulated: beta-PERT estimation has been applied for the worst scenario while the re-calculated rates have been used to simulate the best scenario for COVID-19 in Sardinia, considering the Italian Government measures and assuming \u03b1 infection rate halved.", [["infection", "DISEASE", 256, 265], ["beta-PERT estimation", "TREATMENT", 35, 55], ["the re-calculated rates", "TREATMENT", 102, 125], ["COVID", "TEST", 175, 180], ["infection rate", "PROBLEM", 256, 270], ["infection", "OBSERVATION", 256, 265]]], ["For each scenario, the R0 has been estimated based on recovery rate (\u03b2) and fatality rate (\u03b4), as usual for SIRD models (36).", [["recovery rate", "TEST", 54, 67], ["fatality rate", "TEST", 76, 89]]], ["Giving \u03b2 and \u03b4, an infected rate (\u03b1) approximation can be described by g = \u03b1S \u2212 \u03b3, where \u03b3 is the inverse of the mean recovery time in days [i.e., average time considered for infection resolution 14 days, \u03b3 = 1/14 (4)], thus \u03b1 becomes a function of the initial susceptible population.", [["infection", "DISEASE", 175, 184], ["\u03b2", "GENE_OR_GENE_PRODUCT", 7, 8], ["\u03b4", "GENE_OR_GENE_PRODUCT", 13, 14], ["\u03b2 and \u03b4", "PROTEIN", 7, 14], ["\u03b1S", "PROTEIN", 75, 77], ["\u03b3", "PROTEIN", 89, 90], ["infection", "PROBLEM", 175, 184], ["infected", "OBSERVATION", 19, 27], ["infection", "OBSERVATION", 175, 184]]], ["By 15th March in Sardinia a total of 77 infectious people [I(t0) = 77] were reported, two patients had died [D(t0) = 2], and no patients were recovered.", [["people", "ORGANISM", 51, 57], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 128, 136], ["people", "SPECIES", 51, 57], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 128, 136]]], ["The algorithm is run for 100,000 iterations with a burn-in of the first 70,000 iterations.", [["a burn", "PROBLEM", 49, 55]]], ["In order to highlight the number of elderly that could be involved in COVID-19 spread in Sardinia, based on both scenarios estimated and region specific disease infectious rate (by age classes) calculated by Istituto Superiore di Sanit\u00e0 (39), different scenarios have been simulated.", [["region specific disease infectious rate", "PROBLEM", 137, 176]]], ["Considering the lack of data and the absence of specific parameter estimations among elders, the same parameter values of general SIRD models have been used, projecting the specific rates on the estimated infected overall population.", [["general SIRD models", "TREATMENT", 122, 141], ["infected", "OBSERVATION_MODIFIER", 205, 213], ["overall", "OBSERVATION_MODIFIER", 214, 221], ["population", "OBSERVATION_MODIFIER", 222, 232]]], ["Supposing a number of infected subjects, the proportion of infected by age class has been estimated.ResultsAll variables used for the main goal of this work are reported in Table 1, by 1st period, 2nd period, and overall.", [["number", "OBSERVATION_MODIFIER", 12, 18], ["infected", "OBSERVATION", 22, 30], ["infected", "OBSERVATION", 59, 67]]], ["During the time between the first SARS-CoV-2 infection in Sardinia (2nd March) and the outbreak in Sassari (15th March), a total of 77 cases have been officially declared by Sardinian Region.", [["SARS-CoV-2 infection", "DISEASE", 34, 54], ["SARS-CoV-2", "ORGANISM", 34, 44], ["the first SARS-CoV-2 infection", "PROBLEM", 24, 54], ["infection", "OBSERVATION", 45, 54]]], ["For 68 subjects, data about exposure has been collected: 18 have become infected in the North of Italy (coming back from \u201cRed Zone\u201d) or after direct contact with COVID-19 positive people from \u201cRed Zone,\u201d by out-hospital transmission.", [["people", "ORGANISM", 180, 186], ["people", "SPECIES", 180, 186], ["COVID", "TEST", 162, 167], ["infected", "OBSERVATION", 72, 80], ["Zone", "ANATOMY_MODIFIER", 197, 201]]], ["A total of 50 subjects contracted the disease by 2nd contagious exposure, not through direct contact with people from \u201cRed Zone,\u201d and by intra-hospital transmission (65% of the overall contagious).", [["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["the disease", "PROBLEM", 34, 45], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The intra-hospital contagious involved only medical staff until the 15th March when, for the first time, intra-hospital infection involved patients.", [["infection", "DISEASE", 120, 129], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["intra-hospital infection", "PROBLEM", 105, 129], ["infection", "OBSERVATION", 120, 129]]], ["From that time, the number of cases in Sassari province increased dramatically.", [["increased", "OBSERVATION_MODIFIER", 56, 65], ["dramatically", "OBSERVATION_MODIFIER", 66, 78]]], ["On 8th April, data expressed as number of cases \u00d7 10.000 inhabitants, showed a rate of about 23 in Italy, 5.9 in Sardinia, 13.3 in Sassari, with lower rates having been recorded in the other provinces (Figure 2).", [["a rate", "TEST", 77, 83]]], ["In Sardinia 975 subjects have been infected by SARS-CoV-2, of these 112 are recovered with symptoms, 31 are in ICU, and 59 have resulted in death.", [["death", "DISEASE", 140, 145], ["SARS-CoV-2", "ORGANISM", 47, 57], ["SARS-CoV", "SPECIES", 47, 55], ["CoV", "TEST", 52, 55], ["symptoms", "PROBLEM", 91, 99], ["death", "PROBLEM", 140, 145], ["infected", "OBSERVATION_MODIFIER", 35, 43]]], ["In Sassari the amount of cases increased 18 times from the first official outbreak to 8th April.", [["amount", "OBSERVATION_MODIFIER", 15, 21]]], ["As reported in Table 1 and considering the overall data, the number of asymptomatic patients is around 30% and the hospitals (or nursing homes) confirm their critical role as way of spreading contagions between patients (23% of the total).", [["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 211, 219]]], ["The mean reproductive number R0 calculated using the data until 22nd March results in 1.39 (95% CI 1.05\u20131.79) while until 29th March is 1.82 (95% CI 1.51\u20132.01) (Figure 3).", [["the data", "TEST", 49, 57], ["CI", "TEST", 96, 98], ["CI", "TEST", 146, 148], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["reproductive", "OBSERVATION_MODIFIER", 9, 21]]], ["Fitting the worst scenario SIRD model, the R0 has been estimated as 2.23 (95% CI 1.84\u20132.56).", [["CI", "TEST", 78, 80]]], ["Using the estimated parameter, the trend of Sardinian COVID-19 infection showed an expected peak around the 3rd May 2020 and the number of infected individuals [I(t)] is about 130,000.", [["infection", "DISEASE", 63, 72], ["Sardinian COVID-19", "SPECIES", 44, 62], ["Sardinian COVID", "TEST", 44, 59], ["infection", "PROBLEM", 63, 72], ["infected individuals", "PROBLEM", 139, 159], ["infected", "OBSERVATION", 139, 147]]], ["At the same date, the estimated number of recovered and thus immunized people is 325,000, while for 8,300 inhabitants the disease would be fatal (Figure 4A).", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["the disease", "PROBLEM", 118, 129]]], ["The best scenario fitted using the re-calculated rates showed a lower average of R0 equal to 1.54 (95% CI 1.18\u20131.97).", [["the re-calculated rates", "TEST", 31, 54], ["CI", "TEST", 103, 105], ["lower", "OBSERVATION_MODIFIER", 64, 69]]], ["Under the Italian Government quarantine measures, the expected time for the peak should be later (21st May 2020), with a total number of infected people around 11,500, about 50,000 recovered and a reduced number of deaths (1,800) (Figure 4B).", [["deaths", "DISEASE", 215, 221], ["people", "ORGANISM", 146, 152], ["people", "SPECIES", 146, 152], ["infected", "OBSERVATION", 137, 145], ["reduced", "OBSERVATION_MODIFIER", 197, 204]]], ["Figure 5 shows the proportion of elderly people (by four different age classes) that could be involved in COVID-19 infection, based on the two different worst and best scenarios.", [["infection", "DISEASE", 115, 124], ["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["COVID-19 infection", "PROBLEM", 106, 124], ["infection", "OBSERVATION", 115, 124]]], ["During the first peak time (3rd May 2020) a total of 19,000 people 60\u201369 years old, 13,600 people 70\u201379 years old, 11,000 subjects 80\u201389 years old, and about 6,000 people older than 90 years could be infected by COVID-19 (Figure 5A).", [["people", "ORGANISM", 60, 66], ["people", "ORGANISM", 91, 97], ["people", "ORGANISM", 164, 170], ["people", "SPECIES", 60, 66], ["people", "SPECIES", 91, 97], ["people", "SPECIES", 164, 170], ["COVID", "TEST", 212, 217], ["infected", "OBSERVATION", 200, 208]]], ["At the peak time estimated by the best scenario (21st May 2020), respectively, about 520, 370, 300, and 165 subject by the same age classes has been estimated to be infected (Figure 5B).DiscussionConsidering the WHO Strategic and Technical Advisory Group for Infectious Hazards recommendations about COVID-19, several countries based their disease control strategies on a combination of containment and mitigation activities, to delay major surges of patients and reduce the demand for hospital beds, thereby protecting the most at risk categories (i.e., elderly people and those with comorbidities) (47).", [["patients", "ORGANISM", 451, 459], ["people", "ORGANISM", 563, 569], ["patients", "SPECIES", 451, 459], ["people", "SPECIES", 563, 569], ["their disease control strategies", "TREATMENT", 334, 366], ["a combination of containment", "TREATMENT", 370, 398], ["mitigation activities", "TREATMENT", 403, 424], ["hospital beds", "TREATMENT", 486, 499], ["infected", "OBSERVATION", 165, 173]]], ["Instruments on national risk assessment (i.e., definition of infection period, estimated numbers of infected patients, and hospitalization needed) play a fundamental role in designing a correct health program (41).", [["infection", "DISEASE", 61, 70], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["Instruments on national risk assessment", "TEST", 0, 39], ["infection", "PROBLEM", 61, 70], ["infection", "OBSERVATION", 61, 70]]], ["To date no COVID-19 risk assessment is available for Sardinia region, where the disease control could take advantage as it is an island.", [["COVID", "TEST", 11, 16], ["risk assessment", "TEST", 20, 35], ["Sardinia region", "PROBLEM", 53, 68], ["the disease control", "TREATMENT", 76, 95], ["island", "OBSERVATION", 129, 135]]], ["As underlined by several previous studies, the most difficult prediction to make is the number of infected patients at the time of the disease peak (10, 20, 48).", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["several previous studies", "TEST", 17, 41], ["the disease peak", "TEST", 131, 147], ["infected", "OBSERVATION", 98, 106], ["disease", "OBSERVATION", 135, 142]]], ["However, this prediction is of crucial importance to plan appropriate COVID-19 management programs and to calculate the time period at which additional health resources are needed.", [["appropriate COVID-19 management programs", "TREATMENT", 58, 98]]], ["The present study partially contributes to fill the gaps identified by Bedford et al., based on the WHO national risk assessment about the need to better define the period of infectiousness and transmissibility and to estimate the reproductive number in different regions and countries (41).", [["The present study", "TEST", 0, 17], ["risk assessment", "TEST", 113, 128], ["infectiousness", "PROBLEM", 175, 189], ["infectiousness", "OBSERVATION", 175, 189], ["reproductive", "OBSERVATION_MODIFIER", 231, 243], ["number", "OBSERVATION_MODIFIER", 244, 250]]], ["Based on the COVID-19 Sardinian cases up to 15th March 2020 we estimated the worst and the best scenarios.", [["the COVID", "TEST", 9, 18]]], ["As expected, changing the parameter estimation (i.e., mortality rate, death rate, and number of contact), the number of expected infected patients, recovered patients, and deceased subjects change drastically, as well as the peak date (20, 36).", [["death", "DISEASE", 70, 75], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 158, 166], ["the parameter estimation", "TEST", 22, 46], ["infected", "OBSERVATION_MODIFIER", 129, 137]]], ["Based on the parameters resulting from available bibliography, the peak of the disease seems to be early (3rd May 2020) compared to the peak assessed based on the Sardinian parameters re-calculated (21st May).", [["available bibliography", "TEST", 39, 61], ["the disease", "PROBLEM", 75, 86], ["the Sardinian parameters", "TEST", 159, 183], ["peak", "OBSERVATION_MODIFIER", 67, 71], ["disease", "OBSERVATION", 79, 86], ["seems to be", "UNCERTAINTY", 87, 98]]], ["At the same time, the number of infected patients changed from 130,000 to 11,500.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["infected", "OBSERVATION", 32, 40]]], ["It must be considered that it is not obvious, and it will be very unlikely to observe these estimated cases as the number of infected patients that will be officially reported.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["infected", "OBSERVATION", 125, 133]]], ["As observed by Li et al. (46), 86% of the total COVID-19 infections within China were unreported (95% CI 82\u201390).", [["infections", "DISEASE", 57, 67], ["the total COVID", "TEST", 38, 53], ["infections", "PROBLEM", 57, 67], ["CI", "TEST", 102, 104], ["infections", "OBSERVATION", 57, 67]]], ["If this assessment were valid in our context, a total of about 18,200 (95% CI 13,000\u201323,400) and 1,610 (95% CI 1,150\u20132,070) cases should be observed, based on the worst and best scenario, at the peak time, respectively.", [["this assessment", "TEST", 3, 18], ["CI", "TEST", 75, 77], ["CI", "TEST", 108, 110]]], ["Considering the last estimation of the Imperial College COVID-19 Response Team, the estimation of infected patients in Italy should be about 9% (95% CI 3.2\u201326) of the total population (42).", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["CI", "TEST", 149, 151], ["the total population", "TEST", 163, 183], ["infected", "OBSERVATION_MODIFIER", 98, 106]]], ["If this assessment is applied on the Sardinian population, a total of 140,000 should be or could become infected.", [["this assessment", "TEST", 3, 18], ["infected", "PROBLEM", 104, 112], ["infected", "OBSERVATION", 104, 112]]], ["Two different methods to calculate/estimate the R0 have been applied.", [["Two different methods", "TREATMENT", 0, 21], ["the R0", "TREATMENT", 44, 50]]], ["Furthermore, the value of R0 calculated in this study is in line with the findings in the last COVID-19 R0 revision performed by Liu et al. (48).", [["this study", "TEST", 43, 53], ["the last COVID-19 R0 revision", "TREATMENT", 86, 115]]], ["Currently, the most common COVID-19 lethality rate assessment is based on the ratio between deaths and infected people.", [["deaths", "DISEASE", 92, 98], ["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118], ["lethality rate assessment", "TEST", 36, 61], ["infected", "OBSERVATION", 103, 111]]], ["According to Ghani et al., this method is accurate only at the end of an epidemic, while it can be misleading if, at the time of the analysis, the result is unknown for a not negligible percentage of patients (49).", [["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["the analysis", "TEST", 129, 141]]], ["Based on an alternative calculation method, Baud et al. (44) published a re-estimation of the COVID-19 mortality rate as the number of deaths on a given day over the number of COVID-19 infected 14 days before.", [["deaths", "DISEASE", 135, 141], ["the COVID", "TEST", 90, 99], ["COVID", "TEST", 176, 181]]], ["The study underlines a mortality rate underestimated by 1.5% (95% CI 1.2\u20131.7) at 1st March 2020, compared to recalculated mortality rate of 15.2% (95% CI 12.5\u201317.9) outside China.", [["The study", "TEST", 0, 9], ["a mortality rate", "TEST", 21, 37], ["CI", "TEST", 66, 68], ["recalculated mortality rate", "TEST", 109, 136], ["CI", "TEST", 151, 153]]], ["Applying this re-calculation on Italian data from 8th April, the observed lethality rate changes from 12.7% (95% CI 12.5\u201312.8) to 23.7% (95% CI 23.4\u201324.1).", [["Italian data", "TEST", 32, 44], ["the observed lethality rate changes", "PROBLEM", 61, 96], ["CI", "TEST", 113, 115], ["CI", "TEST", 141, 143]]], ["Essentially, the authors support the measures applied in Italy and Sardinia to control the SARS-CoV-2 spread, which will certainly soon yield encouraging results.", [["SARS", "DISEASE", 91, 95], ["SARS-CoV", "SPECIES", 91, 99], ["the measures", "TREATMENT", 33, 45], ["Sardinia", "TREATMENT", 67, 75], ["the SARS", "PROBLEM", 87, 95], ["CoV", "PROBLEM", 96, 99]]], ["From early March, the Italian and Sardinian Governments made a great effort to limit as much as possible the amount of contact between people, therefore limiting the contagion.", [["people", "ORGANISM", 135, 141], ["people", "SPECIES", 135, 141]]], ["Several Chinese studies showed that the peak value persistently decreases by reducing contact rate, but may either delay or bring forward the peak by 6.5\u20139 days (min\u2013max = 5\u20139).", [["Several Chinese studies", "TEST", 0, 23], ["the peak value", "TEST", 36, 50]]], ["Since the isolation of people can significantly lower the peak and reduce the cumulative number of predicted reported cases, even in an elderly population (38), the results of the present study can suggest that enforcing the restrictive measures can rapidly improve the situation.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["the present study", "TEST", 176, 193], ["restrictive", "OBSERVATION", 225, 236]]], ["When the disease arrived in Sardinia, the restrictive measures were already in place, thus the peak of the disease could occur later than in the rest of Italy.", [["the disease", "PROBLEM", 5, 16], ["the restrictive measures", "TREATMENT", 38, 62], ["the disease", "PROBLEM", 103, 114], ["disease", "OBSERVATION", 9, 16], ["restrictive", "OBSERVATION_MODIFIER", 42, 53], ["peak", "OBSERVATION_MODIFIER", 95, 99], ["disease", "OBSERVATION", 107, 114]]], ["Furthermore, it is necessary to consider the particularly low population density of Sardinia (69 inh./km2) and that the 27% of elderly people (\u226565 years) live alone and isolated (34).", [["people", "ORGANISM", 135, 141], ["people", "SPECIES", 135, 141]]], ["While in early stages of the epidemic most of the contagions were intra-hospital, to date the spread of the disease in Sardinia seems to be occurring mostly in hospital and nursing homes (23\u201341% of total cases, depending on province) (39, 50).", [["the disease", "PROBLEM", 104, 115], ["disease", "OBSERVATION", 108, 115]]], ["Even if this is dramatic for the at risk categories, an appropriate isolation of these cases could drastically suppress the disease spread.", [["the at risk categories", "PROBLEM", 29, 51], ["the disease spread", "PROBLEM", 120, 138], ["dramatic", "OBSERVATION_MODIFIER", 16, 24], ["disease", "OBSERVATION", 124, 131]]], ["This generates a borderline difference between Italy and Sardinia in the average age of the infected/deceased subjects, which hampered the use of national lethality rates in estimating regional lethality.", [["a borderline difference", "PROBLEM", 15, 38], ["national lethality rates", "PROBLEM", 146, 170], ["estimating regional lethality", "PROBLEM", 174, 203], ["borderline", "OBSERVATION_MODIFIER", 17, 27], ["difference", "OBSERVATION_MODIFIER", 28, 38], ["Sardinia", "OBSERVATION_MODIFIER", 57, 65], ["infected", "OBSERVATION", 92, 100], ["regional lethality", "OBSERVATION", 185, 203]]], ["In Sardinia the median age is 83 years old, while in Italy most of the people who died from Covid-19 were 80 years old (50, 51).", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["Covid", "TEST", 92, 97]]], ["Although the results partly suggest that the current Sardinian situation is more similar to the best scenario than the worst one, it should be kept in mind that only if a policy of highly restrictive measures is maintained, a further reduction of R0 is achieved.", [["a further reduction of R0", "TREATMENT", 224, 249], ["highly", "OBSERVATION_MODIFIER", 181, 187], ["restrictive", "OBSERVATION", 188, 199]]], ["However, several authors consider a long-term disease spread, that may last up to the next 18 months.", [["a long-term disease spread", "PROBLEM", 34, 60], ["long-term", "OBSERVATION_MODIFIER", 36, 45], ["disease", "OBSERVATION", 46, 53]]], ["Given the worldwide economic and social difficulties in maintaining such a high level of restrictions, an adaptive policy needs to be considered: social distancing would only be applied after that confirmed cases admitted in ICU exceeds specific threshold, while this policy will be relaxed when ICU case incidence falls below the threshold.", [["social difficulties", "PROBLEM", 33, 52], ["an adaptive policy", "TREATMENT", 103, 121]]], ["On the contrary, case-based policies of home isolation of symptomatic cases must persist (43).", [["home isolation", "TREATMENT", 40, 54], ["symptomatic cases", "PROBLEM", 58, 75]]], ["Finally, different studies underline that healthcare staff in work environments with a high risk of infection experienced feelings of anxiety and extreme fatigue and that subjects in quarantine felt negative feelings such as anger and stress.", [["infection", "DISEASE", 100, 109], ["anxiety", "DISEASE", 134, 141], ["fatigue", "DISEASE", 154, 161], ["different studies", "TEST", 9, 26], ["infection", "PROBLEM", 100, 109], ["anxiety", "PROBLEM", 134, 141], ["extreme fatigue", "PROBLEM", 146, 161], ["infection", "OBSERVATION", 100, 109]]], ["For this reason, although the treatment of the critical infection consequences and the COVID-19 spread containment is the priority, the psychological impact cannot be underestimated and the possibility of offering psychological online support should be considered (52, 53).ConclusionIn our opinion, in order to effectively manage the pandemic it is essential to promptly implement extraordinary and combined measures.", [["infection", "DISEASE", 56, 65], ["the critical infection consequences", "PROBLEM", 43, 78], ["the COVID-19 spread containment", "TREATMENT", 83, 114], ["psychological online support", "TREATMENT", 214, 242], ["infection", "OBSERVATION", 56, 65]]], ["In this respect, health policy strategies should primarily aim at supporting the healthcare system through the enhancement of both human and instrumental resources and preventing the spread of the infection.", [["infection", "DISEASE", 197, 206], ["human", "ORGANISM", 131, 136], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["health policy strategies", "TREATMENT", 17, 41], ["instrumental resources", "TREATMENT", 141, 163], ["the infection", "PROBLEM", 193, 206], ["infection", "OBSERVATION", 197, 206]]], ["Since data on COVID-19 are collected in real time, day by day, by physicians and health authorities, it is not easy, but it is very important to make use of different tools such as SIRD model or graphics trends, with the identification of possible scenarios, to predict how the disease could evolve.", [["COVID-19", "DNA", 14, 22], ["COVID", "TEST", 14, 19], ["the disease", "PROBLEM", 274, 285], ["disease", "OBSERVATION", 278, 285]]], ["In addition, in order to help healthcare professionals to face the increasing workload and to encourage the population to adhere to extraordinary measures such as quarantine, it is important to consider the psychological impacts and provide the most appropriate information in real time.", [["extraordinary measures", "TREATMENT", 132, 154]]], ["We hope that our analysis will be a useful tool for Sardinian political and health authorities in organizing the most appropriate intervention to better face the pandemic effectively and efficiently.Data Availability StatementPublicly available datasets were analyzed in this study.", [["our analysis", "TEST", 13, 25], ["this study", "TEST", 271, 281]]], ["This data can be found here: opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1.Author ContributionsMP, FL, and OF collected the data, designed the model and the computational framework, analyzed the data, and carried out the implementation.", [["the data", "TEST", 236, 244]]], ["MP, FL, OF, and SC wrote the manuscript with input from all authors.", [["MP", "DISEASE", 0, 2], ["FL", "ANATOMY", 4, 6]]], ["SR and CM supervised all planned work.", [["CM", "DISEASE", 7, 9]]]], "fc5430a2acb6d149d7f636c4da59d3f199fde8fe": [["IntroductionSHFV is a member of the family Arteriviridae that also includes equine arteritis virus (EAV), lactate dehydrogenase-elevating virus (LDV), and porcine reproductive and respiratory syndrome virus (PRRSV) .", [["IntroductionSHFV", "CHEMICAL", 0, 16], ["equine arteritis", "DISEASE", 76, 92], ["lactate", "CHEMICAL", 106, 113], ["porcine reproductive and respiratory syndrome", "DISEASE", 155, 200], ["lactate", "CHEMICAL", 106, 113], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 43, 56], ["equine arteritis virus", "ORGANISM", 76, 98], ["EAV", "ORGANISM", 100, 103], ["lactate dehydrogenase-elevating virus", "ORGANISM", 106, 143], ["LDV", "ORGANISM", 145, 148], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 155, 206], ["PRRSV", "ORGANISM", 208, 213], ["lactate dehydrogenase", "PROTEIN", 106, 127], ["equine arteritis virus", "SPECIES", 76, 98], ["porcine", "SPECIES", 155, 162], ["PRRSV", "SPECIES", 208, 213], ["equine arteritis virus", "SPECIES", 76, 98], ["EAV", "SPECIES", 100, 103], ["LDV", "SPECIES", 145, 148], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 155, 206], ["PRRSV", "SPECIES", 208, 213], ["the family Arteriviridae", "TREATMENT", 32, 56], ["equine arteritis virus", "PROBLEM", 76, 98], ["lactate dehydrogenase", "TEST", 106, 127], ["elevating virus (LDV)", "PROBLEM", 128, 149], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 155, 206], ["arteritis", "OBSERVATION", 83, 92], ["respiratory syndrome", "OBSERVATION", 180, 200]]], ["A related virus, wobbly possum disease virus (WPDV), was recently identified (Dunowska, Biggs et al. 2012) .IntroductionArterivirus genomes are positive-sense, single-stranded, polycistronic RNAs with a 5\u2032 type I cap and a 3\u2032 poly(A) tract (Snijder and Spaan 2006) .", [["wobbly possum disease", "DISEASE", 17, 38], ["wobbly possum disease virus", "ORGANISM", 17, 44], ["Arterivirus", "GENE_OR_GENE_PRODUCT", 120, 131], ["Arterivirus genomes", "DNA", 120, 139], ["polycistronic RNAs", "RNA", 177, 195], ["possum disease virus", "SPECIES", 24, 44], ["wobbly possum disease virus", "SPECIES", 17, 44], ["WPDV", "SPECIES", 46, 50], ["A related virus", "PROBLEM", 0, 15], ["wobbly possum disease virus", "PROBLEM", 17, 44], ["IntroductionArterivirus genomes", "TEST", 108, 139], ["polycistronic RNAs", "TREATMENT", 177, 195], ["a 5\u2032 type I cap", "TREATMENT", 201, 216], ["a 3\u2032 poly(A) tract", "TREATMENT", 221, 239], ["virus", "OBSERVATION", 10, 15], ["possum disease", "OBSERVATION", 24, 38], ["polycistronic RNAs", "OBSERVATION", 177, 195]]], ["Among the arteriviruses, EAV has the shortest genome (12.7 kb) while SHFV has the longest (15.7 kb).", [["arteriviruses", "CANCER", 10, 23], ["SHFV", "DNA", 69, 73], ["EAV", "SPECIES", 25, 28]]], ["The genome organization and replication strategies of arteriviruses are similar to those of coronaviruses.", [["arteriviruses", "CANCER", 54, 67], ["coronaviruses", "ORGANISM", 92, 105], ["replication strategies of arteriviruses", "PROBLEM", 28, 67], ["coronaviruses", "PROBLEM", 92, 105], ["genome organization", "OBSERVATION", 4, 23], ["replication", "OBSERVATION_MODIFIER", 28, 39], ["coronaviruses", "OBSERVATION", 92, 105]]], ["However, arterivirus genomes are about half the size of coronavirus genomes and the virions of the two virus groups also differ in their structural protein compositions, capsid types (coronaviruses-helical and arteriviruses-spherical) and virion sizes.IntroductionArteriviruses infect macrophages (M\u03a6s) and dendritic cells (DCs) and have restricted host ranges; EAV infects horses and donkeys, PRRSV infects pigs, LDV infects mice and SHFV infects non-human primates (NHPs) (Snijder and Meulenberg 1998) .", [["virion", "ANATOMY", 239, 245], ["Arteriviruses", "ANATOMY", 264, 277], ["macrophages", "ANATOMY", 285, 296], ["M\u03a6s", "ANATOMY", 298, 301], ["dendritic cells", "ANATOMY", 307, 322], ["DCs", "ANATOMY", 324, 327], ["coronavirus", "ORGANISM", 56, 67], ["Arteriviruses", "GENE_OR_GENE_PRODUCT", 264, 277], ["macrophages", "CELL", 285, 296], ["M\u03a6s", "CELL", 298, 301], ["dendritic cells", "CELL", 307, 322], ["DCs", "CELL", 324, 327], ["EAV", "ORGANISM", 362, 365], ["horses", "ORGANISM", 374, 380], ["donkeys", "ORGANISM", 385, 392], ["PRRSV", "ORGANISM", 394, 399], ["pigs", "ORGANISM", 408, 412], ["LDV", "ORGANISM", 414, 417], ["mice", "ORGANISM", 426, 430], ["SHFV infects", "ORGANISM", 435, 447], ["non-human primates", "ORGANISM", 448, 466], ["NHPs", "ORGANISM", 468, 472], ["arterivirus genomes", "DNA", 9, 28], ["capsid types", "PROTEIN", 170, 182], ["macrophages", "CELL_TYPE", 285, 296], ["M\u03a6s", "CELL_TYPE", 298, 301], ["dendritic cells", "CELL_TYPE", 307, 322], ["DCs", "CELL_TYPE", 324, 327], ["horses", "SPECIES", 374, 380], ["PRRSV", "SPECIES", 394, 399], ["pigs", "SPECIES", 408, 412], ["mice", "SPECIES", 426, 430], ["EAV", "SPECIES", 362, 365], ["donkeys", "SPECIES", 385, 392], ["PRRSV", "SPECIES", 394, 399], ["pigs", "SPECIES", 408, 412], ["LDV", "SPECIES", 414, 417], ["mice", "SPECIES", 426, 430], ["SHFV", "SPECIES", 435, 439], ["arterivirus genomes", "PROBLEM", 9, 28], ["coronavirus genomes", "PROBLEM", 56, 75], ["coronaviruses", "TEST", 184, 197], ["dendritic cells", "PROBLEM", 307, 322], ["EAV infects horses", "PROBLEM", 362, 380], ["size", "OBSERVATION_MODIFIER", 48, 52], ["coronavirus genomes", "OBSERVATION", 56, 75], ["protein compositions", "OBSERVATION", 148, 168], ["capsid types", "OBSERVATION", 170, 182], ["virion", "OBSERVATION_MODIFIER", 239, 245], ["sizes", "OBSERVATION_MODIFIER", 246, 251], ["dendritic cells", "OBSERVATION", 307, 322], ["host ranges", "OBSERVATION_MODIFIER", 349, 360]]], ["Disease symptoms associated with EAV and PRRSV infections include fever, respiratory disease, tissue necrosis and spontaneous abortions while LDV typically causes asymptomatic, persistent infections (Snijder and Spaan 2006) .", [["respiratory", "ANATOMY", 73, 84], ["tissue", "ANATOMY", 94, 100], ["PRRSV infections", "DISEASE", 41, 57], ["fever", "DISEASE", 66, 71], ["respiratory disease", "DISEASE", 73, 92], ["necrosis", "DISEASE", 101, 109], ["abortions", "DISEASE", 126, 135], ["infections", "DISEASE", 188, 198], ["PRRSV", "ORGANISM", 41, 46], ["tissue", "TISSUE", 94, 100], ["PRRSV", "SPECIES", 41, 46], ["EAV", "SPECIES", 33, 36], ["PRRSV", "SPECIES", 41, 46], ["LDV", "SPECIES", 142, 145], ["Disease symptoms", "PROBLEM", 0, 16], ["EAV", "PROBLEM", 33, 36], ["PRRSV infections", "PROBLEM", 41, 57], ["fever", "PROBLEM", 66, 71], ["respiratory disease", "PROBLEM", 73, 92], ["tissue necrosis", "PROBLEM", 94, 109], ["spontaneous abortions", "PROBLEM", 114, 135], ["LDV", "PROBLEM", 142, 145], ["persistent infections", "PROBLEM", 177, 198], ["respiratory disease", "OBSERVATION", 73, 92], ["tissue", "OBSERVATION_MODIFIER", 94, 100], ["necrosis", "OBSERVATION", 101, 109], ["spontaneous", "OBSERVATION_MODIFIER", 114, 125], ["abortions", "OBSERVATION", 126, 135], ["persistent", "OBSERVATION_MODIFIER", 177, 187], ["infections", "OBSERVATION", 188, 198]]], ["The majority of research on arteriviruses has focused on EAV and PRRSV due to the significant agricultural impact of the diseases they cause.SHFV infections in NHPsSHFV was first isolated in 1964 as the causative agent of hemorrhagic fever outbreaks associated with high mortality in macaque colonies in the United States and the USSR (Allen, Palmer et al. 1968 , Shevtsova 1969 , Lapin and Shevtsova 1971 .", [["infections", "DISEASE", 146, 156], ["NHPsSHFV", "CHEMICAL", 160, 168], ["hemorrhagic fever", "DISEASE", 222, 239], ["arteriviruses", "CANCER", 28, 41], ["EAV", "ORGANISM", 57, 60], ["PRRSV", "ORGANISM", 65, 70], ["SHFV", "GENE_OR_GENE_PRODUCT", 141, 145], ["NHPsSHFV", "CANCER", 160, 168], ["macaque", "ORGANISM", 284, 291], ["EAV", "SPECIES", 57, 60], ["PRRSV", "SPECIES", 65, 70], ["SHFV", "SPECIES", 141, 145], ["NHPsSHFV", "SPECIES", 160, 168], ["EAV", "TREATMENT", 57, 60], ["PRRSV", "TREATMENT", 65, 70], ["the diseases", "PROBLEM", 117, 129], ["SHFV infections", "PROBLEM", 141, 156], ["hemorrhagic fever outbreaks", "PROBLEM", 222, 249], ["high mortality in macaque colonies", "PROBLEM", 266, 300], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["agricultural", "OBSERVATION_MODIFIER", 94, 106], ["impact", "OBSERVATION", 107, 113], ["diseases", "OBSERVATION", 121, 129], ["infections", "OBSERVATION", 146, 156], ["hemorrhagic", "OBSERVATION_MODIFIER", 222, 233]]], ["African monkeys, such as baboons and African green, patas and colobus monkeys, are natural hosts of SHFV and typically develop asymptomatic, persistent infections with low level viremia (London 1977 , Lauck, Hyeroba et al. 2011 , Lauck, Sibley et al. 2013 .", [["infections", "DISEASE", 152, 162], ["low level viremia", "DISEASE", 168, 185], ["monkeys", "ORGANISM", 8, 15], ["baboons", "ORGANISM", 25, 32], ["colobus monkeys", "ORGANISM", 62, 77], ["SHFV", "ORGANISM", 100, 104], ["monkeys", "SPECIES", 8, 15], ["colobus monkeys", "SPECIES", 62, 77], ["African monkeys", "SPECIES", 0, 15], ["colobus monkeys", "SPECIES", 62, 77], ["SHFV", "SPECIES", 100, 104], ["persistent infections", "PROBLEM", 141, 162], ["low level viremia", "PROBLEM", 168, 185], ["persistent", "OBSERVATION_MODIFIER", 141, 151], ["infections", "OBSERVATION", 152, 162]]], ["SHFV-infected macaques develop fever, facial edema, anorexia, dehydration, depression and coagulation defects indicated by skin petechiae, retrobulbar hemorrhages and subcutaneous hematomas.", [["facial", "ANATOMY", 38, 44], ["skin", "ANATOMY", 123, 127], ["retrobulbar", "ANATOMY", 139, 150], ["subcutaneous hematomas", "ANATOMY", 167, 189], ["SHFV-infected", "DISEASE", 0, 13], ["fever", "DISEASE", 31, 36], ["facial edema", "DISEASE", 38, 50], ["anorexia", "DISEASE", 52, 60], ["dehydration", "DISEASE", 62, 73], ["depression", "DISEASE", 75, 85], ["coagulation defects", "DISEASE", 90, 109], ["skin petechiae", "DISEASE", 123, 137], ["retrobulbar hemorrhages", "DISEASE", 139, 162], ["hematomas", "DISEASE", 180, 189], ["SHFV", "ORGANISM", 0, 4], ["macaques", "ORGANISM", 14, 22], ["facial edema", "PATHOLOGICAL_FORMATION", 38, 50], ["skin", "ORGAN", 123, 127], ["retrobulbar hemorrhages", "PATHOLOGICAL_FORMATION", 139, 162], ["macaques", "SPECIES", 14, 22], ["SHFV", "SPECIES", 0, 4], ["fever", "PROBLEM", 31, 36], ["facial edema", "PROBLEM", 38, 50], ["anorexia", "PROBLEM", 52, 60], ["dehydration", "PROBLEM", 62, 73], ["depression", "PROBLEM", 75, 85], ["coagulation defects", "PROBLEM", 90, 109], ["skin petechiae", "PROBLEM", 123, 137], ["retrobulbar hemorrhages", "PROBLEM", 139, 162], ["subcutaneous hematomas", "PROBLEM", 167, 189], ["infected macaques", "OBSERVATION", 5, 22], ["facial", "ANATOMY", 38, 44], ["edema", "OBSERVATION", 45, 50], ["anorexia", "OBSERVATION", 52, 60], ["dehydration", "OBSERVATION", 62, 73], ["coagulation defects", "OBSERVATION", 90, 109], ["skin", "ANATOMY", 123, 127], ["petechiae", "OBSERVATION", 128, 137], ["retrobulbar", "ANATOMY", 139, 150], ["hemorrhages", "OBSERVATION", 151, 162], ["subcutaneous", "ANATOMY", 167, 179], ["hematomas", "OBSERVATION", 180, 189]]], ["Death occurs 7 to 13 days after infection (Allen, Palmer et al. 1968 , London 1977 .", [["Death", "DISEASE", 0, 5], ["infection", "DISEASE", 32, 41], ["Death", "PROBLEM", 0, 5], ["infection", "PROBLEM", 32, 41]]], ["The clinical signs and disease course closely resemble those induced in macaques by other hemorrhagic fever virus infections, such as Ebola Zaire, Marburg, and Lassa (Mahanty and Bray 2004, Bray and Geisbert 2005) .", [["hemorrhagic fever", "DISEASE", 90, 107], ["infections", "DISEASE", 114, 124], ["Ebola Zaire, Marburg, and Lassa", "DISEASE", 134, 165], ["macaques", "ORGANISM", 72, 80], ["hemorrhagic fever virus", "ORGANISM", 90, 113], ["Ebola", "ORGANISM", 134, 139], ["macaques", "SPECIES", 72, 80], ["hemorrhagic fever virus", "SPECIES", 90, 113], ["Ebola Zaire", "SPECIES", 134, 145], ["hemorrhagic fever virus", "SPECIES", 90, 113], ["The clinical signs", "PROBLEM", 0, 18], ["disease course", "PROBLEM", 23, 37], ["other hemorrhagic fever virus infections", "PROBLEM", 84, 124], ["hemorrhagic", "OBSERVATION_MODIFIER", 90, 101]]], ["The presence of persistently infected African NHPs in the NIH primate colony and the use of the same needle for tattooing or tuberculosis testing of multiple NHPs of African and Asian origin are thought to have resulted in inadvertent virus transmission to macaques (Allen, Palmer et al. 1968 ).", [["colony", "ANATOMY", 70, 76], ["tuberculosis", "DISEASE", 125, 137], ["NHPs", "ORGANISM", 46, 50], ["NHPs", "ORGANISM", 158, 162], ["macaques", "ORGANISM", 257, 265], ["the same needle", "TREATMENT", 92, 107], ["tattooing", "TREATMENT", 112, 121], ["tuberculosis testing", "TEST", 125, 145], ["persistently", "OBSERVATION_MODIFIER", 16, 28], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["African NHPs", "OBSERVATION", 38, 50], ["tuberculosis", "OBSERVATION", 125, 137], ["multiple", "OBSERVATION_MODIFIER", 149, 157], ["virus", "OBSERVATION", 235, 240]]], ["SHFV is typically transmitted between African NHPs during fighting but can spread efficiently among macaques by both direct and indirect contact (London 1977 , Renquist 1990 ).SHFV infections in NHPsBased on an unpublished number of test animals, it was previously estimated that 1% of baboons, 1% of African green monkeys and 10% of patas monkeys are SHFV-positive (London 1977) .", [["infections", "DISEASE", 181, 191], ["SHFV", "GENE_OR_GENE_PRODUCT", 0, 4], ["NHPs", "ORGANISM", 46, 50], ["macaques", "ORGANISM", 100, 108], ["baboons", "ORGANISM", 286, 293], ["green monkeys", "ORGANISM", 309, 322], ["patas monkeys", "ORGANISM", 334, 347], ["SHFV", "GENE_OR_GENE_PRODUCT", 352, 356], ["green monkeys", "SPECIES", 309, 322], ["SHFV", "SPECIES", 0, 4], ["SHFV", "SPECIES", 176, 180], ["African green monkeys", "SPECIES", 301, 322], ["patas monkeys", "SPECIES", 334, 347], ["SHFV infections", "PROBLEM", 176, 191], ["baboons", "TEST", 286, 293], ["African green monkeys", "TEST", 301, 322], ["patas monkeys", "TEST", 334, 347], ["SHFV", "TEST", 352, 356], ["infections", "OBSERVATION", 181, 191]]], ["In a recent study, sera/plasma samples from 205 baboons from a US colony were tested for SHFV using two RT-PCR assays targeted to conserved sequence regions .", [["sera", "ANATOMY", 19, 23], ["plasma samples", "ANATOMY", 24, 38], ["colony", "ANATOMY", 66, 72], ["sera", "ORGANISM_SUBSTANCE", 19, 23], ["plasma samples", "ORGANISM_SUBSTANCE", 24, 38], ["baboons", "ORGANISM", 48, 55], ["SHFV", "PROTEIN", 89, 93], ["conserved sequence regions", "DNA", 130, 156], ["SHFV", "SPECIES", 89, 93], ["a recent study", "TEST", 3, 17], ["sera/plasma samples", "TEST", 19, 38], ["a US colony", "TEST", 61, 72], ["SHFV", "TEST", 89, 93], ["two RT-PCR assays", "TEST", 100, 117]]], ["Of the wild-caught Olive baboons tested, 14.2% were positive for SHFV.", [["Olive", "ORGANISM", 19, 24], ["baboons", "ORGANISM", 25, 32], ["SHFV", "GENE_OR_GENE_PRODUCT", 65, 69], ["SHFV", "PROTEIN", 65, 69], ["Olive baboons", "SPECIES", 19, 32], ["SHFV", "SPECIES", 65, 69], ["SHFV", "PROBLEM", 65, 69]]], ["However, because none of the archived sera samples tested were collected at the time of capture, it is not known whether these animals were infected in the wild or after capture.", [["sera samples", "ANATOMY", 38, 50], ["sera", "ORGANISM", 38, 42], ["animals", "ORGANISM", 127, 134], ["the archived sera samples", "TEST", 25, 50], ["infected", "OBSERVATION", 140, 148]]], ["Nineteen percent of the opportunistically sampled animals living in the colony were SHFV-positive.", [["colony", "ANATOMY", 72, 78], ["animals", "ORGANISM", 50, 57], ["SHFV", "GENE_OR_GENE_PRODUCT", 84, 88], ["SHFV", "TEST", 84, 88]]], ["However, because most of the colony animals tested were males that were being treated for lacerations obtained during fighting, the percentage of SHFV-positive animals in the entire colony is expected to be lower.", [["colony", "ANATOMY", 182, 188], ["lacerations", "DISEASE", 90, 101], ["animals", "ORGANISM", 36, 43], ["lacerations", "PATHOLOGICAL_FORMATION", 90, 101], ["SHFV", "GENE_OR_GENE_PRODUCT", 146, 150], ["lacerations", "PROBLEM", 90, 101], ["SHFV", "TEST", 146, 150], ["positive animals in the entire colony", "PROBLEM", 151, 188], ["lacerations", "OBSERVATION", 90, 101], ["positive animals", "OBSERVATION", 151, 167], ["entire", "OBSERVATION_MODIFIER", 175, 181], ["colony", "OBSERVATION", 182, 188]]], ["None of the SHFV positive baboons showed any signs of disease.", [["baboons", "ORGANISM", 26, 33], ["SHFV", "SPECIES", 12, 16], ["the SHFV positive baboons", "TEST", 8, 33], ["disease", "PROBLEM", 54, 61], ["disease", "OBSERVATION", 54, 61]]], ["Infections lasting >10 years were documented using serial archived sera samples and the viremia levels were consistently low (100-1000 PFU/ml).SHFV isolatesThe outcomes of experimental infections of patas monkeys with one of four previous SHFV isolates indicated differences in their biological properties (Gravell, London et al. 1986 ).", [["sera samples", "ANATOMY", 67, 79], ["Infections", "DISEASE", 0, 10], ["viremia", "DISEASE", 88, 95], ["infections", "DISEASE", 185, 195], ["sera", "ORGANISM", 67, 71], ["patas monkeys", "ORGANISM", 199, 212], ["patas monkeys", "SPECIES", 199, 212], ["SHFV", "SPECIES", 143, 147], ["SHFV", "SPECIES", 239, 243], ["Infections", "PROBLEM", 0, 10], ["serial archived sera samples", "TEST", 51, 79], ["the viremia levels", "TEST", 84, 102], ["experimental infections of patas monkeys", "PROBLEM", 172, 212], ["four previous SHFV isolates", "TREATMENT", 225, 252], ["experimental", "OBSERVATION_MODIFIER", 172, 184], ["infections", "OBSERVATION", 185, 195]]], ["LVR was isolated from a stump tail macaque that died of hemorrhagic fever disease ), P-248 was isolated from a feral, persistently infected patas monkey, P-180 was isolated from a patas monkey that died from an SHFV infection, and P741 was isolated from a rhesus macaque that died after inoculation of SHFV from an asymptomatic persistently infected patas monkey.", [["stump tail", "ANATOMY", 24, 34], ["hemorrhagic fever", "DISEASE", 56, 73], ["P-248", "CHEMICAL", 85, 90], ["P-180", "CHEMICAL", 154, 159], ["infection", "DISEASE", 216, 225], ["SHFV", "CHEMICAL", 302, 306], ["LVR", "CANCER", 0, 3], ["macaque", "ORGANISM", 35, 42], ["patas monkey", "ORGANISM", 140, 152], ["P-180", "ORGANISM", 154, 159], ["monkey", "ORGANISM", 186, 192], ["SHFV", "CANCER", 211, 215], ["P741", "GENE_OR_GENE_PRODUCT", 231, 235], ["rhesus", "ORGANISM", 256, 262], ["macaque", "ORGANISM", 263, 270], ["SHFV", "CANCER", 302, 306], ["patas monkey", "ORGANISM", 350, 362], ["patas monkey", "SPECIES", 140, 152], ["rhesus macaque", "SPECIES", 256, 270], ["patas monkey", "SPECIES", 350, 362], ["P-248", "SPECIES", 85, 90], ["patas monkey", "SPECIES", 140, 152], ["P-180", "SPECIES", 154, 159], ["patas monkey", "SPECIES", 180, 192], ["SHFV", "SPECIES", 211, 215], ["rhesus macaque", "SPECIES", 256, 270], ["SHFV", "SPECIES", 302, 306], ["patas monkey", "SPECIES", 350, 362], ["LVR", "TEST", 0, 3], ["a stump tail macaque", "TREATMENT", 22, 42], ["hemorrhagic fever disease", "PROBLEM", 56, 81], ["persistently infected patas monkey", "PROBLEM", 118, 152], ["an SHFV infection", "PROBLEM", 208, 225], ["SHFV", "PROBLEM", 302, 306], ["an asymptomatic persistently infected patas monkey", "PROBLEM", 312, 362], ["stump tail", "OBSERVATION_MODIFIER", 24, 34], ["hemorrhagic", "OBSERVATION_MODIFIER", 56, 67], ["persistently", "OBSERVATION_MODIFIER", 118, 130], ["infected", "OBSERVATION", 131, 139], ["SHFV", "OBSERVATION_MODIFIER", 211, 215], ["infection", "OBSERVATION", 216, 225], ["asymptomatic", "OBSERVATION_MODIFIER", 315, 327], ["persistently", "OBSERVATION_MODIFIER", 328, 340], ["infected", "OBSERVATION", 341, 349], ["patas monkey", "OBSERVATION", 350, 362]]], ["Infection of patas monkeys with two of the isolates (LVR and P-180) produced acute transient clinical signs of hemorrhagic disease with p-180 causing more severe disease that was only rarely fatal.", [["LVR and P-180", "CHEMICAL", 53, 66], ["hemorrhagic disease", "DISEASE", 111, 130], ["p-180", "CHEMICAL", 136, 141], ["patas monkeys", "ORGANISM", 13, 26], ["patas monkeys", "SPECIES", 13, 26], ["Infection of patas monkeys", "PROBLEM", 0, 26], ["the isolates", "TEST", 39, 51], ["LVR", "TEST", 53, 56], ["P", "TEST", 61, 62], ["hemorrhagic disease", "PROBLEM", 111, 130], ["more severe disease", "PROBLEM", 150, 169], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["transient", "OBSERVATION_MODIFIER", 83, 92], ["hemorrhagic", "OBSERVATION_MODIFIER", 111, 122], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["disease", "OBSERVATION", 162, 169]]], ["Infection of patas monkeys with either P-248 or P741 produced asymptomatic, long-term persistent infections.", [["P-248", "CHEMICAL", 39, 44], ["P741", "CHEMICAL", 48, 52], ["infections", "DISEASE", 97, 107], ["patas monkeys", "ORGANISM", 13, 26], ["P741", "SIMPLE_CHEMICAL", 48, 52], ["patas monkeys", "SPECIES", 13, 26], ["P-248", "SPECIES", 39, 44], ["Infection of patas monkeys", "PROBLEM", 0, 26], ["asymptomatic, long-term persistent infections", "PROBLEM", 62, 107], ["long-term", "OBSERVATION_MODIFIER", 76, 85], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["infections", "OBSERVATION", 97, 107]]], ["Acutely infected animals produced high levels of anti-viral antibody while antibody titers in persistently infected animals were low.", [["animals", "ORGANISM", 17, 24], ["anti-viral antibody", "PROTEIN", 49, 68], ["Acutely infected animals", "PROBLEM", 0, 24], ["anti-viral antibody", "TEST", 49, 68], ["antibody titers", "TEST", 75, 90], ["infected", "OBSERVATION", 8, 16], ["high levels", "OBSERVATION_MODIFIER", 34, 45], ["anti-viral antibody", "OBSERVATION", 49, 68], ["low", "OBSERVATION_MODIFIER", 129, 132]]], ["Lytic infections were induced by LVR in MA-104 cells, a rhesus macaque kidney cell line, as well as in both patas and rhesus peritoneal M\u03a6s.", [["MA-104 cells", "ANATOMY", 40, 52], ["kidney cell line", "ANATOMY", 71, 87], ["patas", "ANATOMY", 108, 113], ["peritoneal M\u03a6s", "ANATOMY", 125, 139], ["infections", "DISEASE", 6, 16], ["MA-104 cells", "CELL", 40, 52], ["rhesus", "ORGANISM", 56, 62], ["macaque", "ORGANISM", 63, 70], ["kidney cell line", "CELL", 71, 87], ["rhesus", "ORGANISM", 118, 124], ["peritoneal M\u03a6s", "MULTI-TISSUE_STRUCTURE", 125, 139], ["MA-104 cells", "CELL_LINE", 40, 52], ["rhesus macaque kidney cell line", "CELL_LINE", 56, 87], ["patas and rhesus peritoneal M\u03a6s", "CELL_TYPE", 108, 139], ["rhesus macaque", "SPECIES", 56, 70], ["rhesus macaque", "SPECIES", 56, 70], ["Lytic infections", "PROBLEM", 0, 16], ["LVR in MA", "TEST", 33, 42], ["a rhesus macaque kidney cell line", "TREATMENT", 54, 87], ["infections", "OBSERVATION", 6, 16], ["kidney", "ANATOMY", 71, 77], ["cell line", "OBSERVATION", 78, 87], ["both", "ANATOMY_MODIFIER", 103, 107], ["patas", "ANATOMY_MODIFIER", 108, 113], ["rhesus", "ANATOMY_MODIFIER", 118, 124], ["peritoneal", "ANATOMY", 125, 135]]], ["P-180 could lytically infect both types of M\u03a6s but not MA-104 cells while P-248 and P-741 could lytically infect only rhesus macaque M\u03a6s.", [["M\u03a6s", "ANATOMY", 43, 46], ["MA-104 cells", "ANATOMY", 55, 67], ["M\u03a6s", "ANATOMY", 133, 136], ["P-180", "CHEMICAL", 0, 5], ["P-248 and P-741", "CHEMICAL", 74, 89], ["M\u03a6s", "CELL", 43, 46], ["MA-104 cells", "CELL", 55, 67], ["P-248", "SIMPLE_CHEMICAL", 74, 79], ["P-741", "SIMPLE_CHEMICAL", 84, 89], ["rhesus", "ORGANISM", 118, 124], ["macaque", "ORGANISM", 125, 132], ["M\u03a6s", "CELL", 133, 136], ["P-180", "DNA", 0, 5], ["M\u03a6s", "CELL_TYPE", 43, 46], ["MA-104 cells", "CELL_LINE", 55, 67], ["rhesus macaque", "SPECIES", 118, 132], ["P-741", "SPECIES", 84, 89], ["rhesus macaque", "SPECIES", 118, 132], ["P", "TEST", 0, 1], ["M\u03a6s", "TEST", 43, 46], ["MA", "TEST", 55, 57], ["P", "TEST", 74, 75], ["P", "TEST", 84, 85]]], ["All four of these isolates efficiently induced acute fatal hemorrhagic fever disease in macaques.", [["hemorrhagic fever", "DISEASE", 59, 76], ["macaques", "ORGANISM", 88, 96], ["macaques", "SPECIES", 88, 96], ["acute fatal hemorrhagic fever disease in macaques", "PROBLEM", 47, 96], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["fatal", "OBSERVATION_MODIFIER", 53, 58], ["hemorrhagic", "OBSERVATION_MODIFIER", 59, 70], ["fever", "OBSERVATION", 71, 76]]], ["EAV and PRRSV can also efficiently infect MA104 cells.", [["MA104 cells", "ANATOMY", 42, 53], ["EAV", "ORGANISM", 0, 3], ["PRRSV", "ORGANISM", 8, 13], ["MA104 cells", "CELL", 42, 53], ["MA104 cells", "CELL_LINE", 42, 53], ["EAV", "SPECIES", 0, 3], ["PRRSV", "SPECIES", 8, 13], ["EAV", "PROBLEM", 0, 3], ["PRRSV", "PROBLEM", 8, 13]]], ["The M\u03a6-restricted protein sialoadhesion (CD169) mediates virus attachment and internalization by clathrin-mediated endocytosis of EAV and PRRSV (Van Breedam, Delputte et al. 2010 ).", [["M\u03a6", "GENE_OR_GENE_PRODUCT", 4, 6], ["CD169", "GENE_OR_GENE_PRODUCT", 41, 46], ["clathrin", "GENE_OR_GENE_PRODUCT", 97, 105], ["EAV", "ORGANISM", 130, 133], ["PRRSV", "ORGANISM", 138, 143], ["M\u03a6", "PROTEIN", 4, 6], ["CD169", "PROTEIN", 41, 46], ["clathrin", "PROTEIN", 97, 105], ["EAV", "SPECIES", 130, 133], ["PRRSV", "SPECIES", 138, 143], ["The M\u03a6-restricted protein sialoadhesion (CD169) mediates virus attachment", "TREATMENT", 0, 73], ["internalization", "TREATMENT", 78, 93]]], ["CD163 was identified as an arterivirus co-receptor required for nucleocapsid release from endosomes and is also monocyte-macrophage lineage restricted (Welch and Calvert 2010) .", [["endosomes", "ANATOMY", 90, 99], ["monocyte", "ANATOMY", 112, 120], ["macrophage", "ANATOMY", 121, 131], ["CD163", "GENE_OR_GENE_PRODUCT", 0, 5], ["nucleocapsid", "CELLULAR_COMPONENT", 64, 76], ["endosomes", "CELLULAR_COMPONENT", 90, 99], ["monocyte", "CELL", 112, 120], ["macrophage", "CELL", 121, 131], ["CD163", "PROTEIN", 0, 5], ["arterivirus co-receptor", "PROTEIN", 27, 50], ["macrophage lineage", "CELL_TYPE", 121, 139], ["CD163", "TEST", 0, 5], ["an arterivirus co-receptor", "TREATMENT", 24, 50], ["nucleocapsid release", "PROBLEM", 64, 84], ["monocyte", "TEST", 112, 120]]], ["MA104 cells express CD163 and CD151 but not sialoadhesin.", [["MA104 cells", "ANATOMY", 0, 11], ["MA104 cells", "CELL", 0, 11], ["CD163", "GENE_OR_GENE_PRODUCT", 20, 25], ["CD151", "GENE_OR_GENE_PRODUCT", 30, 35], ["sialoadhesin", "GENE_OR_GENE_PRODUCT", 44, 56], ["MA104 cells", "CELL_LINE", 0, 11], ["CD163", "PROTEIN", 20, 25], ["CD151", "PROTEIN", 30, 35], ["sialoadhesin", "PROTEIN", 44, 56], ["CD163", "TEST", 20, 25], ["CD151", "TEST", 30, 35]]], ["It was recently reported that SHFV LVR enters MA104 cells by clathrinmediated endocytosis and that treatment of MA104 cells with anti-CD163 antibody decreased SHFV replication (Cai, Postnikova et al. 2014) .SHFV isolatesOnly the prototype SHFV isolate, LVR v42-0/M6941, survived from the earlier studies of SHFV ).", [["MA104 cells", "ANATOMY", 46, 57], ["MA104 cells", "ANATOMY", 112, 123], ["SHFV LVR", "CELL", 30, 38], ["MA104 cells", "CELL", 46, 57], ["MA104 cells", "CELL", 112, 123], ["anti-CD163 antibody", "GENE_OR_GENE_PRODUCT", 129, 148], ["SHFV", "GENE_OR_GENE_PRODUCT", 159, 163], ["SHFV", "ORGANISM", 239, 243], ["LVR v42-0/M6941", "CELL", 253, 268], ["SHFV", "CANCER", 307, 311], ["LVR", "PROTEIN", 35, 38], ["MA104 cells", "CELL_LINE", 46, 57], ["MA104 cells", "CELL_LINE", 112, 123], ["anti-CD163 antibody", "PROTEIN", 129, 148], ["SHFV", "SPECIES", 30, 34], ["SHFV", "SPECIES", 159, 163], ["SHFV", "SPECIES", 207, 211], ["SHFV", "SPECIES", 239, 243], ["LVR v42-0/M6941", "SPECIES", 253, 268], ["SHFV", "SPECIES", 307, 311], ["SHFV LVR", "TREATMENT", 30, 38], ["clathrinmediated endocytosis", "PROBLEM", 61, 89], ["MA104 cells", "PROBLEM", 112, 123], ["anti-CD163 antibody", "TREATMENT", 129, 148], ["the prototype SHFV isolate", "TEST", 225, 251], ["LVR", "TEST", 253, 256]]], ["The species of African NHP from which LVR originated is not known for certain but patas monkeys housed in the same facility were subsequently shown to be persistently infected with SHFV and the source of the SHFV shown to initiate additional epizootics in macaques in the same facility (London 1977) .", [["epizootics", "DISEASE", 242, 252], ["African NHP", "ORGANISM", 15, 26], ["LVR", "CANCER", 38, 41], ["patas monkeys", "ORGANISM", 82, 95], ["SHFV", "GENE_OR_GENE_PRODUCT", 208, 212], ["macaques", "ORGANISM", 256, 264], ["SHFV", "SPECIES", 181, 185], ["SHFV", "SPECIES", 208, 212], ["LVR", "TEST", 38, 41], ["not known for", "UNCERTAINTY", 56, 69], ["persistently", "OBSERVATION_MODIFIER", 154, 166], ["infected", "OBSERVATION", 167, 175]]], ["A complete sequence of the SHFV LVR genome was obtained in the early 1990s by sequencing \"shot gun\" clones by older methods (GenBank Assession number AF180391.1).", [["SHFV", "GENE_OR_GENE_PRODUCT", 27, 31], ["SHFV LVR genome", "DNA", 27, 42], ["SHFV", "SPECIES", 27, 31], ["the SHFV LVR genome", "TEST", 23, 42]]], ["During the construction of the first infectious SHFV infectious clone, nucleotide differences were detected between RT-PCR amplified cDNA fragments used to construct the full length clone and the GenBank sequence.", [["nucleotide", "CHEMICAL", 71, 81], ["nucleotide", "CHEMICAL", 71, 81], ["clone", "CELL", 64, 69], ["clone", "CELL", 182, 187], ["SHFV infectious clone", "DNA", 48, 69], ["RT-PCR amplified cDNA fragments", "DNA", 116, 147], ["GenBank sequence", "DNA", 196, 212], ["SHFV", "SPECIES", 48, 52], ["the first infectious SHFV infectious clone", "PROBLEM", 27, 69], ["nucleotide differences", "PROBLEM", 71, 93], ["RT-PCR amplified cDNA fragments", "TREATMENT", 116, 147], ["the GenBank sequence", "TEST", 192, 212], ["infectious", "OBSERVATION_MODIFIER", 37, 47]]], ["The SHFV LVR genome RNA was also subjected to 454 sequencing.", [["SHFV", "GENE_OR_GENE_PRODUCT", 4, 8], ["SHFV LVR genome RNA", "RNA", 4, 23], ["SHFV", "SPECIES", 4, 8], ["The SHFV LVR genome RNA", "TREATMENT", 0, 23], ["genome RNA", "OBSERVATION", 13, 23]]], ["The same 18 nt differences compared to the GenBank sequence were detected by both 454 genomic sequencing and individual fragment sequencing and the GenBank sequence was updated (GenBank Assession number AF180391.2).SHFV isolatesAlthough a low dose of SHFV LVR, in sera or culture fluid injected by the intramuscular route consistently induced severe hemorrhagic disease in macaques in the 1960s , no correlation between SHFV LVR dose (50 to 500,000 PFU) and hemorrhagic disease induction in macaques was observed in a 2011 study and the majority of the animals (12 of 16) that did not survive were found to have bacterial sepsis (Johnson, Dodd et al. 2011) .", [["sera", "ANATOMY", 264, 268], ["culture fluid", "ANATOMY", 272, 285], ["intramuscular", "ANATOMY", 302, 315], ["SHFV", "CHEMICAL", 251, 255], ["hemorrhagic disease", "DISEASE", 350, 369], ["LVR", "CHEMICAL", 425, 428], ["hemorrhagic", "DISEASE", 458, 469], ["bacterial sepsis", "DISEASE", 612, 628], ["SHFV", "SIMPLE_CHEMICAL", 251, 255], ["sera", "ORGANISM_SUBSTANCE", 264, 268], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 302, 315], ["macaques", "ORGANISM", 373, 381], ["SHFV", "GENE_OR_GENE_PRODUCT", 420, 424], ["macaques", "ORGANISM", 491, 499], ["GenBank sequence", "DNA", 43, 59], ["GenBank sequence", "DNA", 148, 164], ["SHFV LVR", "PROTEIN", 251, 259], ["SHFV", "SPECIES", 215, 219], ["SHFV", "SPECIES", 251, 255], ["macaques", "SPECIES", 491, 499], ["the GenBank sequence", "TEST", 39, 59], ["individual fragment sequencing", "TEST", 109, 139], ["the GenBank sequence", "TEST", 144, 164], ["a low dose of SHFV LVR", "TREATMENT", 237, 259], ["culture fluid", "TEST", 272, 285], ["the intramuscular route", "TEST", 298, 321], ["severe hemorrhagic disease in macaques", "PROBLEM", 343, 381], ["SHFV LVR dose", "TREATMENT", 420, 433], ["hemorrhagic disease induction", "PROBLEM", 458, 487], ["a 2011 study", "TEST", 516, 528], ["bacterial sepsis", "PROBLEM", 612, 628], ["severe", "OBSERVATION_MODIFIER", 343, 349], ["hemorrhagic", "OBSERVATION_MODIFIER", 350, 361], ["disease", "OBSERVATION", 362, 369], ["hemorrhagic", "OBSERVATION_MODIFIER", 458, 469], ["disease", "OBSERVATION", 470, 477], ["bacterial", "OBSERVATION_MODIFIER", 612, 621], ["sepsis", "OBSERVATION", 622, 628]]], ["The inoculum used in this study was generated by three freeze-thaw cycles of infected MA104 cells.", [["MA104 cells", "ANATOMY", 86, 97], ["MA104 cells", "CELL", 86, 97], ["MA104 cells", "CELL_LINE", 86, 97], ["The inoculum", "TREATMENT", 0, 12], ["this study", "TEST", 21, 31], ["infected MA104 cells", "PROBLEM", 77, 97], ["inoculum", "OBSERVATION", 4, 12], ["infected MA104 cells", "OBSERVATION", 77, 97]]], ["Activation of cell RNA sensors by the large amounts of cell and viral (genomic and sg) RNAs in these lysates may have induced a strong host antiviral response that contributed to the decreased efficiency of hemorrhagic disease induction observed.", [["cell", "ANATOMY", 14, 18], ["cell", "ANATOMY", 55, 59], ["lysates", "ANATOMY", 101, 108], ["hemorrhagic disease", "DISEASE", 207, 226], ["cell", "CELL", 14, 18], ["cell", "CELL", 55, 59], ["genomic", "CELLULAR_COMPONENT", 71, 78], ["lysates", "ORGANISM_SUBSTANCE", 101, 108], ["viral (genomic and sg) RNAs", "RNA", 64, 91], ["Activation of cell RNA sensors", "PROBLEM", 0, 30], ["viral (genomic and sg) RNAs", "TREATMENT", 64, 91], ["these lysates", "TREATMENT", 95, 108], ["hemorrhagic disease induction", "PROBLEM", 207, 236], ["cell RNA", "OBSERVATION", 14, 22], ["large", "OBSERVATION_MODIFIER", 38, 43], ["amounts", "OBSERVATION_MODIFIER", 44, 51], ["decreased", "OBSERVATION_MODIFIER", 183, 192], ["efficiency", "OBSERVATION_MODIFIER", 193, 203], ["hemorrhagic", "OBSERVATION_MODIFIER", 207, 218], ["disease", "OBSERVATION", 219, 226]]], ["Also, defective SHFV genomes present in the LVR stock used may have reduced the efficiency of virus replication ).SHFV isolatesSHFV isolates obtained from two SHFV-positive Olive baboons (B11661 and B11662) that were housed together only in the early 1990s and persistently infected >10 years were amplified by a single passage in primary rhesus macaque M\u03a6s and 454 sequenced ).", [["M\u03a6s", "ANATOMY", 354, 357], ["SHFV", "GENE_OR_GENE_PRODUCT", 16, 20], ["SHFV", "GENE_OR_GENE_PRODUCT", 114, 118], ["SHFV", "ORGANISM", 127, 131], ["Olive baboons", "ORGANISM", 173, 186], ["rhesus", "ORGANISM", 339, 345], ["macaque", "ORGANISM", 346, 353], ["M\u03a6s", "CANCER", 354, 357], ["SHFV genomes", "DNA", 16, 28], ["rhesus macaque", "SPECIES", 339, 353], ["SHFV", "SPECIES", 114, 118], ["SHFV", "SPECIES", 127, 131], ["Olive baboons", "SPECIES", 173, 186], ["rhesus macaque", "SPECIES", 339, 353], ["defective SHFV genomes", "PROBLEM", 6, 28], ["the LVR stock", "TREATMENT", 40, 53], ["virus replication", "TREATMENT", 94, 111], ["SHFV isolatesSHFV isolates", "TEST", 114, 140]]], ["The two sequences were very similar to each other, differing at 15 nt positions within the 15.7 kb genome.", [["15 nt positions", "DNA", 64, 79], ["15.7 kb genome", "DNA", 91, 105], ["The two sequences", "TEST", 0, 17], ["15.7 kb", "OBSERVATION_MODIFIER", 91, 98]]], ["Surprisingly, these genomes sequences were also very similar (differing at 7 or 10 unique positions, respectively) to that of a three times serially plaque-purified stock of SHFV LVR grown in MA104 cells.", [["MA104 cells", "ANATOMY", 192, 203], ["SHFV LVR", "CELL", 174, 182], ["MA104 cells", "CELL", 192, 203], ["SHFV LVR", "CELL_LINE", 174, 182], ["MA104 cells", "CELL_LINE", 192, 203], ["SHFV", "SPECIES", 174, 178], ["these genomes sequences", "TEST", 14, 37], ["a three times serially plaque", "PROBLEM", 126, 155], ["SHFV LVR", "TREATMENT", 174, 182], ["similar", "OBSERVATION_MODIFIER", 53, 60], ["plaque", "OBSERVATION", 149, 155], ["MA104 cells", "OBSERVATION", 192, 203]]], ["Four Japanese macaques injected intravenously with 100 PFU of B11661 developed severe hemorrhagic fever disease, characterized by high level viremia, the production of pro-inflammatory cytokines, elevation of tissue factor and coagulopathy but no evidence of bacterial sepsis.", [["intravenously", "ANATOMY", 32, 45], ["tissue", "ANATOMY", 209, 215], ["B11661", "CHEMICAL", 62, 68], ["hemorrhagic fever", "DISEASE", 86, 103], ["viremia", "DISEASE", 141, 148], ["coagulopathy", "DISEASE", 227, 239], ["bacterial sepsis", "DISEASE", 259, 275], ["macaques", "ORGANISM", 14, 22], ["tissue", "TISSUE", 209, 215], ["factor", "GENE_OR_GENE_PRODUCT", 216, 222], ["pro-inflammatory cytokines", "PROTEIN", 168, 194], ["tissue factor", "PROTEIN", 209, 222], ["macaques", "SPECIES", 14, 22], ["Japanese macaques", "SPECIES", 5, 22], ["severe hemorrhagic fever disease", "PROBLEM", 79, 111], ["high level viremia", "PROBLEM", 130, 148], ["pro-inflammatory cytokines", "PROBLEM", 168, 194], ["elevation of tissue factor", "PROBLEM", 196, 222], ["coagulopathy", "PROBLEM", 227, 239], ["bacterial sepsis", "PROBLEM", 259, 275], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["hemorrhagic", "OBSERVATION_MODIFIER", 86, 97], ["fever", "OBSERVATION", 98, 103], ["high", "OBSERVATION_MODIFIER", 130, 134], ["level viremia", "OBSERVATION", 135, 148], ["pro-inflammatory cytokines", "OBSERVATION", 168, 194], ["elevation", "OBSERVATION_MODIFIER", 196, 205], ["coagulopathy", "OBSERVATION", 227, 239], ["no evidence of", "UNCERTAINTY", 244, 258], ["bacterial", "OBSERVATION_MODIFIER", 259, 268], ["sepsis", "OBSERVATION", 269, 275]]], ["Infected M\u03a6s were detected in liver and spleen tissue sections using antibody to viral nonstructural proteins and the M\u03a6 marker CD68.", [["M\u03a6s", "ANATOMY", 9, 12], ["liver", "ANATOMY", 30, 35], ["spleen tissue sections", "ANATOMY", 40, 62], ["M\u03a6s", "GENE_OR_GENE_PRODUCT", 9, 12], ["liver", "ORGAN", 30, 35], ["spleen tissue sections", "MULTI-TISSUE_STRUCTURE", 40, 62], ["CD68", "GENE_OR_GENE_PRODUCT", 128, 132], ["M\u03a6s", "PROTEIN", 9, 12], ["viral nonstructural proteins", "PROTEIN", 81, 109], ["M\u03a6 marker", "PROTEIN", 118, 127], ["CD68", "PROTEIN", 128, 132], ["Infected M\u03a6s", "PROBLEM", 0, 12], ["antibody", "TEST", 69, 77], ["viral nonstructural proteins", "TEST", 81, 109], ["the M\u03a6 marker CD68", "TEST", 114, 132], ["liver", "ANATOMY", 30, 35], ["spleen", "ANATOMY", 40, 46]]], ["SHFV infection in macaques has been proposed as a BSL2 model for viral hemorrhagic fever disease (Johnson, Dodd et al. 2011 ).SHFV isolatesAnother recent study sequenced SHFV genomes obtained from wild Mikumi yellow baboons and captive Olive baboons in the same US primate facility used for the study described above and found them to be divergent (Bailey, Lauck et al. 2014) .", [["SHFV infection", "DISEASE", 0, 14], ["viral hemorrhagic fever", "DISEASE", 65, 88], ["disease", "DISEASE", 89, 96], ["SHFV", "GENE_OR_GENE_PRODUCT", 0, 4], ["macaques", "ORGANISM", 18, 26], ["Mikumi yellow baboons", "ORGANISM", 202, 223], ["Olive baboons", "ORGANISM", 236, 249], ["SHFV genomes", "DNA", 170, 182], ["macaques", "SPECIES", 18, 26], ["SHFV", "SPECIES", 0, 4], ["SHFV", "SPECIES", 126, 130], ["Mikumi yellow baboons", "SPECIES", 202, 223], ["Olive baboons", "SPECIES", 236, 249], ["SHFV infection", "PROBLEM", 0, 14], ["a BSL2 model", "TREATMENT", 48, 60], ["viral hemorrhagic fever disease", "PROBLEM", 65, 96], ["Another recent study", "TEST", 139, 159], ["captive Olive baboons", "TREATMENT", 228, 249], ["the study", "TEST", 291, 300], ["infection", "OBSERVATION", 5, 14], ["viral", "OBSERVATION_MODIFIER", 65, 70], ["hemorrhagic", "OBSERVATION_MODIFIER", 71, 82], ["fever", "OBSERVATION", 83, 88]]], ["Different SHFV genome sequences obtained from additional wild species of African NHPs, red colobus and red-tailed guenons were previously reported (Lauck, Sibley et al. 2013 , Bailey, Lauck et al. 2014 .", [["NHPs", "ORGANISM", 81, 85], ["red colobus", "ORGANISM", 87, 98], ["SHFV genome sequences", "DNA", 10, 31], ["SHFV", "SPECIES", 10, 14], ["African NHPs", "SPECIES", 73, 85], ["red colobus", "SPECIES", 87, 98], ["Different SHFV genome sequences", "PROBLEM", 0, 31], ["red colobus", "OBSERVATION", 87, 98]]], ["Two different strains of SHFV (krc1 and krc2) were isolated from red colobus animals and sequence diversity was detected among isolates of the same strain from different infected animals.", [["SHFV", "GENE_OR_GENE_PRODUCT", 25, 29], ["krc1", "GENE_OR_GENE_PRODUCT", 31, 35], ["krc2", "GENE_OR_GENE_PRODUCT", 40, 44], ["red colobus animals", "ORGANISM", 65, 84], ["SHFV", "PROTEIN", 25, 29], ["krc1", "PROTEIN", 31, 35], ["krc2", "PROTEIN", 40, 44], ["SHFV", "SPECIES", 25, 29], ["red colobus", "SPECIES", 65, 76], ["SHFV (krc1 and krc2", "TREATMENT", 25, 44], ["red colobus animals", "PROBLEM", 65, 84], ["sequence diversity", "TEST", 89, 107], ["the same strain", "PROBLEM", 139, 154], ["different", "OBSERVATION_MODIFIER", 4, 13], ["strains", "OBSERVATION_MODIFIER", 14, 21], ["red colobus", "OBSERVATION", 65, 76], ["different", "OBSERVATION_MODIFIER", 160, 169], ["infected", "OBSERVATION", 170, 178]]], ["One animal was found to be co-infected with both SHFV strains.", [["animal", "ORGANISM", 4, 10], ["SHFV", "GENE_OR_GENE_PRODUCT", 49, 53], ["SHFV", "SPECIES", 49, 53], ["both SHFV strains", "PROBLEM", 44, 61], ["co-infected", "OBSERVATION", 27, 38], ["SHFV strains", "OBSERVATION", 49, 61]]], ["No signs of disease were observed in SHFV-infected red colobus, even though the viremia levels were high (10 6 -10 7 RNA copies/ml of plasma).", [["red colobus", "ANATOMY", 51, 62], ["plasma", "ANATOMY", 134, 140], ["viremia", "DISEASE", 80, 87], ["SHFV", "ORGANISM", 37, 41], ["red colobus", "ORGANISM", 51, 62], ["plasma", "ORGANISM_SUBSTANCE", 134, 140], ["SHFV", "SPECIES", 37, 41], ["red colobus", "SPECIES", 51, 62], ["disease", "PROBLEM", 12, 19], ["SHFV", "TEST", 37, 41], ["infected red colobus", "PROBLEM", 42, 62], ["the viremia levels", "TEST", 76, 94], ["plasma", "TEST", 134, 140], ["signs of", "UNCERTAINTY", 3, 11], ["disease", "OBSERVATION", 12, 19], ["infected", "OBSERVATION_MODIFIER", 42, 50], ["red colobus", "OBSERVATION", 51, 62], ["viremia", "OBSERVATION", 80, 87]]], ["It is not yet known whether these SHFV isolates can infect macaques and induce hemorrhagic fever disease.Comparison of SHFV replication and cell responses in disease resistant baboon and disease susceptible macaque M\u03a6s and mDCs-It was previouslyreported that pro-inflammatory cytokines released from Ebola infected macaque M\u03a6s and DCs upregulate tissue factor and sequentially induce disseminated intravascular coagulopathy (Bray and Geisbert 2005) .", [["cell", "ANATOMY", 140, 144], ["M\u03a6s", "ANATOMY", 215, 218], ["mDCs", "ANATOMY", 223, 227], ["M\u03a6s", "ANATOMY", 323, 326], ["DCs", "ANATOMY", 331, 334], ["tissue", "ANATOMY", 346, 352], ["intravascular", "ANATOMY", 397, 410], ["hemorrhagic fever", "DISEASE", 79, 96], ["intravascular coagulopathy", "DISEASE", 397, 423], ["SHFV isolates", "ORGANISM", 34, 47], ["macaques", "ORGANISM", 59, 67], ["SHFV", "CELL", 119, 123], ["cell", "CELL", 140, 144], ["baboon", "ORGANISM", 176, 182], ["macaque", "ORGANISM", 207, 214], ["M\u03a6s", "CELL", 215, 218], ["mDCs", "CELL", 223, 227], ["Ebola", "ORGANISM", 300, 305], ["macaque", "ORGANISM", 315, 322], ["M\u03a6s", "CELL", 323, 326], ["DCs", "CELL", 331, 334], ["tissue factor", "GENE_OR_GENE_PRODUCT", 346, 359], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 397, 410], ["M\u03a6s", "CELL_TYPE", 215, 218], ["mDCs", "CELL_TYPE", 223, 227], ["pro-inflammatory cytokines", "PROTEIN", 259, 285], ["M\u03a6s", "CELL_TYPE", 323, 326], ["DCs", "CELL_TYPE", 331, 334], ["tissue factor", "PROTEIN", 346, 359], ["macaques", "SPECIES", 59, 67], ["Ebola infected macaque", "SPECIES", 300, 322], ["SHFV", "SPECIES", 119, 123], ["baboon", "SPECIES", 176, 182], ["these SHFV isolates", "PROBLEM", 28, 47], ["hemorrhagic fever disease", "PROBLEM", 79, 104], ["SHFV replication", "TREATMENT", 119, 135], ["cell responses", "TEST", 140, 154], ["disease resistant baboon", "PROBLEM", 158, 182], ["pro-inflammatory cytokines", "PROBLEM", 259, 285], ["Ebola infected macaque M\u03a6s", "TREATMENT", 300, 326], ["tissue factor", "TEST", 346, 359], ["disseminated intravascular coagulopathy", "PROBLEM", 384, 423], ["hemorrhagic", "OBSERVATION_MODIFIER", 79, 90], ["fever", "OBSERVATION", 91, 96], ["disseminated", "OBSERVATION_MODIFIER", 384, 396], ["coagulopathy", "OBSERVATION", 411, 423]]], ["The ability of an SHFV LVR infection to induce proinflammatory cytokine production was compared in M\u03a6s and myeloid DCs differentiated in culture from peripheral blood mononuclear cells (PBMCs) collected from disease resistant baboons and disease susceptible macaques .", [["M\u03a6s", "ANATOMY", 99, 102], ["myeloid DCs", "ANATOMY", 107, 118], ["peripheral blood mononuclear cells", "ANATOMY", 150, 184], ["PBMCs", "ANATOMY", 186, 191], ["infection", "DISEASE", 27, 36], ["SHFV LVR", "ORGANISM", 18, 26], ["M\u03a6s", "CELL", 99, 102], ["myeloid DCs", "CELL", 107, 118], ["peripheral blood mononuclear cells", "CELL", 150, 184], ["PBMCs", "CELL", 186, 191], ["baboons", "ORGANISM", 226, 233], ["macaques", "ORGANISM", 258, 266], ["proinflammatory cytokine", "PROTEIN", 47, 71], ["M\u03a6s", "CELL_TYPE", 99, 102], ["myeloid DCs", "CELL_TYPE", 107, 118], ["peripheral blood mononuclear cells", "CELL_TYPE", 150, 184], ["PBMCs", "CELL_TYPE", 186, 191], ["macaques", "SPECIES", 258, 266], ["SHFV", "SPECIES", 18, 22], ["an SHFV LVR infection", "PROBLEM", 15, 36], ["proinflammatory cytokine production", "PROBLEM", 47, 82], ["myeloid DCs", "PROBLEM", 107, 118], ["culture", "TEST", 137, 144], ["peripheral blood mononuclear cells", "TEST", 150, 184], ["PBMCs", "TEST", 186, 191], ["disease resistant baboons", "PROBLEM", 208, 233], ["disease susceptible macaques", "PROBLEM", 238, 266], ["infection", "OBSERVATION", 27, 36], ["myeloid DCs", "OBSERVATION", 107, 118], ["peripheral", "ANATOMY_MODIFIER", 150, 160], ["blood", "ANATOMY", 161, 166], ["mononuclear cells", "OBSERVATION", 167, 184], ["resistant baboons", "OBSERVATION", 216, 233], ["susceptible macaques", "OBSERVATION", 246, 266]]], ["Both viral RNA replication and virion production were more robust in macaque M\u03a6s and mDCs than in baboon cells (Table 1) .", [["M\u03a6s", "ANATOMY", 77, 80], ["mDCs", "ANATOMY", 85, 89], ["baboon cells", "ANATOMY", 98, 110], ["macaque", "ORGANISM", 69, 76], ["M\u03a6s", "CELL", 77, 80], ["mDCs", "CELL", 85, 89], ["baboon cells", "CELL", 98, 110], ["macaque M\u03a6s", "CELL_TYPE", 69, 80], ["mDCs", "CELL_TYPE", 85, 89], ["baboon cells", "CELL_TYPE", 98, 110], ["macaque", "SPECIES", 69, 76], ["baboon", "SPECIES", 98, 104], ["Both viral RNA replication", "TREATMENT", 0, 26], ["virion production", "PROBLEM", 31, 48], ["viral", "OBSERVATION", 5, 10], ["RNA replication", "OBSERVATION", 11, 26], ["virion production", "OBSERVATION", 31, 48]]], ["Approximately ~90% of macaque M\u03a6s but only 10% of baboon M\u03a6s were productively infected but the intracellular dsRNA fluorescence signal was similarly bright in the cells from both types of NHPs.", [["M\u03a6s", "ANATOMY", 30, 33], ["M\u03a6s", "ANATOMY", 57, 60], ["intracellular", "ANATOMY", 96, 109], ["cells", "ANATOMY", 164, 169], ["macaque", "ORGANISM", 22, 29], ["M\u03a6s", "CANCER", 30, 33], ["baboon", "ORGANISM", 50, 56], ["M\u03a6s", "GENE_OR_GENE_PRODUCT", 57, 60], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 109], ["cells", "CELL", 164, 169], ["NHPs", "ORGANISM", 189, 193], ["macaque M\u03a6s", "CELL_TYPE", 22, 33], ["baboon M\u03a6s", "CELL_TYPE", 50, 60], ["baboon", "SPECIES", 50, 56], ["macaque M\u03a6s", "TEST", 22, 33], ["baboon M\u03a6s", "PROBLEM", 50, 60], ["the intracellular dsRNA fluorescence signal", "TEST", 92, 135], ["dsRNA fluorescence", "OBSERVATION", 110, 128]]], ["In contrast, a similar percentage of baboon and macaque mDCs were infected (~50%) but the intensity of intracellular dsRNA signal was much higher in macaque mDCs than baboon mDCs suggesting that the higher yield of SHFV produced by macaque mDCs was due to more efficient intracellular virus replication.", [["mDCs", "ANATOMY", 56, 60], ["intracellular", "ANATOMY", 103, 116], ["mDCs", "ANATOMY", 157, 161], ["mDCs", "ANATOMY", 174, 178], ["mDCs", "ANATOMY", 240, 244], ["intracellular", "ANATOMY", 271, 284], ["baboon", "ORGANISM", 37, 43], ["macaque", "ORGANISM", 48, 55], ["mDCs", "CELL", 56, 60], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["macaque", "ORGANISM", 149, 156], ["mDCs", "CELL", 157, 161], ["baboon", "ORGANISM", 167, 173], ["mDCs", "CELL", 174, 178], ["SHFV", "GENE_OR_GENE_PRODUCT", 215, 219], ["macaque", "ORGANISM", 232, 239], ["mDCs", "CELL", 240, 244], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 271, 284], ["baboon and macaque mDCs", "CELL_TYPE", 37, 60], ["macaque mDCs", "CELL_TYPE", 149, 161], ["baboon mDCs", "CELL_TYPE", 167, 178], ["SHFV", "PROTEIN", 215, 219], ["macaque mDCs", "CELL_TYPE", 232, 244], ["baboon", "SPECIES", 37, 43], ["baboon", "SPECIES", 167, 173], ["macaque", "SPECIES", 232, 239], ["intracellular dsRNA signal", "TEST", 103, 129], ["the higher yield of SHFV", "PROBLEM", 195, 219], ["more efficient intracellular virus replication", "PROBLEM", 256, 302], ["percentage", "OBSERVATION_MODIFIER", 23, 33], ["baboon", "OBSERVATION_MODIFIER", 37, 43], ["macaque mDCs", "OBSERVATION", 48, 60], ["intracellular dsRNA", "OBSERVATION", 103, 122], ["virus", "OBSERVATION", 285, 290]]], ["The mechanisms involved in the observed variations in cell susceptibility have not yet been analyzed.Comparison of SHFV replication and cell responses in disease resistant baboon and disease susceptible macaque M\u03a6s and mDCs-It was previouslyConsistent with the observed induction of hemorrhagic fever disease by SHFV infection in macaques, SHFV infection of cultured macaque but not of baboon M\u03a6s and mDCs induced the production of pro-inflammatory cytokines, such as IL-1\u03b2, IL-6, IL-12/23(p40), TNF-\u03b1 and MIP-1\u03b1 .", [["cell", "ANATOMY", 54, 58], ["cell", "ANATOMY", 136, 140], ["M\u03a6s", "ANATOMY", 211, 214], ["mDCs", "ANATOMY", 219, 223], ["M\u03a6s", "ANATOMY", 393, 396], ["mDCs", "ANATOMY", 401, 405], ["hemorrhagic fever", "DISEASE", 283, 300], ["SHFV infection", "DISEASE", 312, 326], ["infection", "DISEASE", 345, 354], ["cell", "CELL", 54, 58], ["SHFV", "CELL", 115, 119], ["cell", "CELL", 136, 140], ["baboon", "ORGANISM", 172, 178], ["macaque", "ORGANISM", 203, 210], ["M\u03a6s", "CELL", 211, 214], ["mDCs", "CELL", 219, 223], ["SHFV", "GENE_OR_GENE_PRODUCT", 312, 316], ["macaques", "ORGANISM", 330, 338], ["SHFV", "ORGANISM", 340, 344], ["macaque", "ORGANISM", 367, 374], ["baboon", "ORGANISM", 386, 392], ["M\u03a6s", "CELL", 393, 396], ["mDCs", "CELL", 401, 405], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 468, 473], ["IL-6", "GENE_OR_GENE_PRODUCT", 475, 479], ["IL-12/23", "GENE_OR_GENE_PRODUCT", 481, 489], ["p40", "GENE_OR_GENE_PRODUCT", 490, 493], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 496, 501], ["MIP-1", "GENE_OR_GENE_PRODUCT", 506, 511], ["mDCs", "CELL_TYPE", 219, 223], ["baboon M\u03a6s", "CELL_TYPE", 386, 396], ["mDCs", "CELL_TYPE", 401, 405], ["pro-inflammatory cytokines", "PROTEIN", 432, 458], ["IL", "PROTEIN", 468, 470], ["IL-6", "PROTEIN", 475, 479], ["TNF", "PROTEIN", 496, 499], ["MIP", "PROTEIN", 506, 509], ["macaques", "SPECIES", 330, 338], ["SHFV", "SPECIES", 115, 119], ["baboon", "SPECIES", 172, 178], ["SHFV", "SPECIES", 312, 316], ["SHFV", "SPECIES", 340, 344], ["baboon", "SPECIES", 386, 392], ["the observed variations in cell susceptibility", "PROBLEM", 27, 73], ["SHFV replication", "TREATMENT", 115, 131], ["cell responses", "TEST", 136, 150], ["disease resistant baboon", "PROBLEM", 154, 178], ["hemorrhagic fever disease", "PROBLEM", 283, 308], ["SHFV infection in macaques", "PROBLEM", 312, 338], ["SHFV infection of cultured macaque", "PROBLEM", 340, 374], ["pro-inflammatory cytokines", "TEST", 432, 458], ["IL", "TEST", 468, 470], ["IL", "TEST", 475, 477], ["IL", "TEST", 481, 483], ["TNF", "TEST", 496, 499], ["MIP", "TEST", 506, 509], ["cell susceptibility", "OBSERVATION", 54, 73], ["hemorrhagic", "OBSERVATION_MODIFIER", 283, 294], ["fever", "OBSERVATION", 295, 300], ["infection", "OBSERVATION", 317, 326], ["infection", "OBSERVATION", 345, 354], ["pro-inflammatory cytokines", "OBSERVATION", 432, 458]]], ["UV-inactivated SHFV induced only transient production of IL-6 and IL-1\u03b2 indicating that early stages of the virus lifecycle can induce this response but that sustained pro-inflammatory cytokine production requires virus replication .", [["UV", "CHEMICAL", 0, 2], ["SHFV", "ORGANISM", 15, 19], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL-6 and IL-1\u03b2", "PROTEIN", 57, 71], ["pro-inflammatory cytokine", "PROTEIN", 168, 193], ["SHFV", "SPECIES", 15, 19], ["UV", "TREATMENT", 0, 2], ["IL", "TEST", 57, 59], ["IL", "TEST", 66, 68], ["the virus lifecycle", "PROBLEM", 104, 123], ["sustained pro-inflammatory cytokine production", "PROBLEM", 158, 204], ["virus replication", "TREATMENT", 214, 231], ["transient", "OBSERVATION_MODIFIER", 33, 42], ["production", "OBSERVATION_MODIFIER", 43, 53]]], ["IL-10 signaling leading to upregulation of suppressor of cytokine signaling 3 (SOCS3) that suppresses pro-inflammatory cytokine production (Moore, de Waal Malefyt et al. 2001) .", [["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["suppressor of cytokine signaling 3", "GENE_OR_GENE_PRODUCT", 43, 77], ["SOCS3", "GENE_OR_GENE_PRODUCT", 79, 84], ["IL-10", "PROTEIN", 0, 5], ["suppressor of cytokine signaling 3", "PROTEIN", 43, 77], ["SOCS3", "PROTEIN", 79, 84], ["pro-inflammatory cytokine", "PROTEIN", 102, 127], ["IL", "TREATMENT", 0, 2], ["cytokine signaling", "PROBLEM", 57, 75], ["pro-inflammatory cytokine production", "PROBLEM", 102, 138], ["pro-inflammatory", "OBSERVATION_MODIFIER", 102, 118]]], ["Cultured baboon M\u03a6s and mDCs expressed higher basal levels of IL-10 than macaque cells and the levels of both the inducible IL-10 receptor subunit 1 (IL-10R1) and SOCS3 were upregulated in SHFV-infected baboon M\u03a6s and mDCs.", [["M\u03a6s", "ANATOMY", 16, 19], ["mDCs", "ANATOMY", 24, 28], ["cells", "ANATOMY", 81, 86], ["M\u03a6s", "ANATOMY", 210, 213], ["mDCs", "ANATOMY", 218, 222], ["baboon", "ORGANISM", 9, 15], ["M\u03a6s", "CELL", 16, 19], ["mDCs", "CELL", 24, 28], ["IL-10", "GENE_OR_GENE_PRODUCT", 62, 67], ["macaque", "ORGANISM", 73, 80], ["cells", "CELL", 81, 86], ["IL-10 receptor subunit 1", "GENE_OR_GENE_PRODUCT", 124, 148], ["IL-10R1", "GENE_OR_GENE_PRODUCT", 150, 157], ["SOCS3", "GENE_OR_GENE_PRODUCT", 163, 168], ["SHFV", "CELL", 189, 193], ["baboon", "ORGANISM", 203, 209], ["M\u03a6s", "CELL", 210, 213], ["mDCs", "CELL", 218, 222], ["baboon M\u03a6s", "CELL_TYPE", 9, 19], ["mDCs", "CELL_TYPE", 24, 28], ["IL-10", "PROTEIN", 62, 67], ["macaque cells", "CELL_TYPE", 73, 86], ["IL-10 receptor subunit 1", "PROTEIN", 124, 148], ["IL", "PROTEIN", 150, 152], ["10R1", "PROTEIN", 153, 157], ["SOCS3", "PROTEIN", 163, 168], ["M\u03a6s", "CELL_TYPE", 210, 213], ["mDCs", "CELL_TYPE", 218, 222], ["SHFV", "SPECIES", 189, 193], ["baboon", "SPECIES", 203, 209], ["IL", "TEST", 62, 64], ["the levels", "TEST", 91, 101], ["the inducible IL", "TEST", 110, 126], ["SOCS3", "PROBLEM", 163, 168], ["infected baboon M\u03a6s", "OBSERVATION", 194, 213]]], ["In contrast, in SHFV-infected macaque M\u03a6s and mDCs, the levels of IL-10R1 were downregulated with time after infection and SOCS3 expression was not induced.", [["M\u03a6s", "ANATOMY", 38, 41], ["mDCs", "ANATOMY", 46, 50], ["SHFV", "CELL", 16, 20], ["macaque", "ORGANISM", 30, 37], ["M\u03a6s", "CELL", 38, 41], ["mDCs", "CELL", 46, 50], ["IL-10R1", "GENE_OR_GENE_PRODUCT", 66, 73], ["SOCS3", "GENE_OR_GENE_PRODUCT", 123, 128], ["SHFV-infected macaque M\u03a6s", "CELL_LINE", 16, 41], ["mDCs", "CELL_TYPE", 46, 50], ["IL", "PROTEIN", 66, 68], ["10R1", "PROTEIN", 69, 73], ["SOCS3", "PROTEIN", 123, 128], ["SHFV", "SPECIES", 16, 20], ["macaque", "SPECIES", 30, 37], ["IL", "TEST", 66, 68], ["infection", "PROBLEM", 109, 118], ["SOCS3 expression", "PROBLEM", 123, 139], ["infected macaque", "OBSERVATION", 21, 37]]], ["Treatment of macaque M\u03a6s and mDCs with recombinant human IL-10 starting prior to or at the time of infection with SHFV suppressed IL-6 and MIP-1\u03b1 but not TNF-\u03b1 production in macaque cells without altering viral yields or cell viability.", [["M\u03a6s", "ANATOMY", 21, 24], ["mDCs", "ANATOMY", 29, 33], ["cells", "ANATOMY", 182, 187], ["cell", "ANATOMY", 221, 225], ["infection", "DISEASE", 99, 108], ["macaque", "ORGANISM", 13, 20], ["M\u03a6s", "CELL", 21, 24], ["mDCs", "CELL", 29, 33], ["human", "ORGANISM", 51, 56], ["IL-10", "GENE_OR_GENE_PRODUCT", 57, 62], ["SHFV", "SIMPLE_CHEMICAL", 114, 118], ["IL-6", "GENE_OR_GENE_PRODUCT", 130, 134], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 139, 145], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 154, 159], ["macaque", "ORGANISM", 174, 181], ["cells", "CELL", 182, 187], ["cell", "CELL", 221, 225], ["macaque M\u03a6s", "CELL_TYPE", 13, 24], ["mDCs", "CELL_TYPE", 29, 33], ["recombinant human IL-10", "PROTEIN", 39, 62], ["TNF", "PROTEIN", 154, 157], ["macaque cells", "CELL_TYPE", 174, 187], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["SHFV", "SPECIES", 114, 118], ["macaque M\u03a6s", "TREATMENT", 13, 24], ["recombinant human IL", "TREATMENT", 39, 59], ["infection", "PROBLEM", 99, 108], ["SHFV suppressed IL", "TEST", 114, 132], ["MIP", "TEST", 139, 142], ["TNF", "TEST", 154, 157], ["altering viral yields", "PROBLEM", 196, 217], ["cell viability", "PROBLEM", 221, 235], ["infection", "OBSERVATION", 99, 108], ["cell viability", "OBSERVATION", 221, 235]]], ["Treatment of baboon cells with anti-IL-10 antibody did not result in the production of proinflammatory cytokines and SOCS3 expression was upregulated prior to the upregulation of IL-10R1 suggesting that SOCS3 expression may be induced by SHFV infection.Artervirus open reading framesThe arterivirus major and minor structural proteins are encoded within the 3\u2032 one-third of the genome and are translated from a nested set of 5\u2032 and 3\u2032 coterminal subgenomic mRNAs (sg mRNAs) (Zeng, Godeny et al. 1995 , Godeny, deVries et al. 1998 , Snijder and Spaan 2006 .", [["baboon cells", "ANATOMY", 13, 25], ["infection", "DISEASE", 243, 252], ["baboon", "ORGANISM", 13, 19], ["cells", "CELL", 20, 25], ["anti-IL-10", "GENE_OR_GENE_PRODUCT", 31, 41], ["SOCS3", "GENE_OR_GENE_PRODUCT", 117, 122], ["IL-10R1", "GENE_OR_GENE_PRODUCT", 179, 186], ["SOCS3", "GENE_OR_GENE_PRODUCT", 203, 208], ["SHFV", "GENE_OR_GENE_PRODUCT", 238, 242], ["genome", "CELLULAR_COMPONENT", 378, 384], ["\u2032", "GENE_OR_GENE_PRODUCT", 426, 427], ["baboon cells", "CELL_TYPE", 13, 25], ["anti-IL-10 antibody", "PROTEIN", 31, 50], ["proinflammatory cytokines", "PROTEIN", 87, 112], ["SOCS3", "PROTEIN", 117, 122], ["IL-10R1", "PROTEIN", 179, 186], ["SOCS3", "PROTEIN", 203, 208], ["Artervirus open reading frames", "DNA", 253, 283], ["arterivirus major and minor structural proteins", "PROTEIN", 287, 334], ["3\u2032 one-third of the genome", "DNA", 358, 384], ["5\u2032 and 3\u2032 coterminal subgenomic mRNAs", "RNA", 425, 462], ["sg mRNAs", "RNA", 464, 472], ["SHFV", "SPECIES", 238, 242], ["baboon cells", "PROBLEM", 13, 25], ["anti-IL-10 antibody", "TEST", 31, 50], ["proinflammatory cytokines", "PROBLEM", 87, 112], ["SOCS3 expression", "PROBLEM", 117, 133], ["the upregulation of IL", "TREATMENT", 159, 181], ["SOCS3 expression", "PROBLEM", 203, 219], ["SHFV infection", "PROBLEM", 238, 252], ["a nested set", "TEST", 409, 421], ["baboon cells", "OBSERVATION", 13, 25], ["SOCS3 expression", "OBSERVATION", 203, 219], ["may be", "UNCERTAINTY", 220, 226], ["infection", "OBSERVATION", 243, 252], ["minor", "OBSERVATION_MODIFIER", 309, 314], ["structural proteins", "OBSERVATION", 315, 334], ["genome", "OBSERVATION", 378, 384], ["subgenomic mRNAs", "OBSERVATION", 446, 462]]], ["The 5\u2032 two-thirds of the genome encodes two polyproteins 1a and 1ab.", [["polyproteins 1a and 1ab", "PROTEIN", 44, 67]]], ["Polyprotein 1ab is produced when a \u22121 ribosomal frameshift occurs on a slippery sequence located near the polyprotein 1a stop codon (Snijder and Spaan 2006) .", [["ribosomal", "ANATOMY", 38, 47], ["Polyprotein 1", "GENE_OR_GENE_PRODUCT", 0, 13], ["\u22121 ribosomal frameshift", "DNA", 35, 58], ["slippery sequence", "DNA", 71, 88], ["polyprotein 1a stop codon", "DNA", 106, 131], ["Polyprotein", "TREATMENT", 0, 11], ["a \u22121 ribosomal frameshift", "PROBLEM", 33, 58], ["a slippery sequence", "TREATMENT", 69, 88], ["frameshift", "OBSERVATION", 48, 58]]], ["A second frameshift (-2) can occur in nsp2 producing a truncated nsp2 protein with a different C-terminal sequence (nsp2TF) (Fang, Treffers et al. 2012) .", [["C", "CHEMICAL", 95, 96], ["nsp2", "GENE_OR_GENE_PRODUCT", 38, 42], ["nsp2", "GENE_OR_GENE_PRODUCT", 65, 69], ["nsp2", "PROTEIN", 38, 42], ["truncated nsp2 protein", "PROTEIN", 55, 77], ["C-terminal sequence", "DNA", 95, 114], ["A second frameshift", "PROBLEM", 0, 19], ["nsp2", "PROBLEM", 38, 42], ["a truncated nsp2 protein", "PROBLEM", 53, 77], ["a different C-terminal sequence", "TREATMENT", 83, 114], ["frameshift", "OBSERVATION", 9, 19]]], ["Polyproteins 1a and 1ab are posttranslationally cleaved by viral proteases to generate the nonstructural proteins (nsp) involved in replication and transcription of the viral genome and sg mRNAs Meulenberg 1998, Beerens, Selisko et al. 2007 ).", [["Polyproteins 1a", "GENE_OR_GENE_PRODUCT", 0, 15], ["1", "GENE_OR_GENE_PRODUCT", 20, 21], ["nsp", "GENE_OR_GENE_PRODUCT", 115, 118], ["Polyproteins 1a and 1ab", "PROTEIN", 0, 23], ["viral proteases", "PROTEIN", 59, 74], ["nonstructural proteins", "PROTEIN", 91, 113], ["nsp", "PROTEIN", 115, 118], ["viral genome", "DNA", 169, 181], ["Polyproteins 1a", "TREATMENT", 0, 15], ["viral proteases", "PROBLEM", 59, 74]]], ["The SHFV genome encodes additional proteins at both its 5\u2032 and 3\u2032 ends compared to the genomes of the other known arteriviruses.Artervirus open reading framesThe nsp1 proteins are encoded at the N-terminus of polyproteins 1a and are cleaved from the polyprotein by viral papain-like protease 1 (PLP1) domains.", [["N", "CHEMICAL", 195, 196], ["SHFV", "GENE_OR_GENE_PRODUCT", 4, 8], ["arteriviruses", "CANCER", 114, 127], ["nsp1", "GENE_OR_GENE_PRODUCT", 162, 166], ["1a", "GENE_OR_GENE_PRODUCT", 222, 224], ["papain-like protease 1", "GENE_OR_GENE_PRODUCT", 271, 293], ["PLP1", "GENE_OR_GENE_PRODUCT", 295, 299], ["SHFV genome", "DNA", 4, 15], ["5\u2032 and 3\u2032 ends", "DNA", 56, 70], ["Artervirus open reading frames", "DNA", 128, 158], ["nsp1 proteins", "PROTEIN", 162, 175], ["N-terminus", "PROTEIN", 195, 205], ["polyproteins 1a", "PROTEIN", 209, 224], ["viral papain-like protease 1 (PLP1) domains", "PROTEIN", 265, 308], ["SHFV", "SPECIES", 4, 8], ["The nsp1 proteins", "TEST", 158, 175], ["polyproteins 1a", "PROBLEM", 209, 224], ["the polyprotein", "TREATMENT", 246, 261], ["viral papain-like protease", "TREATMENT", 265, 291], ["nsp1 proteins", "OBSERVATION", 162, 175], ["viral papain", "OBSERVATION", 265, 277]]], ["All of the arterivirus nsp1 proteins function as interferon pathway antagonists, inhibiting IRF-3 and NF-\u03baB mediated IFN\u03b2 promoter activity as well as the ISRE promotor activity (Beura, Sarkar et al. 2010 , Fang and Snijder 2010 , Kim, Sun et al. 2010 , Song, Krell et al. 2010 , Beura, Subramaniam et al. 2012 , Han, Kim et al. 2014 .", [["nsp1", "GENE_OR_GENE_PRODUCT", 23, 27], ["IRF-3", "GENE_OR_GENE_PRODUCT", 92, 97], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 102, 107], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 117, 121], ["arterivirus nsp1 proteins", "PROTEIN", 11, 36], ["interferon", "PROTEIN", 49, 59], ["IRF", "PROTEIN", 92, 95], ["NF-\u03baB", "PROTEIN", 102, 107], ["IFN\u03b2 promoter", "DNA", 117, 130], ["ISRE promotor", "DNA", 155, 168], ["the arterivirus nsp1 proteins function", "TREATMENT", 7, 45], ["interferon pathway antagonists", "TREATMENT", 49, 79], ["IRF", "TEST", 92, 95], ["NF", "TEST", 102, 104], ["B mediated IFN\u03b2 promoter activity", "TREATMENT", 106, 139]]], ["The N-terminal zinc-finger domain in EAV nsp1 and PRRSV nsp1\u03b1 was shown to regulate sg mRNA and genome transcription abundance (van Dinten, den Boon et al. 1997 , Kroese, Zevenhoven-Dobbe et al. 2008 , Nedialkova, Gorbalenya et al. 2010 ).Arterivirus proteasesThe arterivirus ORF1a polyprotein encodes multiple proteases: PLP1 domains in the nsp1 region, a PLP2 domain in nsp2, and the main serine protease domain in nsp4 (Snijder and Spaan 2006) .", [["zinc", "CHEMICAL", 15, 19], ["serine", "CHEMICAL", 391, 397], ["EAV", "ORGANISM", 37, 40], ["nsp1", "GENE_OR_GENE_PRODUCT", 41, 45], ["PRRSV nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 50, 61], ["sg", "GENE_OR_GENE_PRODUCT", 84, 86], ["ORF1a", "GENE_OR_GENE_PRODUCT", 276, 281], ["PLP1", "GENE_OR_GENE_PRODUCT", 322, 326], ["nsp1", "GENE_OR_GENE_PRODUCT", 342, 346], ["PLP2", "GENE_OR_GENE_PRODUCT", 357, 361], ["nsp2", "GENE_OR_GENE_PRODUCT", 372, 376], ["nsp4", "GENE_OR_GENE_PRODUCT", 417, 421], ["N-terminal zinc-finger domain", "PROTEIN", 4, 33], ["EAV nsp1", "PROTEIN", 37, 45], ["PRRSV nsp1\u03b1", "PROTEIN", 50, 61], ["sg mRNA", "RNA", 84, 91], ["Arterivirus proteases", "PROTEIN", 239, 260], ["arterivirus ORF1a polyprotein", "PROTEIN", 264, 293], ["proteases", "PROTEIN", 311, 320], ["PLP1 domains", "PROTEIN", 322, 334], ["nsp1 region", "PROTEIN", 342, 353], ["PLP2 domain", "PROTEIN", 357, 368], ["nsp2", "PROTEIN", 372, 376], ["serine protease domain", "PROTEIN", 391, 413], ["nsp4", "PROTEIN", 417, 421], ["Snijder", "PROTEIN", 423, 430], ["Spaan 2006", "PROTEIN", 435, 445], ["PRRSV", "SPECIES", 50, 55], ["EAV", "SPECIES", 37, 40], ["PRRSV", "SPECIES", 50, 55], ["The N-terminal zinc-finger domain", "PROBLEM", 0, 33], ["EAV nsp1", "TREATMENT", 37, 45], ["PRRSV nsp1", "TREATMENT", 50, 60], ["Arterivirus proteases", "PROBLEM", 239, 260], ["The arterivirus ORF1a polyprotein encodes multiple proteases", "TREATMENT", 260, 320], ["PLP1 domains in the nsp1 region", "PROBLEM", 322, 353], ["a PLP2 domain in nsp2", "PROBLEM", 355, 376], ["the main serine protease domain", "TREATMENT", 382, 413], ["nsp4", "PROBLEM", 417, 421], ["finger", "ANATOMY", 20, 26], ["PRRSV nsp1", "OBSERVATION", 50, 60], ["multiple", "OBSERVATION_MODIFIER", 302, 310], ["proteases", "OBSERVATION", 311, 320], ["nsp1", "ANATOMY", 342, 346], ["region", "ANATOMY_MODIFIER", 347, 353]]], ["Arterivirus PLP2s are similar to coronavirus PLPs (PLP1, PLP2, and PLpro) in having a catalytic Cys-His-Asp triad and the ability to cleave both in cis and in trans (Mielech, Chen et al. 2014) .", [["Cys", "CHEMICAL", 96, 99], ["His", "CHEMICAL", 100, 103], ["Asp", "CHEMICAL", 104, 107], ["PLP2s", "GENE_OR_GENE_PRODUCT", 12, 17], ["coronavirus", "ORGANISM", 33, 44], ["PLPs", "GENE_OR_GENE_PRODUCT", 45, 49], ["PLP1", "GENE_OR_GENE_PRODUCT", 51, 55], ["PLP2", "GENE_OR_GENE_PRODUCT", 57, 61], ["PLpro", "GENE_OR_GENE_PRODUCT", 67, 72], ["PLP2s", "PROTEIN", 12, 17], ["coronavirus PLPs", "PROTEIN", 33, 49], ["PLP1", "PROTEIN", 51, 55], ["PLP2", "PROTEIN", 57, 61], ["PLpro", "PROTEIN", 67, 72], ["catalytic Cys-His-Asp triad", "PROTEIN", 86, 113], ["coronavirus", "SPECIES", 33, 44], ["Arterivirus PLP2s", "TEST", 0, 17], ["coronavirus PLPs", "TEST", 33, 49], ["PLP1", "TEST", 51, 55], ["PLP2", "TEST", 57, 61], ["a catalytic Cys", "TEST", 84, 99], ["Asp triad", "PROBLEM", 104, 113]]], ["In contrast, arterivirus PLP1s have a Cys-His catalytic tandem (Sun, Xue et al. 2009 , Xue, Sun et al. 2010 .", [["Cys", "CHEMICAL", 38, 41], ["His", "CHEMICAL", 42, 45], ["arterivirus PLP1s", "ORGANISM", 13, 30], ["a Cys", "TEST", 36, 41], ["His catalytic tandem", "TREATMENT", 42, 62]]], ["EAV, LDV and PRRSV PLP1s were shown to cleave exclusively in cis at a single site downstream of the catalytic domain (Snijder and Spaan 2006) .", [["EAV", "ORGANISM", 0, 3], ["LDV", "ORGANISM", 5, 8], ["PRRSV", "ORGANISM", 13, 18], ["PLP1s", "GENE_OR_GENE_PRODUCT", 19, 24], ["EAV, LDV and PRRSV PLP1s", "DNA", 0, 24], ["catalytic domain", "PROTEIN", 100, 116], ["PRRSV", "SPECIES", 13, 18], ["EAV", "SPECIES", 0, 3], ["LDV", "SPECIES", 5, 8], ["PRRSV", "SPECIES", 13, 18], ["EAV", "PROBLEM", 0, 3], ["LDV", "TREATMENT", 5, 8], ["PRRSV PLP1s", "TREATMENT", 13, 24]]], ["All of the coronavirus PLPs and the arterivirus PLP2s also have deubiquitinating and deISGylating activities (van Kasteren, Bailey-Elkin et al. 2013 , Mielech, Chen et al. 2014 .", [["coronavirus", "ORGANISM", 11, 22], ["PLPs", "GENE_OR_GENE_PRODUCT", 23, 27], ["PLP2s", "GENE_OR_GENE_PRODUCT", 48, 53], ["coronavirus PLPs", "PROTEIN", 11, 27], ["arterivirus PLP2s", "DNA", 36, 53], ["the coronavirus PLPs", "TEST", 7, 27], ["coronavirus", "OBSERVATION", 11, 22]]], ["Most coronavirus PLPs cleave at a canonical -Leu-X-Gly\u2193Gly site but the cleavage sites of arterivirus PLPs are not well conserved (Sun, Xue et al. 2009 , Xue, Sun et al. 2010 , Mielech, Chen et al. 2014 .", [["Leu", "CHEMICAL", 45, 48], ["Gly", "CHEMICAL", 51, 54], ["Gly", "CHEMICAL", 55, 58], ["coronavirus", "ORGANISM", 5, 16], ["PLPs", "GENE_OR_GENE_PRODUCT", 17, 21], ["Gly", "AMINO_ACID", 55, 58], ["arterivirus PLPs", "GENE_OR_GENE_PRODUCT", 90, 106], ["coronavirus PLPs", "PROTEIN", 5, 21], ["arterivirus PLPs", "PROTEIN", 90, 106], ["coronavirus", "SPECIES", 5, 16], ["Most coronavirus PLPs", "PROBLEM", 0, 21], ["Gly site", "PROBLEM", 55, 63], ["the cleavage sites of arterivirus PLPs", "PROBLEM", 68, 106]]], ["Autocleavage by LDV and PRRSV PLP1\u03b1 and PLP1\u03b2 generate nsp1\u03b1 and nsp1\u03b2, respectively (den Boon, Faaberg et al. 1995 , Sun, Xue et al. 2009 , Xue, Sun et al. 2010 ) ( Figure 1A ).", [["LDV", "ORGANISM", 16, 19], ["PRRSV", "ORGANISM", 24, 29], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 30, 35], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 40, 45], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 55, 60], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 65, 70], ["PRRSV PLP1\u03b1", "PROTEIN", 24, 35], ["PLP1\u03b2", "PROTEIN", 40, 45], ["nsp1\u03b1", "PROTEIN", 55, 60], ["nsp1\u03b2", "PROTEIN", 65, 70], ["PRRSV", "SPECIES", 24, 29], ["LDV", "SPECIES", 16, 19], ["PRRSV", "SPECIES", 24, 29]]], ["The EAV PLP1\u03b1 domain is inactive due to a Lys substitution of the catalytic Cys residue and a single nsp1 fusion protein is produced (Snijder, Wassenaar et al. 1992 , Ziebuhr, Snijder et al. 2000 .Functional analysis of the SHFV PLP1s in the nsp1 regionSHFV is unique among arteriviruses in encoding a longer nsp1 region containing three predicted PLP1 domains (PLP1\u03b1, PLP1\u03b2, and PLP1\u03b3) ( Figure 1A ).", [["Lys", "CHEMICAL", 42, 45], ["Lys", "CHEMICAL", 42, 45], ["Cys", "CHEMICAL", 76, 79], ["EAV", "ORGANISM", 4, 7], ["PLP1", "GENE_OR_GENE_PRODUCT", 8, 12], ["Lys", "AMINO_ACID", 42, 45], ["nsp1", "GENE_OR_GENE_PRODUCT", 101, 105], ["SHFV", "GENE_OR_GENE_PRODUCT", 224, 228], ["nsp1", "GENE_OR_GENE_PRODUCT", 242, 246], ["arteriviruses", "CANCER", 274, 287], ["PLP1", "GENE_OR_GENE_PRODUCT", 348, 352], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 362, 367], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 369, 374], ["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 380, 385], ["EAV PLP1\u03b1 domain", "PROTEIN", 4, 20], ["catalytic Cys residue", "PROTEIN", 66, 87], ["nsp1 fusion protein", "PROTEIN", 101, 120], ["SHFV PLP1s", "DNA", 224, 234], ["nsp1 regionSHFV", "DNA", 242, 257], ["nsp1 region", "DNA", 309, 320], ["PLP1 domains", "DNA", 348, 360], ["PLP1\u03b1", "DNA", 362, 367], ["PLP1\u03b2", "DNA", 369, 374], ["PLP1\u03b3", "DNA", 380, 385], ["Figure 1A", "DNA", 389, 398], ["EAV", "SPECIES", 4, 7], ["a Lys substitution", "TREATMENT", 40, 58], ["the catalytic Cys residue", "TREATMENT", 62, 87], ["a single nsp1 fusion protein", "TREATMENT", 92, 120], ["Functional analysis", "TEST", 197, 216], ["a longer nsp1 region", "TREATMENT", 300, 320], ["PLP1 domains", "TEST", 348, 360], ["PLP1", "TEST", 362, 366], ["PLP1", "TEST", 369, 373], ["nsp1 fusion", "OBSERVATION", 101, 112]]], ["The SHFV LVR nsp1 sequences were homology modeled on crystal structures of PRRSV nsp1\u03b1 and nsp1\u03b2 (Sun, Xue et al. 2009 , Xue, Sun et al. 2010 .", [["SHFV", "GENE_OR_GENE_PRODUCT", 4, 8], ["PRRSV", "ORGANISM", 75, 80], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 81, 86], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 91, 96], ["SHFV LVR nsp1 sequences", "DNA", 4, 27], ["PRRSV nsp1\u03b1", "PROTEIN", 75, 86], ["nsp1", "PROTEIN", 91, 95], ["SHFV", "SPECIES", 4, 8], ["PRRSV", "SPECIES", 75, 80], ["The SHFV LVR nsp1 sequences", "TEST", 0, 27], ["nsp1", "PROBLEM", 91, 95], ["PRRSV nsp1", "OBSERVATION", 75, 85]]], ["SHFV nsp1\u03b1 modeled well on the PRRSV nsp1\u03b1 structure and SHFV nsp1\u03b2 modeled well on the PRRSV nsp1\u03b2 structure.", [["SHFV nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 0, 10], ["PRRSV", "ORGANISM", 31, 36], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 37, 42], ["SHFV nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 57, 67], ["PRRSV", "ORGANISM", 88, 93], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 94, 99], ["SHFV nsp1\u03b1", "PROTEIN", 0, 10], ["PRRSV nsp1\u03b1 structure", "PROTEIN", 31, 52], ["SHFV nsp1\u03b2", "PROTEIN", 57, 67], ["PRRSV nsp1\u03b2 structure", "PROTEIN", 88, 109], ["PRRSV", "SPECIES", 31, 36], ["SHFV", "SPECIES", 0, 4], ["PRRSV", "SPECIES", 31, 36], ["PRRSV", "SPECIES", 88, 93]]], ["SHFV nsp1\u03b3 was modeled on both the PRRSV nsp1\u03b1 and nsp1\u03b2 structures and appeared to be more similar to PRRSV nsp1\u03b1 than nsp1\u03b2.", [["SHFV nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 0, 10], ["PRRSV", "ORGANISM", 35, 40], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 41, 46], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 51, 56], ["PRRSV", "ORGANISM", 103, 108], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 109, 114], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 120, 125], ["SHFV nsp1\u03b3", "PROTEIN", 0, 10], ["PRRSV nsp1\u03b1 and nsp1\u03b2 structures", "DNA", 35, 67], ["PRRSV nsp1\u03b1", "PROTEIN", 103, 114], ["nsp1\u03b2", "PROTEIN", 120, 125], ["SHFV", "SPECIES", 0, 4], ["PRRSV", "SPECIES", 35, 40], ["PRRSV", "SPECIES", 103, 108], ["PRRSV nsp1", "OBSERVATION", 35, 45]]], ["The catalytic residues of other arterivirus PLP1s were previously identified as a Cys and a His located about 60 amino acids downstream.", [["amino acids", "CHEMICAL", 113, 124], ["Cys", "CHEMICAL", 82, 85], ["His", "CHEMICAL", 92, 95], ["amino acids", "CHEMICAL", 113, 124], ["PLP1s", "GENE_OR_GENE_PRODUCT", 44, 49], ["amino acids", "AMINO_ACID", 113, 124], ["arterivirus PLP1s", "PROTEIN", 32, 49], ["The catalytic residues of other arterivirus PLP1s", "PROBLEM", 0, 49], ["a Cys", "TEST", 80, 85], ["60 amino acids downstream", "TREATMENT", 110, 135], ["catalytic residues", "OBSERVATION", 4, 22]]], ["In all previously studied active arterivirus PLP1s, a Trp follows the catalytic Cys (den Boon, Faaberg et al. 1995 , Sun, Xue et al. 2009 , Xue, Sun et al. 2010 ).", [["Trp", "CHEMICAL", 54, 57], ["Trp", "CHEMICAL", 54, 57], ["Cys", "CHEMICAL", 80, 83], ["arterivirus PLP1s", "CELL", 33, 50], ["Trp", "AMINO_ACID", 54, 57], ["arterivirus PLP1s", "PROTEIN", 33, 50]]], ["Alignment of the three SHFV PLP1 sequences with each other using a conserved GV[Q/T]G motif as an anchor ) predicted Cys246 as a catalytic residue of PLP1\u03b2 and Cys378 as a catalytic residue of PLP1\u03b3.", [["PLP1", "GENE_OR_GENE_PRODUCT", 28, 32], ["Cys246", "GENE_OR_GENE_PRODUCT", 117, 123], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 150, 155], ["Cys378", "GENE_OR_GENE_PRODUCT", 160, 166], ["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 193, 198], ["SHFV PLP1 sequences", "DNA", 23, 42], ["PLP1\u03b2", "PROTEIN", 150, 155], ["Cys378", "PROTEIN", 160, 166], ["PLP1\u03b3", "PROTEIN", 193, 198], ["a conserved GV[Q/T]G motif", "TREATMENT", 65, 91], ["a catalytic residue of PLP1\u03b3", "PROBLEM", 170, 198]]], ["Each of these Cys residues was adjacent to a Trp Brinton et al. Page 6 Virus Res. Author manuscript; available in PMC 2016 April 16. and located 62 and 64 aa upstream, respectively, of the predicted catalytic His.", [["Cys", "CHEMICAL", 14, 17], ["Trp", "CHEMICAL", 45, 48], ["His", "CHEMICAL", 209, 212], ["62 and 64 aa upstream", "DNA", 145, 166], ["catalytic His", "PROTEIN", 199, 212], ["these Cys residues", "PROBLEM", 8, 26], ["a Trp Brinton et al", "TREATMENT", 43, 62], ["Cys residues", "OBSERVATION", 14, 26]]], ["In PLP1\u03b1, the only Cys adjacent to a Trp was Cys115 located only 14 amino acids upstream of the predicted catalytic His.", [["Cys115", "CHEMICAL", 45, 51], ["amino acids", "CHEMICAL", 68, 79], ["Cys", "CHEMICAL", 19, 22], ["Trp", "CHEMICAL", 37, 40], ["Cys", "CHEMICAL", 45, 48], ["amino acids", "CHEMICAL", 68, 79], ["His", "CHEMICAL", 116, 119], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 3, 8], ["Trp", "AMINO_ACID", 37, 40], ["Cys115", "AMINO_ACID", 45, 51], ["amino acids", "AMINO_ACID", 68, 79], ["PLP1\u03b1", "PROTEIN", 3, 8], ["Cys115", "PROTEIN", 45, 51], ["catalytic His", "PROTEIN", 106, 119], ["a Trp", "TEST", 35, 40], ["Cys", "TEST", 45, 48], ["amino acids", "TEST", 68, 79]]], ["Cys63 located 67 amino acids upstream of the predicted catalytic His aligned with the predicted catalytic Cys residues of SHFV PLP1\u03b2 and PLP1\u03b3 but was adjacent to an Ala.", [["Cys63", "CHEMICAL", 0, 5], ["amino acids", "CHEMICAL", 17, 28], ["Cys63", "CHEMICAL", 0, 5], ["amino acids", "CHEMICAL", 17, 28], ["His", "CHEMICAL", 65, 68], ["Cys", "CHEMICAL", 106, 109], ["Ala", "CHEMICAL", 166, 169], ["Cys63", "AMINO_ACID", 0, 5], ["amino acids", "AMINO_ACID", 17, 28], ["SHFV PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 122, 132], ["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 137, 142], ["catalytic Cys residues", "PROTEIN", 96, 118], ["SHFV", "PROTEIN", 122, 126], ["PLP1\u03b2", "PROTEIN", 127, 132], ["PLP1\u03b3", "PROTEIN", 137, 142], ["amino acids", "TEST", 17, 28], ["Ala", "ANATOMY", 166, 169]]], ["Alignment of SHFV, PRRSV and LDV PLP1\u03b1 sequences also predicted Cys63 as the catalytic Cys.", [["Cys", "CHEMICAL", 87, 90], ["SHFV", "GENE_OR_GENE_PRODUCT", 13, 17], ["PRRSV", "ORGANISM", 19, 24], ["LDV", "ORGANISM", 29, 32], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 33, 38], ["Cys63", "GENE_OR_GENE_PRODUCT", 64, 69], ["SHFV, PRRSV and LDV PLP1\u03b1 sequences", "DNA", 13, 48], ["Cys63", "DNA", 64, 69], ["SHFV", "SPECIES", 13, 17], ["PRRSV", "SPECIES", 19, 24], ["LDV", "SPECIES", 29, 32], ["SHFV", "TEST", 13, 17]]], ["Arterivirus PLP1 cleavage site sequences are not well conserved (den Boon, Faaberg et al. 1995 , Sun, Xue et al. 2009 , Xue, Sun et al. 2010 .", [["PLP1", "GENE_OR_GENE_PRODUCT", 12, 16], ["Arterivirus PLP1 cleavage site sequences", "DNA", 0, 40], ["Arterivirus PLP1 cleavage site sequences", "TREATMENT", 0, 40]]], ["The alignments predicted that SHFV PLP1\u03b1 cleaved at either Gly170/Thr171 or Gly164/Gly165, that PLP1\u03b2 cleaved at Gly350/Gly351 and that PLP1\u03b3 cleaved at Gly484/Gly485.Functional analysis of the SHFV PLP1s in the nsp1 regionIn vitro autocleavage products of wild type and mutant polyproteins consisting of the SHFV LVR nsp1 region plus the N-terminal part of nsp2 with an N-terminal Flag tag and a Cterminal c-Myc tag were analyzed ).", [["Thr", "CHEMICAL", 66, 69], ["Gly", "CHEMICAL", 83, 86], ["Gly", "CHEMICAL", 120, 123], ["Gly484", "CHEMICAL", 153, 159], ["Gly", "CHEMICAL", 160, 163], ["N", "CHEMICAL", 339, 340], ["N", "CHEMICAL", 371, 372], ["SHFV PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 30, 40], ["Thr171", "AMINO_ACID", 66, 72], ["Gly165", "AMINO_ACID", 83, 89], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 96, 101], ["Gly351", "AMINO_ACID", 120, 126], ["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 136, 141], ["Gly485", "AMINO_ACID", 160, 166], ["nsp2", "GENE_OR_GENE_PRODUCT", 358, 362], ["c-Myc", "GENE_OR_GENE_PRODUCT", 407, 412], ["SHFV PLP1\u03b1", "PROTEIN", 30, 40], ["PLP1\u03b2", "PROTEIN", 96, 101], ["Gly350", "PROTEIN", 113, 119], ["PLP1\u03b3", "PROTEIN", 136, 141], ["SHFV PLP1s", "DNA", 194, 204], ["nsp1 region", "DNA", 212, 223], ["In vitro autocleavage products", "PROTEIN", 223, 253], ["mutant polyproteins", "PROTEIN", 271, 290], ["SHFV LVR nsp1 region", "PROTEIN", 309, 329], ["N-terminal part", "PROTEIN", 339, 354], ["nsp2", "PROTEIN", 358, 362], ["N-terminal Flag tag", "PROTEIN", 371, 390], ["Cterminal c", "PROTEIN", 397, 408], ["Myc tag", "PROTEIN", 409, 416], ["Gly164/Gly", "TEST", 76, 86], ["PLP1", "TEST", 96, 100], ["PLP1", "TEST", 136, 140], ["Functional analysis", "TEST", 167, 186], ["vitro autocleavage products", "TREATMENT", 226, 253], ["wild type and mutant polyproteins", "PROBLEM", 257, 290], ["the SHFV LVR nsp1 region", "TREATMENT", 305, 329], ["nsp2", "PROBLEM", 358, 362], ["an N-terminal Flag tag", "TREATMENT", 368, 390], ["a Cterminal c-Myc tag", "TREATMENT", 395, 416], ["nsp1", "ANATOMY", 212, 216], ["region", "ANATOMY_MODIFIER", 217, 223]]], ["In addition to the expected precursors and cleavage products, a ~30 kDa band was consistently detected in the wild type lysate, Flag and c-Myc immunoprecipitation lanes, suggesting the existence of an extra cleavage site within the PLP1\u03b2 catalytic domain that generates N-and C-terminal ~30 kDa cleavage products.", [["lysate", "ANATOMY", 120, 126], ["N", "CHEMICAL", 270, 271], ["C", "CHEMICAL", 276, 277], ["Flag", "GENE_OR_GENE_PRODUCT", 128, 132], ["c-Myc", "GENE_OR_GENE_PRODUCT", 137, 142], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 232, 237], ["cleavage products", "PROTEIN", 43, 60], ["Flag", "PROTEIN", 128, 132], ["Myc", "PROTEIN", 139, 142], ["PLP1\u03b2 catalytic domain", "PROTEIN", 232, 254], ["N-and C-terminal ~30 kDa cleavage products", "PROTEIN", 270, 312], ["cleavage products", "TREATMENT", 43, 60], ["a ~30 kDa band", "TEST", 62, 76], ["c-Myc immunoprecipitation lanes", "TREATMENT", 137, 168], ["an extra cleavage site", "PROBLEM", 198, 220], ["terminal ~30 kDa cleavage products", "TREATMENT", 278, 312], ["extra cleavage", "OBSERVATION", 201, 215]]], ["Substitution of Cys63 with Ala in PLP1\u03b1 abrogated cleavage between nsp1\u03b1 and nsp1\u03b2 and substitution of Cys378 in PLP1\u03b3 abrogated cleavage between nsp1\u03b3 and nsp2, identifying these Cys as functional catalytic residues ( Figure 1B ) ).", [["Cys63", "CHEMICAL", 16, 21], ["Ala", "CHEMICAL", 27, 30], ["Cys63", "CHEMICAL", 16, 21], ["Ala", "CHEMICAL", 27, 30], ["Cys", "CHEMICAL", 180, 183], ["Cys63", "AMINO_ACID", 16, 21], ["Ala", "AMINO_ACID", 27, 30], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 34, 39], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 67, 72], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 77, 82], ["Cys378", "AMINO_ACID", 103, 109], ["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 113, 118], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 146, 151], ["nsp2", "GENE_OR_GENE_PRODUCT", 156, 160], ["PLP1\u03b1", "PROTEIN", 34, 39], ["nsp1\u03b1", "PROTEIN", 67, 72], ["nsp1\u03b2", "PROTEIN", 77, 82], ["Cys378", "PROTEIN", 103, 109], ["PLP1\u03b3", "PROTEIN", 113, 118], ["nsp1\u03b3", "PROTEIN", 146, 151], ["nsp2", "PROTEIN", 156, 160], ["Substitution of Cys63", "TREATMENT", 0, 21], ["Ala in PLP1", "TREATMENT", 27, 38], ["abrogated cleavage", "TREATMENT", 40, 58], ["nsp1\u03b1", "TREATMENT", 67, 72], ["nsp1\u03b2", "TREATMENT", 77, 82], ["substitution of Cys378 in PLP1", "TREATMENT", 87, 117], ["nsp1\u03b3", "TREATMENT", 146, 151], ["nsp2", "TREATMENT", 156, 160], ["these Cys", "TEST", 174, 183], ["functional catalytic residues", "PROBLEM", 187, 216]]], ["However, substitution of Cys246 with Ala in PLP1\u03b2 reduced but did not inhibit cleavage between nsp1\u03b2 and nsp1\u03b3 suggesting that Cys246 is a PLP1\u03b2 catalytic residue but that another PLP1 can also cleave at the nsp1\u03b2/nsp1\u03b3 junction.", [["Cys246", "CHEMICAL", 25, 31], ["Ala", "CHEMICAL", 37, 40], ["Cys246", "CHEMICAL", 25, 31], ["Ala", "CHEMICAL", 37, 40], ["Cys246", "AMINO_ACID", 25, 31], ["Ala", "AMINO_ACID", 37, 40], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 44, 49], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 95, 100], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 105, 110], ["Cys246", "GENE_OR_GENE_PRODUCT", 127, 133], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 139, 144], ["PLP1", "GENE_OR_GENE_PRODUCT", 180, 184], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 208, 213], ["nsp1", "GENE_OR_GENE_PRODUCT", 214, 218], ["PLP1\u03b2", "PROTEIN", 44, 49], ["nsp1\u03b2", "PROTEIN", 95, 100], ["nsp1\u03b3", "PROTEIN", 105, 110], ["PLP1\u03b2 catalytic residue", "PROTEIN", 139, 162], ["PLP1", "PROTEIN", 180, 184], ["nsp1\u03b2", "PROTEIN", 208, 213], ["nsp1\u03b3 junction", "PROTEIN", 214, 228], ["Ala in PLP1", "TREATMENT", 37, 48], ["nsp1", "TEST", 95, 99], ["a PLP1\u03b2 catalytic residue", "PROBLEM", 137, 162], ["another PLP1", "PROBLEM", 172, 184]]], ["Inefficient cleavage at the nsp1\u03b1/nsp1\u03b2 junction as well as within nsp1\u03b2 by PLP1\u03b1 was observed when both the PLP1\u03b2 and PLP1\u03b3 catalytic Cys residues were substituted with Ala.", [["Cys", "CHEMICAL", 135, 138], ["Ala", "CHEMICAL", 170, 173], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 28, 33], ["nsp1", "GENE_OR_GENE_PRODUCT", 34, 38], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 67, 72], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 76, 81], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 109, 114], ["PLP1", "GENE_OR_GENE_PRODUCT", 119, 123], ["Ala", "AMINO_ACID", 170, 173], ["nsp1\u03b1", "PROTEIN", 28, 33], ["nsp1\u03b2", "PROTEIN", 34, 39], ["nsp1\u03b2", "PROTEIN", 67, 72], ["PLP1\u03b1", "PROTEIN", 76, 81], ["PLP1\u03b2", "PROTEIN", 109, 114], ["PLP1", "PROTEIN", 119, 123], ["Inefficient cleavage", "PROBLEM", 0, 20], ["the nsp1\u03b1/nsp1\u03b2 junction", "TREATMENT", 24, 48], ["the PLP1", "TEST", 105, 113], ["PLP1\u03b3 catalytic Cys residues", "TREATMENT", 119, 147], ["cleavage", "OBSERVATION", 12, 20]]], ["Efficient cleavage at the nsp1\u03b2/ nsp1\u03b3 junction as well as within nsp1\u03b2 by PLP1\u03b2 was observed when the catalytic Cys residues of both PLP1\u03b1 and PLP1\u03b3 were mutated.", [["Cys", "CHEMICAL", 113, 116], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["nsp1", "GENE_OR_GENE_PRODUCT", 33, 37], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 66, 71], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 75, 80], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 134, 139], ["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 144, 149], ["nsp1\u03b2", "PROTEIN", 26, 31], ["nsp1\u03b3 junction", "PROTEIN", 33, 47], ["nsp1\u03b2", "PROTEIN", 66, 71], ["PLP1\u03b2", "PROTEIN", 75, 80], ["catalytic Cys residues", "PROTEIN", 103, 125], ["PLP1\u03b1", "PROTEIN", 134, 139], ["PLP1\u03b3", "PROTEIN", 144, 149], ["Efficient cleavage at the nsp1\u03b2/ nsp1\u03b3 junction", "TREATMENT", 0, 47], ["the catalytic Cys residues", "TEST", 99, 125], ["PLP1", "TEST", 134, 138], ["cleavage", "OBSERVATION", 10, 18]]], ["However, efficient cleavage at the nsp1\u03b3/ nsp2 junction, within nsp1\u03b2 and also at the nsp1\u03b2/nsp1\u03b3 junction by PLP1\u03b3 was observed when the PLP1\u03b1 and PLP1\u03b2 catalytic Cys residues were mutated indicating that SHFV PLP1\u03b3 can cleave at upstream sites as well as at a downstream site ( Figure 1B ).Functional analysis of the SHFV PLP1s in the nsp1 regionConstructs with the \u22121 and \u22122 amino acids of each predicted cleavage site substituted were used to functionally identify the SHFV PLP1 cleavage sites .", [["amino acids", "CHEMICAL", 378, 389], ["Cys", "CHEMICAL", 164, 167], ["amino acids", "CHEMICAL", 378, 389], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 35, 40], ["nsp2", "GENE_OR_GENE_PRODUCT", 42, 46], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 64, 69], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 86, 91], ["nsp1", "GENE_OR_GENE_PRODUCT", 92, 96], ["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 110, 115], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 138, 143], ["PLP1\u03b2", "GENE_OR_GENE_PRODUCT", 148, 153], ["SHFV PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 206, 216], ["SHFV", "GENE_OR_GENE_PRODUCT", 319, 323], ["nsp1", "GENE_OR_GENE_PRODUCT", 337, 341], ["\u22121", "GENE_OR_GENE_PRODUCT", 368, 370], ["\u22122", "SIMPLE_CHEMICAL", 375, 377], ["amino acids", "AMINO_ACID", 378, 389], ["PLP1", "GENE_OR_GENE_PRODUCT", 478, 482], ["nsp1\u03b3", "PROTEIN", 35, 40], ["nsp2", "PROTEIN", 42, 46], ["nsp1\u03b2", "PROTEIN", 64, 69], ["nsp1\u03b2", "PROTEIN", 86, 91], ["nsp1", "PROTEIN", 92, 96], ["PLP1\u03b3", "PROTEIN", 110, 115], ["PLP1\u03b1", "PROTEIN", 138, 143], ["PLP1", "PROTEIN", 148, 152], ["SHFV PLP1\u03b3", "PROTEIN", 206, 216], ["upstream sites", "DNA", 231, 245], ["downstream site", "DNA", 262, 277], ["SHFV PLP1s", "DNA", 319, 329], ["nsp1 regionConstructs", "DNA", 337, 358], ["\u22121 and \u22122 amino acids", "DNA", 368, 389], ["SHFV PLP1 cleavage sites", "DNA", 473, 497], ["SHFV", "SPECIES", 319, 323], ["efficient cleavage at the nsp1\u03b3/ nsp2 junction", "TREATMENT", 9, 55], ["the PLP1", "TEST", 134, 142], ["PLP1\u03b2 catalytic Cys residues", "TREATMENT", 148, 176], ["SHFV PLP1", "PROBLEM", 206, 215], ["Functional analysis", "TEST", 292, 311], ["the SHFV PLP1s", "TEST", 315, 329], ["the \u22121 and \u22122 amino acids of each predicted cleavage site", "TREATMENT", 364, 421], ["cleavage", "OBSERVATION", 19, 27], ["nsp2 junction", "ANATOMY", 42, 55], ["nsp1", "ANATOMY_MODIFIER", 92, 96], ["PLP1 cleavage", "OBSERVATION", 478, 491]]], ["Two putative cleavage sites were predicted for PLP1\u03b1; no cleavage at the nsp1\u03b1/nsp1\u03b2 junction was detected when Gly164/Gly165 were substituted while substitution of the Gly171/ Thr172 site only reduced cleavage, suggesting that the Gly164/Gly165 site is the preferred cleavage site at the nsp1\u03b1/nsp1\u03b2 junction ( Figure 1B) .", [["Gly164", "CHEMICAL", 112, 118], ["Gly", "CHEMICAL", 119, 122], ["Gly171", "CHEMICAL", 169, 175], ["Thr", "CHEMICAL", 177, 180], ["Gly164", "CHEMICAL", 232, 238], ["Gly", "CHEMICAL", 239, 242], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 47, 52], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 73, 78], ["nsp1", "GENE_OR_GENE_PRODUCT", 79, 83], ["Gly165", "AMINO_ACID", 119, 125], ["Thr172", "AMINO_ACID", 177, 183], ["Gly165", "AMINO_ACID", 239, 245], ["PLP1\u03b1", "PROTEIN", 47, 52], ["nsp1\u03b1", "PROTEIN", 73, 78], ["nsp1\u03b2", "PROTEIN", 79, 84], ["Gly164/Gly165 site", "DNA", 232, 250], ["nsp1\u03b1", "PROTEIN", 289, 294], ["nsp1\u03b2 junction", "PROTEIN", 295, 309], ["Figure 1B", "PROTEIN", 312, 321], ["Two putative cleavage sites", "PROBLEM", 0, 27], ["PLP1\u03b1", "TEST", 47, 52], ["cleavage", "PROBLEM", 57, 65], ["the nsp1\u03b1/nsp1\u03b2 junction", "TREATMENT", 69, 93], ["the Gly171/ Thr", "TREATMENT", 165, 180], ["reduced cleavage", "PROBLEM", 194, 210], ["the Gly164/Gly165 site", "TREATMENT", 228, 250], ["cleavage site", "PROBLEM", 268, 281]]], ["This finding was supported by a mass spectroscopy analysis of the immunoprecipitated nsp1\u03b1 cleavage product that detected ten trypsin generated peptides ending at aa164 and only one peptide ending at aa171.", [["nsp1", "GENE_OR_GENE_PRODUCT", 85, 89], ["trypsin", "GENE_OR_GENE_PRODUCT", 126, 133], ["immunoprecipitated nsp1\u03b1 cleavage product", "PROTEIN", 66, 107], ["trypsin", "PROTEIN", 126, 133], ["aa171", "PROTEIN", 200, 205], ["a mass spectroscopy analysis", "TEST", 30, 58], ["the immunoprecipitated nsp1\u03b1 cleavage product", "TREATMENT", 62, 107], ["ten trypsin generated peptides", "PROBLEM", 122, 152], ["mass", "OBSERVATION", 32, 36]]], ["Substitution of the predicted Gly350/Gly351 site resulted in loss of cleavage at the nsp1\u03b2/ nsp1\u03b3 junction, indicating this is the cleavage site used.", [["Gly", "CHEMICAL", 37, 40], ["Gly351", "AMINO_ACID", 37, 43], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 85, 90], ["Gly350/Gly351 site", "DNA", 30, 48], ["nsp1\u03b2", "PROTEIN", 85, 90], ["nsp1", "PROTEIN", 92, 96], ["Substitution of the predicted Gly350/Gly", "TREATMENT", 0, 40], ["loss of cleavage", "PROBLEM", 61, 77], ["the nsp1\u03b2/ nsp1\u03b3 junction", "TREATMENT", 81, 106], ["the cleavage site", "PROBLEM", 127, 144], ["loss", "OBSERVATION_MODIFIER", 61, 65]]], ["Three adjacent Gly residues are present at the predicted cleavage site between nsp1\u03b3 and nsp2.", [["Gly", "CHEMICAL", 15, 18], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 79, 84], ["nsp2", "GENE_OR_GENE_PRODUCT", 89, 93], ["nsp1\u03b3", "PROTEIN", 79, 84], ["nsp2", "PROTEIN", 89, 93], ["Three adjacent Gly residues", "PROBLEM", 0, 27], ["nsp2", "PROBLEM", 89, 93], ["Gly residues", "OBSERVATION", 15, 27], ["cleavage", "OBSERVATION_MODIFIER", 57, 65], ["site", "OBSERVATION_MODIFIER", 66, 70]]], ["Substitution of either Gly484/ Gly485 or Gly485/Gly486 resulted in loss of cleavage between nsp1\u03b3 and nsp2.", [["Gly485/Gly486", "CHEMICAL", 41, 54], ["Gly484", "CHEMICAL", 23, 29], ["Gly485", "CHEMICAL", 31, 37], ["Gly485", "CHEMICAL", 41, 47], ["Gly486", "CHEMICAL", 48, 54], ["Gly484", "GENE_OR_GENE_PRODUCT", 23, 29], ["Gly485", "AMINO_ACID", 31, 37], ["Gly486", "AMINO_ACID", 48, 54], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 92, 97], ["nsp2", "GENE_OR_GENE_PRODUCT", 102, 106], ["nsp1\u03b3", "PROTEIN", 92, 97], ["nsp2", "PROTEIN", 102, 106], ["loss of cleavage", "PROBLEM", 67, 83], ["nsp1\u03b3", "TREATMENT", 92, 97], ["nsp2", "PROBLEM", 102, 106]]], ["Mass spectroscopy analyses of immunoprecipitated cleavage products nsp1\u03b1+\u03b2 and nsp1\u03b1+\u03b2+\u03b3 confirmed the locations of the cleavage sites at the nsp1\u03b2/nsp1\u03b3 and nsp1\u03b3/nsp2 junctions.Functional analysis of the SHFV PLP1s in the nsp1 regionSubstitution of the Gly271/Val272 site within nsp1\u03b2 resulted in the loss of cleavage within nsp1\u03b2, indicating that this site can be cleaved in in vitro reactions.Functional analysis of the SHFV PLP1s in the nsp1 regionAnalysis of SHFV nsp1 region autoprocessing in infected cells by Western blotting using SHFV nsp1\u03b1-, nsp1\u03b2-(N-or C-terminal) or nsp1\u03b3-specific antibodies detected only the mature nsp1\u03b1, nsp1\u03b2 and nsp1\u03b3 proteins, respectively ).", [["cells", "ANATOMY", 509, 514], ["Val272", "CHEMICAL", 262, 268], ["Val", "CHEMICAL", 262, 265], ["C", "CHEMICAL", 566, 567], ["nsp1\u03b1+\u03b2", "GENE_OR_GENE_PRODUCT", 67, 74], ["nsp1\u03b1+\u03b2+\u03b3", "GENE_OR_GENE_PRODUCT", 79, 88], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 142, 147], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 148, 153], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 158, 163], ["nsp2", "GENE_OR_GENE_PRODUCT", 164, 168], ["SHFV PLP1s", "GENE_OR_GENE_PRODUCT", 206, 216], ["nsp1", "GENE_OR_GENE_PRODUCT", 224, 228], ["Gly271", "GENE_OR_GENE_PRODUCT", 255, 261], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 281, 286], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 327, 332], ["SHFV PLP1s", "GENE_OR_GENE_PRODUCT", 424, 434], ["SHFV nsp1", "GENE_OR_GENE_PRODUCT", 465, 474], ["cells", "CELL", 509, 514], ["SHFV nsp1\u03b1-", "GENE_OR_GENE_PRODUCT", 541, 552], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 554, 559], ["N-or C-terminal)", "GENE_OR_GENE_PRODUCT", 561, 577], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 581, 586], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 632, 637], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 639, 644], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 649, 654], ["immunoprecipitated cleavage products", "PROTEIN", 30, 66], ["nsp1", "PROTEIN", 67, 71], ["\u03b1", "PROTEIN", 71, 72], ["\u03b2", "PROTEIN", 73, 74], ["nsp1", "PROTEIN", 79, 83], ["\u03b1", "PROTEIN", 83, 84], ["+\u03b2", "PROTEIN", 84, 86], ["\u03b3", "PROTEIN", 87, 88], ["cleavage sites", "PROTEIN", 120, 134], ["nsp1\u03b2", "PROTEIN", 142, 147], ["nsp1", "PROTEIN", 148, 152], ["\u03b3", "PROTEIN", 152, 153], ["nsp1\u03b3", "PROTEIN", 158, 163], ["nsp2", "PROTEIN", 164, 168], ["SHFV PLP1s", "DNA", 206, 216], ["Gly271/Val272 site", "DNA", 255, 273], ["nsp1\u03b2", "DNA", 281, 286], ["nsp1\u03b2", "PROTEIN", 327, 332], ["SHFV PLP1s", "DNA", 424, 434], ["SHFV nsp1 region", "DNA", 465, 481], ["infected cells", "CELL_TYPE", 500, 514], ["SHFV", "PROTEIN", 541, 545], ["nsp1\u03b2", "PROTEIN", 554, 559], ["N-or C-terminal", "PROTEIN", 561, 576], ["nsp1\u03b3", "PROTEIN", 581, 586], ["specific antibodies", "PROTEIN", 587, 606], ["nsp1\u03b1", "PROTEIN", 632, 637], ["nsp1\u03b2", "PROTEIN", 639, 644], ["nsp1\u03b3 proteins", "PROTEIN", 649, 663], ["SHFV", "SPECIES", 465, 469], ["Mass spectroscopy analyses", "TEST", 0, 26], ["immunoprecipitated cleavage products", "TEST", 30, 66], ["nsp1", "TEST", 67, 71], ["nsp1", "TEST", 79, 83], ["the cleavage sites", "PROBLEM", 116, 134], ["Functional analysis", "TEST", 179, 198], ["the SHFV PLP1s", "TEST", 202, 216], ["the Gly271/Val", "TREATMENT", 251, 265], ["the loss of cleavage", "PROBLEM", 299, 319], ["this site", "PROBLEM", 350, 359], ["Functional analysis", "TEST", 397, 416], ["the SHFV PLP1s", "TREATMENT", 420, 434], ["SHFV nsp1 region autoprocessing", "PROBLEM", 465, 496], ["infected cells", "PROBLEM", 500, 514], ["Western blotting", "TEST", 518, 534], ["SHFV", "TEST", 541, 545], ["nsp1", "TEST", 546, 550], ["nsp1\u03b2", "TEST", 554, 559], ["nsp1\u03b3", "TEST", 581, 586], ["specific antibodies", "TEST", 587, 606], ["nsp1", "TEST", 639, 643], ["cleavage sites", "OBSERVATION", 120, 134], ["nsp1", "ANATOMY_MODIFIER", 148, 152], ["nsp2 junctions", "OBSERVATION", 164, 178], ["loss", "OBSERVATION_MODIFIER", 303, 307], ["infected cells", "OBSERVATION", 500, 514]]], ["The lack of detection of any intermediate precursor bands or truncated nsp1\u03b2 proteins suggested that rapid processing of the nsp1 polyprotein occurs in infected cells.", [["cells", "ANATOMY", 161, 166], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 71, 76], ["nsp1", "GENE_OR_GENE_PRODUCT", 125, 129], ["cells", "CELL", 161, 166], ["intermediate precursor bands", "PROTEIN", 29, 57], ["nsp1\u03b2 proteins", "PROTEIN", 71, 85], ["nsp1 polyprotein", "PROTEIN", 125, 141], ["infected cells", "CELL_TYPE", 152, 166], ["any intermediate precursor bands", "PROBLEM", 25, 57], ["truncated nsp1\u03b2 proteins", "PROBLEM", 61, 85], ["the nsp1 polyprotein", "PROBLEM", 121, 141], ["infected cells", "PROBLEM", 152, 166], ["nsp1 polyprotein", "OBSERVATION", 125, 141], ["infected cells", "OBSERVATION", 152, 166]]], ["Cleavage at the Gly271/ Val272 site within nsp1\u03b2 in the in vitro assays but not in infected cells could be due to misfolding of some of the in vitro translated polyproteins and/or the lack of posttranslational modifications and/or chaperones.Functional analysis of the SHFV PLP1s in the nsp1 regionA recent study on arterivirus nsp1 proteins used SHFV nsp1 expression constructs made from a different stock of SHFV LVR than the one used for the study described above to analyze autocleavage in HeLa cells (Han, Kim et al. 2014) .", [["cells", "ANATOMY", 92, 97], ["HeLa cells", "ANATOMY", 494, 504], ["Gly271", "GENE_OR_GENE_PRODUCT", 16, 22], ["Val272", "GENE_OR_GENE_PRODUCT", 24, 30], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 43, 48], ["cells", "CELL", 92, 97], ["SHFV", "GENE_OR_GENE_PRODUCT", 269, 273], ["nsp1", "GENE_OR_GENE_PRODUCT", 287, 291], ["arterivirus nsp1", "GENE_OR_GENE_PRODUCT", 316, 332], ["SHFV", "ORGANISM", 347, 351], ["nsp1", "GENE_OR_GENE_PRODUCT", 352, 356], ["HeLa cells", "CELL", 494, 504], ["Gly271/ Val272 site", "DNA", 16, 35], ["nsp1\u03b2", "PROTEIN", 43, 48], ["infected cells", "CELL_TYPE", 83, 97], ["in vitro translated polyproteins", "PROTEIN", 140, 172], ["chaperones", "PROTEIN", 231, 241], ["SHFV PLP1s", "DNA", 269, 279], ["arterivirus nsp1 proteins", "PROTEIN", 316, 341], ["SHFV nsp1 expression constructs", "DNA", 347, 378], ["SHFV LVR", "DNA", 410, 418], ["HeLa cells", "CELL_LINE", 494, 504], ["SHFV", "SPECIES", 269, 273], ["SHFV", "SPECIES", 347, 351], ["SHFV", "SPECIES", 410, 414], ["Cleavage", "TREATMENT", 0, 8], ["the in vitro assays", "TEST", 52, 71], ["infected cells", "PROBLEM", 83, 97], ["misfolding", "PROBLEM", 114, 124], ["the in vitro translated polyproteins", "PROBLEM", 136, 172], ["posttranslational modifications", "TREATMENT", 192, 223], ["the nsp1 regionA recent study", "TEST", 283, 312], ["arterivirus nsp1 proteins", "TREATMENT", 316, 341], ["SHFV nsp1 expression constructs", "TREATMENT", 347, 378], ["a different stock of SHFV LVR", "TREATMENT", 389, 418], ["the study", "TEST", 441, 450], ["infected cells", "OBSERVATION", 83, 97], ["misfolding", "OBSERVATION", 114, 124]]], ["This study predicted C115 as a catalytic residue of PLP1\u03b1 and did not observe cleavage at the nsp1\u03b1/nsp1\u03b2 junction.Arterivirus structural proteinsArteriviruses differ from coronaviruses in having a spherical nucleocapsid composed of interacting nucleocapsid (N) protein dimers.", [["C115", "GENE_OR_GENE_PRODUCT", 21, 25], ["PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 52, 57], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 94, 99], ["nucleocapsid (N) protein dimers", "GENE_OR_GENE_PRODUCT", 245, 276], ["C115", "PROTEIN", 21, 25], ["PLP1\u03b1", "PROTEIN", 52, 57], ["nsp1\u03b1", "PROTEIN", 94, 99], ["nsp1\u03b2 junction", "PROTEIN", 100, 114], ["Arterivirus structural proteins", "PROTEIN", 115, 146], ["Arteriviruses", "PROTEIN", 146, 159], ["interacting nucleocapsid (N) protein dimers", "PROTEIN", 233, 276], ["This study", "TEST", 0, 10], ["coronaviruses", "PROBLEM", 172, 185], ["a spherical nucleocapsid", "PROBLEM", 196, 220], ["interacting nucleocapsid (N) protein dimers", "PROBLEM", 233, 276], ["proteinsArteriviruses", "OBSERVATION", 138, 159], ["coronaviruses", "OBSERVATION", 172, 185], ["spherical", "OBSERVATION_MODIFIER", 198, 207], ["nucleocapsid", "OBSERVATION", 208, 220]]], ["The capsid is surrounded by an envelope that contains two major envelop proteins, the non-glycosylated membrane (M) protein and the major glycoprotein (GP5), which form disulfide-linked heterodimers (Delputte, Vanderheijden et al. 2002 , Delputte, Van Breedam et al. 2007 ).", [["membrane", "ANATOMY", 103, 111], ["disulfide", "CHEMICAL", 169, 178], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["GP5", "GENE_OR_GENE_PRODUCT", 152, 155], ["major envelop proteins", "PROTEIN", 58, 80], ["non-glycosylated membrane (M) protein", "PROTEIN", 86, 123], ["major glycoprotein", "PROTEIN", 132, 150], ["GP5", "PROTEIN", 152, 155], ["disulfide-linked heterodimers", "PROTEIN", 169, 198], ["the major glycoprotein (GP5", "TREATMENT", 128, 155], ["capsid", "OBSERVATION", 4, 10]]], ["Three minor glycoproteins (GPs), GP2, GP3 and GP4, form a complex that is located periodically on the virion envelope Spaan 2006, Tian, Wei et al. 2012) .", [["GPs", "GENE_OR_GENE_PRODUCT", 27, 30], ["GP2", "GENE_OR_GENE_PRODUCT", 33, 36], ["GP3", "GENE_OR_GENE_PRODUCT", 38, 41], ["GP4", "GENE_OR_GENE_PRODUCT", 46, 49], ["minor glycoproteins", "PROTEIN", 6, 25], ["GPs", "PROTEIN", 27, 30], ["GP2", "PROTEIN", 33, 36], ["GP3", "PROTEIN", 38, 41], ["GP4", "PROTEIN", 46, 49], ["GP2", "TEST", 33, 36], ["minor", "OBSERVATION_MODIFIER", 6, 11], ["glycoproteins", "OBSERVATION", 12, 25]]], ["Another minor structural protein E forms oligomers in the virion envelope and is thought to function as an ion-channel during viral entry (Snijder, van Tol et al. 1999, Lee and Yoo 2006 ).", [["E", "GENE_OR_GENE_PRODUCT", 33, 34], ["minor structural protein E", "PROTEIN", 8, 34], ["Another minor structural protein E forms oligomers", "PROBLEM", 0, 50], ["protein E forms oligomers", "OBSERVATION", 25, 50], ["virion envelope", "OBSERVATION", 58, 73]]], ["An additional recently discovered minor structural protein 5a was detected in purified PRRSV particles and inhibition of 5a expression reduced EAV yields (Johnson, Griggs et al. 2011 , Sun, Li et al. 2013 .", [["PRRSV", "ORGANISM", 87, 92], ["5a", "GENE_OR_GENE_PRODUCT", 121, 123], ["minor structural protein 5a", "PROTEIN", 34, 61], ["PRRSV", "SPECIES", 87, 92], ["EAV", "SPECIES", 143, 146], ["minor structural protein 5a", "PROBLEM", 34, 61], ["purified PRRSV particles", "TREATMENT", 78, 102], ["protein 5a", "OBSERVATION", 51, 61], ["PRRSV particles", "OBSERVATION", 87, 102]]], ["SHFV is unique among the arteriviruses in encoding two adjacent sets of four minor structural proteins (Godeny, deVries et al. 1998) .", [["SHFV", "GENE_OR_GENE_PRODUCT", 0, 4], ["SHFV", "PROTEIN", 0, 4], ["minor structural proteins", "PROTEIN", 77, 102], ["SHFV", "SPECIES", 0, 4], ["four minor", "OBSERVATION_MODIFIER", 72, 82], ["structural proteins", "OBSERVATION", 83, 102]]], ["These genes, listed in their order from 5\u2032 to 3\u2032 in the genome, were recently renamed GP2\u2032, E\u2032, GP3\u2032, GP4\u2032 and E, GP2, GP3, GP4 ( Figure 2A) .", [["\u2032", "GENE_OR_GENE_PRODUCT", 41, 42], ["3", "GENE_OR_GENE_PRODUCT", 46, 47], ["GP2", "GENE_OR_GENE_PRODUCT", 86, 89], ["\u2032", "GENE_OR_GENE_PRODUCT", 89, 90], ["E\u2032", "GENE_OR_GENE_PRODUCT", 92, 94], ["GP3", "GENE_OR_GENE_PRODUCT", 96, 99], ["GP4\u2032", "GENE_OR_GENE_PRODUCT", 102, 106], ["E", "GENE_OR_GENE_PRODUCT", 111, 112], ["GP2", "GENE_OR_GENE_PRODUCT", 114, 117], ["GP3", "GENE_OR_GENE_PRODUCT", 119, 122], ["5\u2032 to 3\u2032", "DNA", 40, 48], ["GP2", "PROTEIN", 86, 89], ["E\u2032", "DNA", 92, 94], ["GP3", "DNA", 96, 99], ["GP4", "DNA", 102, 105], ["E", "DNA", 111, 112], ["GP2", "DNA", 114, 117], ["GP3", "DNA", 119, 122], ["GP4", "DNA", 124, 127], ["Figure 2A", "DNA", 130, 139], ["E\u2032", "TEST", 92, 94], ["GP3", "TEST", 96, 99], ["GP4", "TEST", 102, 105], ["E", "TEST", 111, 112], ["GP2", "TEST", 114, 117], ["GP3", "TEST", 119, 122], ["GP4", "TEST", 124, 127]]], ["Notably, the order of the open reading frames (ORFs) encoding the GP2 and E protein orthologs differ between the two sets ( Figure 2B ) (Snijder and Spaan 2006) .Analysis of SHFV sg mRNAsEAV encodes a single set of the four minor structural proteins that are produced from three sg mRNAs because GP2 and E are both expressed from the bicistronic sg mRNA 2 (van Berlo, Horzinek et al. 1982 , Snijder and Meulenberg 1998 , Snijder, van Tol et al. 1999 .", [["GP2", "GENE_OR_GENE_PRODUCT", 66, 69], ["E protein", "GENE_OR_GENE_PRODUCT", 74, 83], ["SHFV sg mRNAsEAV", "GENE_OR_GENE_PRODUCT", 174, 190], ["GP2", "GENE_OR_GENE_PRODUCT", 296, 299], ["E", "GENE_OR_GENE_PRODUCT", 304, 305], ["open reading frames", "DNA", 26, 45], ["ORFs", "DNA", 47, 51], ["GP2 and E protein orthologs", "DNA", 66, 93], ["SHFV sg mRNAsEAV", "DNA", 174, 190], ["structural proteins", "PROTEIN", 230, 249], ["sg mRNAs", "RNA", 279, 287], ["GP2", "PROTEIN", 296, 299], ["E", "PROTEIN", 304, 305], ["SHFV sg mRNAsEAV", "SPECIES", 174, 190], ["the GP2 and E protein orthologs", "TEST", 62, 93], ["Analysis", "TEST", 162, 170], ["the four minor structural proteins", "PROBLEM", 215, 249], ["proteins", "OBSERVATION", 241, 249], ["bicistronic sg", "OBSERVATION", 334, 348]]], ["SHFV encodes two adjacent sets of the four minor structural proteins and six sg mRNAs were expected for their expression ( Figure 2C ).", [["SHFV", "GENE_OR_GENE_PRODUCT", 0, 4], ["sg", "GENE_OR_GENE_PRODUCT", 77, 79], ["SHFV", "DNA", 0, 4], ["minor structural proteins", "PROTEIN", 43, 68], ["sg mRNAs", "RNA", 77, 85], ["SHFV", "SPECIES", 0, 4]]], ["However, the leader-body junction sequence for the GP3\u2032 sg mRNA was not detected suggesting that SHFV GP2\u2032 and GP3\u2032 were expressed from a bicistronic sg mRNA 2\u2032 (Godeny, deVries et al. 1998 ).", [["body", "ANATOMY", 20, 24], ["GP3\u2032 sg", "GENE_OR_GENE_PRODUCT", 51, 58], ["SHFV GP2\u2032", "GENE_OR_GENE_PRODUCT", 97, 106], ["GP3\u2032", "GENE_OR_GENE_PRODUCT", 111, 115], ["leader-body junction sequence", "DNA", 13, 42], ["GP3\u2032 sg mRNA", "RNA", 51, 63], ["SHFV GP2", "PROTEIN", 97, 105], ["\u2032", "PROTEIN", 105, 106], ["GP3", "PROTEIN", 111, 114], ["\u2032", "PROTEIN", 114, 115], ["the leader-body junction sequence", "TREATMENT", 9, 42], ["the GP3\u2032 sg mRNA", "TEST", 47, 63], ["bicistronic sg", "OBSERVATION", 138, 152]]], ["The subsequent discovery of an ORF for the E\u2032 protein which overlaps the GP2\u2032 ORF and the demonstration of bicistronic expression of E and GP2 from the EAV sg mRNA 2 (Snijder, van Tol et al. 1999 ) made it unlikely that three minor structural proteins, GP2\u2032, E\u2032 and GP3\u2032, would be expressed from the SHFV sg mRNA2\u2032.", [["E\u2032", "GENE_OR_GENE_PRODUCT", 43, 45], ["GP2", "GENE_OR_GENE_PRODUCT", 73, 76], ["E", "GENE_OR_GENE_PRODUCT", 133, 134], ["GP2", "GENE_OR_GENE_PRODUCT", 139, 142], ["GP2", "GENE_OR_GENE_PRODUCT", 253, 256], ["\u2032", "GENE_OR_GENE_PRODUCT", 256, 257], ["E\u2032", "GENE_OR_GENE_PRODUCT", 259, 261], ["GP3", "GENE_OR_GENE_PRODUCT", 266, 269], ["ORF", "DNA", 31, 34], ["E\u2032 protein", "PROTEIN", 43, 53], ["GP2", "PROTEIN", 73, 76], ["ORF", "DNA", 78, 81], ["E", "DNA", 133, 134], ["GP2", "PROTEIN", 139, 142], ["structural proteins", "PROTEIN", 232, 251], ["GP2", "PROTEIN", 253, 256], ["\u2032", "PROTEIN", 256, 257], ["E\u2032", "PROTEIN", 259, 261], ["GP3", "PROTEIN", 266, 269], ["\u2032", "PROTEIN", 269, 270], ["SHFV", "PROTEIN", 300, 304], ["mRNA2", "PROTEIN", 308, 313], ["an ORF", "PROBLEM", 28, 34], ["the E\u2032 protein", "TEST", 39, 53], ["ORF", "PROBLEM", 78, 81], ["bicistronic expression of E and GP2", "PROBLEM", 107, 142]]], ["A recent Northern blotting analysis of the sg mRNAs produced in infected MA104 cells detected six minor structural protein sg mRNAs including one of the size predicted for a separate GP3\u2032 sg mRNA (sg mRNA 3\u2032) .", [["MA104 cells", "ANATOMY", 73, 84], ["sg", "GENE_OR_GENE_PRODUCT", 43, 45], ["MA104 cells", "CELL", 73, 84], ["sg", "GENE_OR_GENE_PRODUCT", 123, 125], ["GP3\u2032 sg", "GENE_OR_GENE_PRODUCT", 183, 190], ["sg mRNAs", "RNA", 43, 51], ["MA104 cells", "CELL_LINE", 73, 84], ["structural protein sg mRNAs", "RNA", 104, 131], ["GP3\u2032 sg mRNA", "RNA", 183, 195], ["sg mRNA", "RNA", 197, 204], ["A recent Northern blotting analysis", "TEST", 0, 35], ["the sg mRNAs", "PROBLEM", 39, 51], ["infected MA104 cells", "PROBLEM", 64, 84], ["sg mRNAs", "OBSERVATION", 43, 51], ["infected", "OBSERVATION_MODIFIER", 64, 72], ["MA104 cells", "OBSERVATION", 73, 84], ["protein sg mRNAs", "OBSERVATION", 115, 131], ["size", "OBSERVATION_MODIFIER", 153, 157]]], ["The existence of sg mRNA 3\u2032 was confirmed by leader-body sequencing data.", [["sg", "GENE_OR_GENE_PRODUCT", 17, 19], ["3", "GENE_OR_GENE_PRODUCT", 25, 26], ["sg mRNA", "RNA", 17, 24], ["leader-body sequencing data", "TEST", 45, 72]]], ["The ORFs for GP2\u2032, E\u2032 and GP3\u2032 were renamed ORF2a\u2032, ORF2b\u2032 and ORF3\u2032, respectively ( Figure 2 ).", [["GP2\u2032", "GENE_OR_GENE_PRODUCT", 13, 17], ["E\u2032", "GENE_OR_GENE_PRODUCT", 19, 21], ["GP3\u2032", "GENE_OR_GENE_PRODUCT", 26, 30], ["ORF2a\u2032", "GENE_OR_GENE_PRODUCT", 44, 50], ["ORF2b\u2032", "GENE_OR_GENE_PRODUCT", 52, 58], ["ORF3\u2032", "GENE_OR_GENE_PRODUCT", 63, 68], ["ORFs", "DNA", 4, 8], ["GP2\u2032", "DNA", 13, 17], ["E\u2032", "DNA", 19, 21], ["GP3", "DNA", 26, 29], ["ORF2a\u2032", "DNA", 44, 50], ["ORF2b\u2032", "DNA", 52, 58], ["ORF3\u2032", "DNA", 63, 68], ["The ORFs", "TEST", 0, 8], ["GP2\u2032", "TEST", 13, 17], ["E\u2032", "TEST", 19, 21], ["GP3", "TEST", 26, 29], ["ORF2b\u2032", "TEST", 52, 58], ["ORF3\u2032", "TEST", 63, 68]]], ["The identification of sg mRNA3\u2032 for GP3\u2032 led to the interesting observation that the relative abundance of the corresponding sg mRNAs in the duplicated sets of the SHFV minor structural proteins was similar, with sg mRNAs 2\u2032 and 2 being more abundant and sg mRNAs 3\u2032, 3, 4\u2032 and 4 being less abundant.", [["sg mRNA3\u2032", "GENE_OR_GENE_PRODUCT", 22, 31], ["GP3\u2032", "GENE_OR_GENE_PRODUCT", 36, 40], ["sg", "GENE_OR_GENE_PRODUCT", 125, 127], ["SHFV", "GENE_OR_GENE_PRODUCT", 164, 168], ["2", "GENE_OR_GENE_PRODUCT", 229, 230], ["sg", "GENE_OR_GENE_PRODUCT", 255, 257], ["3", "GENE_OR_GENE_PRODUCT", 268, 269], ["\u2032", "GENE_OR_GENE_PRODUCT", 272, 273], ["4", "GENE_OR_GENE_PRODUCT", 278, 279], ["sg mRNA3\u2032", "PROTEIN", 22, 31], ["GP3\u2032", "PROTEIN", 36, 40], ["sg mRNAs", "RNA", 125, 133], ["SHFV minor structural proteins", "PROTEIN", 164, 194], ["sg mRNAs", "RNA", 213, 221], ["sg mRNAs", "RNA", 255, 263], ["the corresponding sg mRNAs", "PROBLEM", 107, 133], ["mRNAs", "TEST", 258, 263], ["abundance", "OBSERVATION_MODIFIER", 94, 103], ["sg mRNAs", "OBSERVATION", 125, 133], ["proteins", "OBSERVATION", 186, 194], ["abundant", "OBSERVATION_MODIFIER", 242, 250], ["less", "OBSERVATION_MODIFIER", 286, 290], ["abundant", "OBSERVATION_MODIFIER", 291, 299]]], ["This finding indicated that regulation of the expression of the individual minor structural protein sg mRNAs in the duplicated sets is conserved.", [["sg", "GENE_OR_GENE_PRODUCT", 100, 102], ["minor structural protein sg mRNAs", "RNA", 75, 108], ["the individual minor structural protein sg mRNAs", "PROBLEM", 60, 108], ["minor", "OBSERVATION_MODIFIER", 75, 80], ["structural protein", "OBSERVATION", 81, 99], ["sg mRNAs", "OBSERVATION", 100, 108]]], ["The different order of the ORFs for the GP2 and E orthologs in the two sets suggests that the second set of SHFV minor structural proteins was not generated by a simple duplication event.Regulation of SHFV RNA replicationLittle work has so far been done on the viral and cell proteins and cis acting viral RNA elements involved in regulating SHFV RNA replication.", [["cell", "ANATOMY", 271, 275], ["GP2", "GENE_OR_GENE_PRODUCT", 40, 43], ["E", "GENE_OR_GENE_PRODUCT", 48, 49], ["SHFV", "GENE_OR_GENE_PRODUCT", 201, 205], ["cell", "CELL", 271, 275], ["SHFV", "GENE_OR_GENE_PRODUCT", 342, 346], ["ORFs", "DNA", 27, 31], ["GP2 and E orthologs", "DNA", 40, 59], ["SHFV minor structural proteins", "PROTEIN", 108, 138], ["SHFV RNA", "RNA", 201, 209], ["viral and cell proteins", "PROTEIN", 261, 284], ["cis acting viral RNA elements", "DNA", 289, 318], ["SHFV RNA", "RNA", 342, 350], ["SHFV", "SPECIES", 342, 346], ["the ORFs", "TEST", 23, 31], ["the GP2 and E orthologs", "TEST", 36, 59], ["SHFV minor structural proteins", "PROBLEM", 108, 138], ["a simple duplication event", "PROBLEM", 160, 186], ["the viral and cell proteins", "TREATMENT", 257, 284], ["viral RNA elements", "TREATMENT", 300, 318]]], ["However, RNA structures in the 3\u2032 noncoding region (NCR) of the genome and the 3\u2032 NCR of the minus strand (\u2212) RNA were previously predicted and cell proteins binding to these RNA regions that may be involved in regulating the functions of the genomic 3' NCRs during initiation of RNA synthesis were identified (You-Kyung and Brinton 1998 , Maines, Young et al. 2005 .", [["cell", "ANATOMY", 144, 148], ["genome", "CELLULAR_COMPONENT", 64, 70], ["cell", "CELL", 144, 148], ["NCRs", "GENE_OR_GENE_PRODUCT", 254, 258], ["RNA structures", "RNA", 9, 23], ["3\u2032 noncoding region", "DNA", 31, 50], ["NCR", "DNA", 52, 55], ["3\u2032 NCR", "DNA", 79, 85], ["minus strand (\u2212) RNA", "RNA", 93, 113], ["RNA regions", "DNA", 175, 186], ["genomic 3' NCRs", "DNA", 243, 258], ["the minus strand (\u2212) RNA", "PROBLEM", 89, 113], ["cell proteins binding", "PROBLEM", 144, 165], ["RNA synthesis", "TREATMENT", 280, 293], ["RNA structures", "OBSERVATION", 9, 23], ["region", "ANATOMY_MODIFIER", 44, 50], ["genome", "ANATOMY", 64, 70], ["minus strand", "OBSERVATION", 93, 105]]], ["Two cell proteins, p56 and p42, that bound specifically to an SHFV 3\u2032(+)NCR RNA probe were identified as polypyrimidine tract-binding protein (PTB) and fructose bisphosphate aldolase A, respectively.", [["cell", "ANATOMY", 4, 8], ["fructose bisphosphate", "CHEMICAL", 152, 173], ["polypyrimidine", "CHEMICAL", 105, 119], ["fructose bisphosphate", "CHEMICAL", 152, 173], ["cell", "CELL", 4, 8], ["p56", "GENE_OR_GENE_PRODUCT", 19, 22], ["p42", "GENE_OR_GENE_PRODUCT", 27, 30], ["SHFV 3", "GENE_OR_GENE_PRODUCT", 62, 68], ["polypyrimidine tract-binding protein", "GENE_OR_GENE_PRODUCT", 105, 141], ["PTB", "GENE_OR_GENE_PRODUCT", 143, 146], ["fructose bisphosphate aldolase A", "GENE_OR_GENE_PRODUCT", 152, 184], ["cell proteins", "PROTEIN", 4, 17], ["p56", "PROTEIN", 19, 22], ["p42", "PROTEIN", 27, 30], ["SHFV 3\u2032(+)NCR RNA probe", "DNA", 62, 85], ["polypyrimidine tract-binding protein", "PROTEIN", 105, 141], ["PTB", "PROTEIN", 143, 146], ["fructose bisphosphate aldolase A", "PROTEIN", 152, 184], ["Two cell proteins", "TEST", 0, 17], ["p42", "TEST", 27, 30], ["an SHFV", "TEST", 59, 66], ["NCR RNA probe", "TREATMENT", 72, 85], ["polypyrimidine tract", "TEST", 105, 125], ["binding protein", "TEST", 126, 141], ["fructose bisphosphate aldolase A", "TEST", 152, 184], ["cell proteins", "OBSERVATION", 4, 17]]], ["PTB binding sites in the SHFV 3'SL structure were mapped to a terminal loop and a bulged region and the aldolase A binding site to a region near the top of the 3\u2032SL.", [["PTB", "GENE_OR_GENE_PRODUCT", 0, 3], ["aldolase A", "GENE_OR_GENE_PRODUCT", 104, 114], ["PTB binding sites", "DNA", 0, 17], ["SHFV 3'SL structure", "DNA", 25, 44], ["bulged region", "DNA", 82, 95], ["aldolase A binding site", "DNA", 104, 127], ["3\u2032SL", "DNA", 160, 164], ["PTB binding sites", "PROBLEM", 0, 17], ["a terminal loop", "TREATMENT", 60, 75], ["a bulged region", "PROBLEM", 80, 95], ["the aldolase A binding site", "PROBLEM", 100, 127], ["sites", "OBSERVATION_MODIFIER", 12, 17], ["terminal", "OBSERVATION_MODIFIER", 62, 70], ["loop", "OBSERVATION", 71, 75], ["bulged", "OBSERVATION", 82, 88], ["binding site", "OBSERVATION", 115, 127], ["top", "OBSERVATION_MODIFIER", 149, 152], ["3\u2032", "ANATOMY_MODIFIER", 160, 162]]], ["Four SHFV 3\u2032(\u2212) NCR RNA binding cell proteins (103, 86, 55, and 36 kDa) were detected in UV-induced cross-linking assays, and three of these proteins (103, 55, and 36 kDa) were also detected by Northwestern blotting assays.", [["cell", "ANATOMY", 32, 36], ["NCR RNA binding cell proteins", "PROTEIN", 16, 45], ["103, 86, 55, and 36 kDa", "PROTEIN", 47, 70], ["Four SHFV", "TEST", 0, 9], ["NCR RNA binding cell proteins", "TEST", 16, 45], ["kDa", "TEST", 67, 70], ["UV", "TEST", 89, 91], ["these proteins", "TEST", 135, 149], ["kDa", "TEST", 167, 170]]], ["The binding sites for these four cellular proteins were mapped to the region between nt 117 and 184 from the 3' end of the negative strand RNA.", [["cellular", "ANATOMY", 33, 41], ["cellular", "CELL", 33, 41], ["3' end", "CELLULAR_COMPONENT", 109, 115], ["binding sites", "DNA", 4, 17], ["cellular proteins", "PROTEIN", 33, 50], ["nt 117 and 184", "DNA", 85, 99], ["3' end", "DNA", 109, 115], ["negative strand RNA", "RNA", 123, 142], ["The binding sites", "PROBLEM", 0, 17], ["these four cellular proteins", "TEST", 22, 50], ["nt", "TEST", 85, 87], ["region", "ANATOMY_MODIFIER", 70, 76], ["negative", "OBSERVATION", 123, 131], ["strand RNA", "OBSERVATION", 132, 142]]], ["This 68-nt sequence was predicted to form two stem-loops, SL4 and SL5.", [["SL4", "GENE_OR_GENE_PRODUCT", 58, 61], ["SL5", "GENE_OR_GENE_PRODUCT", 66, 69], ["68-nt sequence", "DNA", 5, 19], ["SL4", "DNA", 58, 61], ["SL5", "DNA", 66, 69], ["loops", "ANATOMY_MODIFIER", 51, 56]]], ["Additional data obtained with (+) and (\u2212) 3\u2032NCR RNAs of other arteriviruses suggested that the RNA elements interacting with the identified cell proteins are conserved among arteriviruses.Functional analysis of the two sets of SHFV minor structural proteinsMutant SHFV infectious clones lacking the expression of either one of the minor structural proteins or of a pair of minor structural protein orthologs were made ).", [["cell", "ANATOMY", 140, 144], ["(+) and (\u2212) 3\u2032", "CHEMICAL", 30, 44], ["cell", "CELL", 140, 144], ["SHFV", "GENE_OR_GENE_PRODUCT", 227, 231], ["NCR RNAs", "RNA", 44, 52], ["RNA elements", "DNA", 95, 107], ["cell proteins", "PROTEIN", 140, 153], ["SHFV minor structural proteins", "PROTEIN", 227, 257], ["SHFV infectious clones", "CELL_LINE", 264, 286], ["minor structural proteins", "PROTEIN", 331, 356], ["minor structural protein orthologs", "PROTEIN", 373, 407], ["Additional data", "TEST", 0, 15], ["the RNA elements", "PROBLEM", 91, 107], ["the identified cell proteins", "PROBLEM", 125, 153], ["Mutant SHFV infectious clones", "PROBLEM", 257, 286], ["cell proteins", "OBSERVATION", 140, 153]]], ["None of these clones produced infectious virus.", [["clones", "CELL", 14, 20], ["infectious virus", "ORGANISM", 30, 46], ["infectious virus", "PROBLEM", 30, 46], ["infectious", "OBSERVATION_MODIFIER", 30, 40]]], ["However, the ability of each clone to produce extracellular virions was assessed by quantitative real-time RT-PCR of extracellular viral RNA.", [["clone", "ANATOMY", 29, 34], ["extracellular virions", "ANATOMY", 46, 67], ["extracellular", "ANATOMY", 117, 130], ["clone", "CELL", 29, 34], ["extracellular virions", "CELLULAR_COMPONENT", 46, 67], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["extracellular viral RNA", "RNA", 117, 140], ["extracellular virions", "PROBLEM", 46, 67], ["extracellular viral RNA", "PROBLEM", 117, 140], ["extracellular", "OBSERVATION", 117, 130], ["viral RNA", "OBSERVATION", 131, 140]]], ["Cells transfected with the \u0394GP4\u2032, \u0394GP2 or \u0394GP3 mutant infectious clone RNAs produced a sustained low level of extracellular viral RNA beginning at 24 h after transfection (Table 2 ).", [["Cells", "ANATOMY", 0, 5], ["extracellular", "ANATOMY", 110, 123], ["Cells", "CELL", 0, 5], ["\u0394GP4\u2032", "GENE_OR_GENE_PRODUCT", 27, 32], ["\u0394GP2", "GENE_OR_GENE_PRODUCT", 34, 38], ["\u0394GP3", "GENE_OR_GENE_PRODUCT", 42, 46], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["\u0394GP4\u2032, \u0394GP2 or \u0394GP3 mutant infectious clone RNAs", "RNA", 27, 75], ["extracellular viral RNA", "RNA", 110, 133], ["Cells", "TEST", 0, 5], ["the \u0394GP4\u2032", "TEST", 23, 32], ["\u0394GP2", "TEST", 34, 38], ["\u0394GP3 mutant infectious clone RNAs", "PROBLEM", 42, 75], ["extracellular viral RNA", "PROBLEM", 110, 133], ["viral RNA", "OBSERVATION", 124, 133]]], ["In contrast, after transfection of wildtype infectious clone RNA, extracellular viral RNA increased dramatically starting at 96 h after transfection.", [["extracellular", "ANATOMY", 66, 79], ["clone", "CELL", 55, 60], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 79], ["wildtype infectious clone RNA", "RNA", 35, 64], ["extracellular viral RNA", "RNA", 66, 89], ["wildtype infectious clone RNA", "PROBLEM", 35, 64], ["extracellular viral RNA", "PROBLEM", 66, 89], ["infectious", "OBSERVATION_MODIFIER", 44, 54], ["clone RNA", "OBSERVATION", 55, 64], ["viral RNA", "OBSERVATION", 80, 89], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["dramatically", "OBSERVATION_MODIFIER", 100, 112]]], ["The lack of amplification of extracellular viral RNA at later times observed for all of the mutants indicated that the extracellular virus particles produced were non-infectious.", [["extracellular", "ANATOMY", 29, 42], ["extracellular", "ANATOMY", 119, 132], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["extracellular virus particles", "ORGANISM", 119, 148], ["extracellular viral RNA", "RNA", 29, 52], ["extracellular viral RNA", "PROBLEM", 29, 52], ["the mutants", "PROBLEM", 88, 99], ["the extracellular virus particles", "PROBLEM", 115, 148], ["non-infectious", "PROBLEM", 163, 177], ["viral RNA", "OBSERVATION", 43, 52], ["non-infectious", "OBSERVATION", 163, 177]]], ["The \u0394GP4 infectious clone RNA also produced a low level of extracellular viral RNA beginning at 24 h after transfection, but the level was not sustained indicating a potential role for GP4 in virion stability.", [["extracellular", "ANATOMY", 59, 72], ["virion", "ANATOMY", 192, 198], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 72], ["GP4", "GENE_OR_GENE_PRODUCT", 185, 188], ["\u0394GP4 infectious clone RNA", "RNA", 4, 29], ["extracellular viral RNA", "RNA", 59, 82], ["GP4", "PROTEIN", 185, 188], ["The \u0394GP4 infectious clone RNA", "PROBLEM", 0, 29], ["extracellular viral RNA", "PROBLEM", 59, 82], ["GP4 in virion stability", "PROBLEM", 185, 208], ["infectious", "OBSERVATION_MODIFIER", 9, 19], ["clone RNA", "OBSERVATION", 20, 29], ["low", "OBSERVATION_MODIFIER", 46, 49], ["viral RNA", "OBSERVATION", 73, 82], ["virion stability", "OBSERVATION", 192, 208]]], ["The \u0394GP2\u2032, \u0394GP3\u2032, \u0394E\u2032 and \u0394E mutant infectious clone RNAs did not produce extracellular viral RNA above background levels suggesting that each of these proteins plays an essential role in virus replication or virion production.", [["extracellular", "ANATOMY", 74, 87], ["\u0394GP2\u2032", "GENE_OR_GENE_PRODUCT", 4, 9], ["\u0394GP3\u2032", "GENE_OR_GENE_PRODUCT", 11, 16], ["\u0394E\u2032", "GENE_OR_GENE_PRODUCT", 18, 21], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["\u0394GP2\u2032, \u0394GP3\u2032, \u0394E\u2032 and \u0394E mutant infectious clone RNAs", "RNA", 4, 57], ["extracellular viral RNA", "RNA", 74, 97], ["The \u0394GP2\u2032", "TEST", 0, 9], ["\u0394GP3\u2032", "TEST", 11, 16], ["\u0394E mutant infectious clone RNAs", "PROBLEM", 26, 57], ["extracellular viral RNA above background levels", "PROBLEM", 74, 121], ["these proteins", "PROBLEM", 146, 160], ["virus replication", "TREATMENT", 188, 205], ["virion production", "PROBLEM", 209, 226], ["infectious", "OBSERVATION", 36, 46], ["viral RNA", "OBSERVATION", 88, 97]]], ["No extracellular viral RNA production was detected from MA104 cells transfected with any of the double mutant RNAs.", [["extracellular", "ANATOMY", 3, 16], ["MA104 cells", "ANATOMY", 56, 67], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 3, 16], ["MA104 cells", "CELL", 56, 67], ["MA104 cells", "CELL_LINE", 56, 67], ["double mutant RNAs", "RNA", 96, 114], ["extracellular viral RNA production", "PROBLEM", 3, 37], ["the double mutant RNAs", "PROBLEM", 92, 114], ["extracellular", "OBSERVATION_MODIFIER", 3, 16], ["viral RNA production", "OBSERVATION", 17, 37]]], ["No intracellular viral proteins were detected in lysates from any of the mutant RNA transfected cells by Western blotting, which is consistent with a lack of virus spread.", [["intracellular", "ANATOMY", 3, 16], ["lysates", "ANATOMY", 49, 56], ["cells", "ANATOMY", 96, 101], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 3, 16], ["lysates", "ORGANISM_SUBSTANCE", 49, 56], ["cells", "CELL", 96, 101], ["intracellular viral proteins", "PROTEIN", 3, 31], ["mutant RNA transfected cells", "CELL_LINE", 73, 101], ["intracellular viral proteins", "PROBLEM", 3, 31], ["lysates", "TEST", 49, 56], ["the mutant RNA transfected cells", "PROBLEM", 69, 101], ["Western blotting", "TEST", 105, 121], ["virus spread", "PROBLEM", 158, 170], ["intracellular", "OBSERVATION_MODIFIER", 3, 16], ["viral proteins", "OBSERVATION", 17, 31], ["RNA transfected cells", "OBSERVATION", 80, 101], ["consistent with", "UNCERTAINTY", 132, 147], ["virus spread", "OBSERVATION", 158, 170]]], ["Although the abundance of sg mRNA orthologs in the duplicated sets of SHFV minor structural proteins is similar, the functions of the orthologs are not redundant.", [["sg", "GENE_OR_GENE_PRODUCT", 26, 28], ["SHFV", "GENE_OR_GENE_PRODUCT", 70, 74], ["sg mRNA orthologs", "RNA", 26, 43], ["SHFV minor structural proteins", "PROTEIN", 70, 100], ["sg mRNA orthologs", "PROBLEM", 26, 43], ["SHFV minor structural proteins", "PROBLEM", 70, 100], ["abundance", "OBSERVATION_MODIFIER", 13, 22], ["sg mRNA", "OBSERVATION", 26, 33], ["minor", "OBSERVATION_MODIFIER", 75, 80], ["structural proteins", "OBSERVATION", 81, 100], ["similar", "OBSERVATION_MODIFIER", 104, 111], ["not", "UNCERTAINTY", 148, 151], ["redundant", "OBSERVATION", 152, 161]]], ["The finding that both sets of minor structural proteins are required for efficient production of infectious extracellular virus indicates that SHFV virus production and virion structure are more complex than those of other known arteriviruses.ConclusionsSHFV typically causes benign persistent infections in African NFPs which are natural hosts but fatal hemorrhagic fever disease in Asian macaques which are not natural hosts.", [["extracellular", "ANATOMY", 108, 121], ["SHFV", "CHEMICAL", 254, 258], ["infections", "DISEASE", 294, 304], ["hemorrhagic fever", "DISEASE", 355, 372], ["infectious", "ORGANISM", 97, 107], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["virus", "ORGANISM", 122, 127], ["SHFV virus", "ORGANISM", 143, 153], ["arteriviruses", "CANCER", 229, 242], ["SHFV", "GENE_OR_GENE_PRODUCT", 254, 258], ["macaques", "ORGANISM", 390, 398], ["minor structural proteins", "PROTEIN", 30, 55], ["Asian macaques", "SPECIES", 384, 398], ["SHFV", "SPECIES", 143, 147], ["SHFV", "SPECIES", 254, 258], ["Asian macaques", "SPECIES", 384, 398], ["minor structural proteins", "PROBLEM", 30, 55], ["infectious extracellular virus", "PROBLEM", 97, 127], ["SHFV virus production and virion structure", "PROBLEM", 143, 185], ["benign persistent infections in African NFPs", "PROBLEM", 276, 320], ["fatal hemorrhagic fever disease in Asian macaques", "PROBLEM", 349, 398], ["minor", "OBSERVATION_MODIFIER", 30, 35], ["structural proteins", "OBSERVATION", 36, 55], ["infectious", "OBSERVATION_MODIFIER", 97, 107], ["virion structure", "OBSERVATION", 169, 185], ["benign", "OBSERVATION_MODIFIER", 276, 282], ["persistent", "OBSERVATION_MODIFIER", 283, 293], ["infections", "OBSERVATION", 294, 304], ["fatal", "OBSERVATION_MODIFIER", 349, 354], ["hemorrhagic", "OBSERVATION_MODIFIER", 355, 366], ["fever", "OBSERVATION", 367, 372], ["Asian macaques", "OBSERVATION", 384, 398]]], ["M\u03a6s from the two types of animals differed in the percentage of susceptible cells present while mDCs from the two animals differed in their ability to efficiently replicate virus.", [["cells", "ANATOMY", 76, 81], ["mDCs", "ANATOMY", 96, 100], ["cells", "CELL", 76, 81], ["mDCs", "CELL", 96, 100], ["M\u03a6s", "CELL_TYPE", 0, 3], ["susceptible cells", "CELL_TYPE", 64, 81], ["mDCs", "CELL_TYPE", 96, 100], ["susceptible cells", "PROBLEM", 64, 81], ["susceptible cells", "OBSERVATION", 64, 81]]], ["Consistent with the different symptoms observed in SHFV infected African NHPs and macaques, SHFV infection of cultured macaque M\u03a6s and mDCs induced proinflammatrory cytokine production while infections in baboon cells did not.", [["M\u03a6s", "ANATOMY", 127, 130], ["mDCs", "ANATOMY", 135, 139], ["cells", "ANATOMY", 212, 217], ["infection", "DISEASE", 97, 106], ["infections", "DISEASE", 191, 201], ["African NHPs", "ORGANISM", 65, 77], ["macaques", "ORGANISM", 82, 90], ["SHFV", "GENE_OR_GENE_PRODUCT", 92, 96], ["macaque", "ORGANISM", 119, 126], ["M\u03a6s", "CELL", 127, 130], ["mDCs", "CELL", 135, 139], ["baboon", "ORGANISM", 205, 211], ["cells", "CELL", 212, 217], ["cultured macaque M\u03a6s", "CELL_LINE", 110, 130], ["mDCs", "CELL_TYPE", 135, 139], ["proinflammatrory cytokine", "PROTEIN", 148, 173], ["baboon cells", "CELL_TYPE", 205, 217], ["macaques", "SPECIES", 82, 90], ["SHFV", "SPECIES", 51, 55], ["African NHPs", "SPECIES", 65, 77], ["SHFV", "SPECIES", 92, 96], ["baboon", "SPECIES", 205, 211], ["the different symptoms", "PROBLEM", 16, 38], ["SHFV infection", "PROBLEM", 92, 106], ["mDCs induced proinflammatrory cytokine production", "PROBLEM", 135, 184], ["infections in baboon cells", "PROBLEM", 191, 217], ["infected", "OBSERVATION_MODIFIER", 56, 64], ["African", "OBSERVATION_MODIFIER", 65, 72], ["infection", "OBSERVATION", 97, 106]]], ["The data suggest that there is a balance between upregulation of cell anti-viral and inflammatory responses and viral-mediated counteraction/modulation of these responses that is beneficial to both the host and the virus in African NHPs but not in macaques.", [["cell", "ANATOMY", 65, 69], ["cell", "CELL", 65, 69], ["NHPs", "ORGANISM", 232, 236], ["macaques", "ORGANISM", 248, 256], ["macaques", "SPECIES", 248, 256], ["African NHPs", "SPECIES", 224, 236], ["cell anti-viral", "TREATMENT", 65, 80], ["inflammatory responses", "PROBLEM", 85, 107], ["viral-mediated counteraction", "PROBLEM", 112, 140], ["cell anti-viral", "OBSERVATION", 65, 80], ["inflammatory", "OBSERVATION_MODIFIER", 85, 97], ["virus", "OBSERVATION", 215, 220]]], ["All previous isolates of SHFV caused severe hemorrhagic fever disease in macaques but varied in their ability to cause signs of hemorrhagic disease that was rarely fatal in patas monkeys.", [["SHFV", "CHEMICAL", 25, 29], ["hemorrhagic fever", "DISEASE", 44, 61], ["hemorrhagic disease", "DISEASE", 128, 147], ["SHFV", "ORGANISM", 25, 29], ["macaques", "ORGANISM", 73, 81], ["patas monkeys", "ORGANISM", 173, 186], ["macaques", "SPECIES", 73, 81], ["SHFV", "SPECIES", 25, 29], ["patas monkeys", "SPECIES", 173, 186], ["severe hemorrhagic fever disease in macaques", "PROBLEM", 37, 81], ["hemorrhagic disease", "PROBLEM", 128, 147], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["hemorrhagic", "OBSERVATION_MODIFIER", 44, 55], ["fever", "OBSERVATION", 56, 61], ["hemorrhagic", "OBSERVATION_MODIFIER", 128, 139], ["disease", "OBSERVATION", 140, 147]]], ["A new SHFV isolate from persistently infected baboons lytically infected rhesus macaque M\u03a6s and MA104 cells and caused long term asymptomatic persistent infections in baboons but fatal hemorrhagic fever disease in macaques.", [["M\u03a6s", "ANATOMY", 88, 91], ["MA104 cells", "ANATOMY", 96, 107], ["infections", "DISEASE", 153, 163], ["hemorrhagic fever", "DISEASE", 185, 202], ["SHFV", "ORGANISM", 6, 10], ["baboons", "ORGANISM", 46, 53], ["rhesus", "ORGANISM", 73, 79], ["macaque", "ORGANISM", 80, 87], ["M\u03a6s", "CELL", 88, 91], ["MA104 cells", "CELL", 96, 107], ["baboons", "ORGANISM", 167, 174], ["macaques", "ORGANISM", 214, 222], ["SHFV isolate", "CELL_LINE", 6, 18], ["MA104 cells", "CELL_LINE", 96, 107], ["rhesus macaque", "SPECIES", 73, 87], ["macaques", "SPECIES", 214, 222], ["SHFV", "SPECIES", 6, 10], ["rhesus macaque", "SPECIES", 73, 87], ["A new SHFV isolate", "PROBLEM", 0, 18], ["persistently infected baboons lytically infected rhesus", "PROBLEM", 24, 79], ["MA104 cells", "PROBLEM", 96, 107], ["long term asymptomatic persistent infections in baboons", "PROBLEM", 119, 174], ["fatal hemorrhagic fever disease in macaques", "PROBLEM", 179, 222], ["new", "OBSERVATION_MODIFIER", 2, 5], ["persistently", "OBSERVATION_MODIFIER", 24, 36], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["baboons", "OBSERVATION_MODIFIER", 46, 53], ["long term", "OBSERVATION_MODIFIER", 119, 128], ["asymptomatic", "OBSERVATION_MODIFIER", 129, 141], ["persistent", "OBSERVATION_MODIFIER", 142, 152], ["infections", "OBSERVATION", 153, 163], ["fatal", "OBSERVATION_MODIFIER", 179, 184], ["hemorrhagic", "OBSERVATION_MODIFIER", 185, 196], ["fever", "OBSERVATION", 197, 202]]], ["Although divergent SHFV genome sequences obtained from additional NHP species have recently been reported, data from experimental infection studies with these isolates in different types of NHPs and cells have not yet been reported.ConclusionsThe SHFV genome encodes five additional proteins compared to other known arteriviruses.", [["cells", "ANATOMY", 199, 204], ["infection", "DISEASE", 130, 139], ["SHFV", "GENE_OR_GENE_PRODUCT", 19, 23], ["NHP species", "ORGANISM", 66, 77], ["NHPs", "ORGANISM", 190, 194], ["cells", "CELL", 199, 204], ["SHFV", "GENE_OR_GENE_PRODUCT", 247, 251], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 316, 329], ["SHFV genome sequences", "DNA", 19, 40], ["SHFV genome", "DNA", 247, 258], ["SHFV", "SPECIES", 19, 23], ["SHFV", "SPECIES", 247, 251], ["divergent SHFV genome sequences", "PROBLEM", 9, 40], ["additional NHP species", "PROBLEM", 55, 77], ["experimental infection studies", "TEST", 117, 147], ["these isolates", "TEST", 153, 167]]], ["The additional nsp1 protein nsp1\u03b3 was predicted to be more similar to PRRSV nsp1\u03b1 than to PRRSV nsp1\u03b2.", [["nsp1", "GENE_OR_GENE_PRODUCT", 15, 19], ["nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 28, 33], ["PRRSV", "ORGANISM", 70, 75], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 76, 81], ["PRRSV nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 90, 101], ["nsp1 protein", "PROTEIN", 15, 27], ["nsp1\u03b3", "PROTEIN", 28, 33], ["PRRSV nsp1\u03b1", "PROTEIN", 70, 81], ["PRRSV nsp1\u03b2", "PROTEIN", 90, 101], ["PRRSV", "SPECIES", 70, 75], ["PRRSV", "SPECIES", 90, 95], ["The additional nsp1 protein nsp1\u03b3", "TEST", 0, 33], ["PRRSV nsp1", "PROBLEM", 70, 80], ["nsp1 protein", "OBSERVATION", 15, 27], ["nsp1\u03b3", "OBSERVATION", 28, 33]]], ["However, PLP1\u03b3 is able to cleave at upstream as well as downstream sites, which is a characteristic of the PLP2s but not PLP1s of other arteriviruses.", [["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 9, 14], ["PLP2s", "GENE_OR_GENE_PRODUCT", 107, 112], ["PLP1s", "GENE_OR_GENE_PRODUCT", 121, 126], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 136, 149], ["PLP1\u03b3", "PROTEIN", 9, 14], ["downstream sites", "DNA", 56, 72], ["PLP2s", "DNA", 107, 112], ["PLP1s", "PROTEIN", 121, 126]]], ["Arterivirus PLP2s have a Cya-His-Asp catalytic triad and deubiquitinating as well as deISGylating activities in addition to protease activity.", [["Asp", "CHEMICAL", 33, 36], ["PLP2s", "GENE_OR_GENE_PRODUCT", 12, 17], ["Cya-His", "PROTEIN", 25, 32], ["protease", "PROTEIN", 124, 132], ["Asp catalytic triad", "TREATMENT", 33, 52], ["deISGylating activities", "TREATMENT", 85, 108], ["protease activity", "TREATMENT", 124, 141]]], ["SHFV PLP1\u03b3 has a Cys-His catalytic dyad and is not predicted to have deubiquitinating or deISGylating activity.", [["Cys", "CHEMICAL", 17, 20], ["His", "CHEMICAL", 21, 24], ["SHFV PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 0, 10], ["SHFV", "PROTEIN", 0, 4], ["PLP1\u03b3", "PROTEIN", 5, 10], ["Cys-His catalytic dyad", "PROTEIN", 17, 39], ["SHFV", "SPECIES", 0, 4], ["a Cys", "TEST", 15, 20], ["His catalytic dyad", "PROBLEM", 21, 39]]], ["SHFV nsp1\u03b3 may have originated by a duplication of nsp1\u03b1.", [["SHFV nsp1\u03b3", "GENE_OR_GENE_PRODUCT", 0, 10], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["SHFV nsp1\u03b3", "PROTEIN", 0, 10], ["nsp1\u03b1", "PROTEIN", 51, 56], ["SHFV", "SPECIES", 0, 4], ["a duplication of nsp1\u03b1", "PROBLEM", 34, 56], ["duplication", "OBSERVATION", 36, 47], ["nsp1\u03b1", "OBSERVATION", 51, 56]]], ["It is possible that SHFV PLP1\u03b1 may also be able to cleave upstream but due to its location at the 5\u2032 end of the 1a polyprotein, this ability was not tested.", [["SHFV PLP1\u03b1", "GENE_OR_GENE_PRODUCT", 20, 30], ["SHFV PLP1\u03b1", "PROTEIN", 20, 30], ["5\u2032 end", "DNA", 98, 104], ["SHFV", "SPECIES", 20, 24], ["SHFV PLP1", "PROBLEM", 20, 29], ["the 1a polyprotein", "TREATMENT", 108, 126]]], ["Sequence alignment indicated that the three SHFV PLP1s are more similar to each other that to those of other arteriviruses.", [["PLP1s", "GENE_OR_GENE_PRODUCT", 49, 54], ["arteriviruses", "CANCER", 109, 122], ["SHFV PLP1s", "DNA", 44, 54], ["Sequence alignment", "TEST", 0, 18], ["the three SHFV PLP1s", "PROBLEM", 34, 54]]], ["Additional functional studies of the SHFV PLP1s, including analysis of possible trans cleavage activities, as well as crystal structures of the three SHFV nsp1s are needed to provide insights about the origin of the additional SHFV nsp1 region.ConclusionsA duplicated set of four additional minor structural proteins is encoded in the 3\u2032 end of the SHFV genome.", [["SHFV", "GENE_OR_GENE_PRODUCT", 37, 41], ["SHFV nsp1s", "GENE_OR_GENE_PRODUCT", 150, 160], ["nsp1", "GENE_OR_GENE_PRODUCT", 232, 236], ["SHFV", "GENE_OR_GENE_PRODUCT", 349, 353], ["SHFV PLP1s", "DNA", 37, 47], ["SHFV nsp1s", "PROTEIN", 150, 160], ["SHFV nsp1 region", "DNA", 227, 243], ["minor structural proteins", "PROTEIN", 291, 316], ["3\u2032 end", "DNA", 335, 341], ["SHFV genome", "DNA", 349, 360], ["the SHFV PLP1s", "TEST", 33, 47], ["analysis", "TEST", 59, 67], ["trans cleavage activities", "PROBLEM", 80, 105], ["the three SHFV nsp1s", "TREATMENT", 140, 160], ["origin", "ANATOMY_MODIFIER", 202, 208], ["nsp1 region", "OBSERVATION", 232, 243], ["minor", "OBSERVATION_MODIFIER", 291, 296], ["structural", "OBSERVATION_MODIFIER", 297, 307], ["proteins", "OBSERVATION", 308, 316], ["SHFV genome", "OBSERVATION", 349, 360]]], ["The finding that each of the minor structural proteins from both sets is required for the production of infectious SHFV suggests that the SHF virion composition is more complex than that of other known arteriviruses.", [["SHFV", "GENE_OR_GENE_PRODUCT", 115, 119], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 202, 215], ["minor structural proteins", "PROTEIN", 29, 54], ["the minor structural proteins", "PROBLEM", 25, 54], ["infectious SHFV", "PROBLEM", 104, 119], ["the SHF virion composition", "PROBLEM", 134, 160], ["infectious", "OBSERVATION", 104, 114], ["virion", "OBSERVATION", 142, 148]]], ["Cells transfected with mutant viral RNAs that did not express GP2\u2032, GP3\u2032, E, or E\u2032 did not produce extracellular virus particles suggesting that these proteins have essential functions during earlier stages of the virus life cycle.", [["Cells", "ANATOMY", 0, 5], ["extracellular", "ANATOMY", 99, 112], ["Cells", "CELL", 0, 5], ["GP2", "GENE_OR_GENE_PRODUCT", 62, 65], ["GP3\u2032", "GENE_OR_GENE_PRODUCT", 68, 72], ["E", "GENE_OR_GENE_PRODUCT", 74, 75], ["E\u2032", "GENE_OR_GENE_PRODUCT", 80, 82], ["extracellular virus particles", "ORGANISM", 99, 128], ["GP2", "PROTEIN", 62, 65], ["GP3", "PROTEIN", 68, 71], ["E", "PROTEIN", 74, 75], ["E\u2032", "PROTEIN", 80, 82], ["mutant viral RNAs", "PROBLEM", 23, 40], ["GP2", "TEST", 62, 65], ["GP3", "TEST", 68, 71], ["extracellular virus particles", "PROBLEM", 99, 128], ["these proteins", "PROBLEM", 145, 159], ["the virus life cycle", "TREATMENT", 210, 230], ["viral RNAs", "OBSERVATION", 30, 40], ["virus", "OBSERVATION", 113, 118]]], ["However, some or all of these proteins may also be functionally important for virion infectivity.", [["virion", "ANATOMY", 78, 84], ["virion infectivity", "PROBLEM", 78, 96], ["may also be", "UNCERTAINTY", 39, 50]]], ["The EAV, PRRSV and LDV E proteins have a conserved N-terminal myristoylation site (Thaa, Kabatek et al. 2009 ).", [["N", "CHEMICAL", 51, 52], ["EAV", "ORGANISM", 4, 7], ["PRRSV", "ORGANISM", 9, 14], ["LDV E", "GENE_OR_GENE_PRODUCT", 19, 24], ["EAV, PRRSV and LDV E proteins", "PROTEIN", 4, 33], ["N-terminal myristoylation site", "PROTEIN", 51, 81], ["EAV", "SPECIES", 4, 7], ["PRRSV", "SPECIES", 9, 14], ["LDV", "SPECIES", 19, 22], ["The EAV", "TREATMENT", 0, 7], ["LDV E proteins", "TREATMENT", 19, 33], ["terminal myristoylation site", "TREATMENT", 53, 81]]], ["The observation of a decrease in virus infectivity and plaque size but not in the yield of extracellular virions when myristoylation was inhibited in EAV-infected cells suggested that E protein myristoylation is required for virion infectivity but not for virion budding (Thaa, Kabatek et al. 2009 ).", [["plaque", "ANATOMY", 55, 61], ["extracellular virions", "ANATOMY", 91, 112], ["cells", "ANATOMY", 163, 168], ["plaque", "DISEASE", 55, 61], ["plaque", "PATHOLOGICAL_FORMATION", 55, 61], ["extracellular virions", "CELLULAR_COMPONENT", 91, 112], ["EAV", "ORGANISM", 150, 153], ["cells", "CELL", 163, 168], ["E protein", "GENE_OR_GENE_PRODUCT", 184, 193], ["EAV-infected cells", "CELL_LINE", 150, 168], ["E protein", "PROTEIN", 184, 193], ["EAV", "SPECIES", 150, 153], ["a decrease in virus infectivity", "PROBLEM", 19, 50], ["plaque size", "PROBLEM", 55, 66], ["extracellular virions", "PROBLEM", 91, 112], ["EAV", "PROBLEM", 150, 153], ["infected cells", "PROBLEM", 154, 168], ["E protein myristoylation", "TREATMENT", 184, 208], ["virion infectivity", "PROBLEM", 225, 243], ["virion budding", "PROBLEM", 256, 270], ["decrease", "OBSERVATION_MODIFIER", 21, 29], ["virus infectivity", "OBSERVATION", 33, 50], ["plaque", "OBSERVATION_MODIFIER", 55, 61], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["This finding is consistent with E protein ion channel function being required for virion entry.", [["virion", "ANATOMY", 82, 88], ["virion", "CELLULAR_COMPONENT", 82, 88], ["E protein", "PROTEIN", 32, 41], ["E protein ion channel function", "TREATMENT", 32, 62], ["virion entry", "TREATMENT", 82, 94], ["consistent with", "UNCERTAINTY", 16, 31], ["ion channel function", "OBSERVATION", 42, 62]]], ["The SHFV E protein sequence contains the conserved N-terminal myristoylation site but the SHFV E\u2032 protein sequence does not.", [["N", "CHEMICAL", 51, 52], ["SHFV E\u2032", "GENE_OR_GENE_PRODUCT", 90, 97], ["E protein sequence", "DNA", 9, 27], ["N-terminal myristoylation site", "DNA", 51, 81], ["SHFV E\u2032 protein sequence", "DNA", 90, 114], ["SHFV", "SPECIES", 4, 8], ["E protein sequence", "TEST", 9, 27], ["terminal myristoylation site", "PROBLEM", 53, 81], ["the SHFV E\u2032 protein sequence", "TEST", 86, 114], ["terminal", "ANATOMY_MODIFIER", 53, 61], ["myristoylation site", "OBSERVATION", 62, 81]]], ["Both of the SHFV E proteins appear to have intracellular functions during the virus replication cycle but one or both may also function during virion entry.", [["intracellular", "ANATOMY", 43, 56], ["virion", "ANATOMY", 143, 149], ["SHFV E", "GENE_OR_GENE_PRODUCT", 12, 18], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 56], ["virion", "CELLULAR_COMPONENT", 143, 149], ["SHFV E proteins", "PROTEIN", 12, 27], ["SHFV", "SPECIES", 12, 16], ["intracellular functions", "PROBLEM", 43, 66], ["the virus replication cycle", "TREATMENT", 74, 101], ["intracellular functions", "OBSERVATION", 43, 66]]], ["The SHFV E protein is more homologous to the EAV and LDV E proteins and the orientation of the overlapping E and GP2 ORFs in these genomes is similar.", [["E", "GENE_OR_GENE_PRODUCT", 9, 10], ["LDV E", "GENE_OR_GENE_PRODUCT", 53, 58], ["E", "GENE_OR_GENE_PRODUCT", 107, 108], ["GP2", "GENE_OR_GENE_PRODUCT", 113, 116], ["E protein", "PROTEIN", 9, 18], ["EAV and LDV E proteins", "PROTEIN", 45, 67], ["E and GP2 ORFs", "DNA", 107, 121], ["SHFV", "SPECIES", 4, 8], ["EAV", "SPECIES", 45, 48], ["E protein", "TEST", 9, 18], ["the EAV", "TEST", 41, 48], ["LDV E proteins", "TEST", 53, 67], ["the overlapping E and GP2 ORFs", "TEST", 91, 121], ["more homologous", "OBSERVATION_MODIFIER", 22, 37], ["GP2 ORFs", "OBSERVATION", 113, 121], ["genomes", "OBSERVATION", 131, 138], ["similar", "OBSERVATION_MODIFIER", 142, 149]]], ["SHFV E\u2032 is more homologous to the PRRSV E and the genomes both have the opposite orientation of the E and GP2 ORFs.", [["E\u2032", "GENE_OR_GENE_PRODUCT", 5, 7], ["PRRSV E", "GENE_OR_GENE_PRODUCT", 34, 41], ["GP2", "GENE_OR_GENE_PRODUCT", 106, 109], ["E\u2032", "DNA", 5, 7], ["PRRSV E", "DNA", 34, 41], ["E and GP2 ORFs", "DNA", 100, 114], ["SHFV", "SPECIES", 0, 4], ["PRRSV E", "SPECIES", 34, 41], ["more homologous", "OBSERVATION_MODIFIER", 11, 26], ["GP2 ORFs", "OBSERVATION", 106, 114]]], ["All of these data more support acquisition of an additional set of minor SHFV structural proteins by a recombination event with the genome of another arterivirus than by a \"duplication\" recombination event between SHFV genomes.", [["SHFV", "GENE_OR_GENE_PRODUCT", 214, 218], ["SHFV structural proteins", "PROTEIN", 73, 97], ["SHFV genomes", "DNA", 214, 226], ["minor SHFV structural proteins", "PROBLEM", 67, 97], ["a \"duplication\" recombination", "TREATMENT", 170, 199]]], ["All of the newly discovered SHFV genomes in additional species of NHPs that have been recently sequenced encode two similar sets of minor structural proteins indicating that the addition of the second set of genes is not a recent event.", [["SHFV", "GENE_OR_GENE_PRODUCT", 28, 32], ["NHPs", "ORGANISM", 66, 70], ["SHFV genomes", "DNA", 28, 40], ["minor structural proteins", "PROTEIN", 132, 157], ["SHFV genomes", "PROBLEM", 28, 40], ["minor structural proteins", "PROBLEM", 132, 157], ["SHFV genomes", "OBSERVATION", 28, 40], ["species", "OBSERVATION_MODIFIER", 55, 62], ["minor structural", "OBSERVATION_MODIFIER", 132, 148], ["proteins", "OBSERVATION", 149, 157]]], ["The identity of the ancestral arterivirus contributing the additional set of SHFV minor structural proteins and the circumstances under which a co-infection occurred are not known.Highlights\u2022 SHFV induces hemorrhagic fever in macaques but not in African nonhuman primates.Highlights\u2022 A new baboon SHFV isolate induces hemorrhagic fever disease in macaques.Highlights\u2022 SHFV infection of macaque but not baboon cells induces proinflammatory cytokines.Highlights\u2022 Unique N-and C-terminal genes encoded by SHFV were functionally analyzed.Highlights\u2022 PLP1\u03b3 can cleave at upstream sites as well as at the expected downstream site.Highlights\u2022 Eight minor structural proteins are required for infectious virus production.", [["arterivirus", "ANATOMY", 30, 41], ["baboon cells", "ANATOMY", 402, 414], ["co-infection", "DISEASE", 144, 156], ["SHFV", "CHEMICAL", 192, 196], ["hemorrhagic fever", "DISEASE", 205, 222], ["SHFV", "CHEMICAL", 297, 301], ["hemorrhagic fever", "DISEASE", 318, 335], ["infection", "DISEASE", 373, 382], ["arterivirus", "GENE_OR_GENE_PRODUCT", 30, 41], ["SHFV", "GENE_OR_GENE_PRODUCT", 192, 196], ["macaques", "ORGANISM", 226, 234], ["nonhuman primates", "ORGANISM", 254, 271], ["baboon", "ORGANISM", 290, 296], ["SHFV", "ORGANISM", 297, 301], ["macaques", "ORGANISM", 347, 355], ["SHFV", "GENE_OR_GENE_PRODUCT", 368, 372], ["macaque", "ORGANISM", 386, 393], ["baboon cells", "CELL", 402, 414], ["C-terminal", "GENE_OR_GENE_PRODUCT", 474, 484], ["SHFV", "GENE_OR_GENE_PRODUCT", 502, 506], ["PLP1\u03b3", "GENE_OR_GENE_PRODUCT", 546, 551], ["infectious virus", "ORGANISM", 685, 701], ["SHFV minor structural proteins", "PROTEIN", 77, 107], ["macaque but not baboon cells", "CELL_TYPE", 386, 414], ["proinflammatory cytokines", "PROTEIN", 423, 448], ["N-and C-terminal genes", "DNA", 468, 490], ["SHFV", "PROTEIN", 502, 506], ["PLP1\u03b3", "PROTEIN", 546, 551], ["upstream sites", "DNA", 566, 580], ["downstream site", "DNA", 608, 623], ["macaques", "SPECIES", 226, 234], ["macaques", "SPECIES", 347, 355], ["SHFV", "SPECIES", 192, 196], ["African nonhuman primates", "SPECIES", 246, 271], ["SHFV", "SPECIES", 368, 372], ["SHFV minor structural proteins", "PROBLEM", 77, 107], ["a co-infection", "PROBLEM", 142, 156], ["hemorrhagic fever in macaques", "PROBLEM", 205, 234], ["A new baboon SHFV isolate", "TREATMENT", 284, 309], ["hemorrhagic fever disease in macaques", "PROBLEM", 318, 355], ["\u2022 SHFV infection of macaque", "PROBLEM", 366, 393], ["baboon cells", "PROBLEM", 402, 414], ["proinflammatory cytokines", "PROBLEM", 423, 448], ["Unique N-and C-terminal genes", "TREATMENT", 461, 490], ["Eight minor structural proteins", "PROBLEM", 636, 667], ["infectious virus production", "PROBLEM", 685, 712], ["structural proteins", "OBSERVATION", 88, 107], ["co-infection", "OBSERVATION", 144, 156], ["hemorrhagic", "OBSERVATION_MODIFIER", 205, 216], ["fever", "OBSERVATION", 217, 222], ["hemorrhagic", "OBSERVATION_MODIFIER", 318, 329], ["infection", "OBSERVATION", 373, 382], ["not", "UNCERTAINTY", 398, 401], ["baboon cells", "OBSERVATION", 402, 414], ["proinflammatory cytokines", "OBSERVATION", 423, 448]]], ["Summary of the SHFV minor structural protein functionsFunctions SHFV minor structural proteinsVirion production GP2\u2032, GP3\u2032, E, and E\u2032 Virion infectivity GP2, GP3, GP4, and GP4\u2032Virion stability GP4Virus Res. Author manuscript; available in PMC 2016 April 16.", [["GP2", "GENE_OR_GENE_PRODUCT", 112, 115], ["GP3", "GENE_OR_GENE_PRODUCT", 118, 121], ["E", "GENE_OR_GENE_PRODUCT", 124, 125], ["E\u2032", "GENE_OR_GENE_PRODUCT", 131, 133], ["GP2", "GENE_OR_GENE_PRODUCT", 153, 156], ["GP3", "GENE_OR_GENE_PRODUCT", 158, 161], ["GP4", "GENE_OR_GENE_PRODUCT", 163, 166], ["SHFV minor structural protein functions", "PROTEIN", 15, 54], ["SHFV minor structural proteins", "PROTEIN", 64, 94], ["Virion", "PROTEIN", 94, 100], ["GP2", "PROTEIN", 112, 115], ["GP3", "PROTEIN", 118, 121], ["E", "PROTEIN", 124, 125], ["E\u2032", "PROTEIN", 131, 133], ["GP2", "PROTEIN", 153, 156], ["GP3", "PROTEIN", 158, 161], ["GP4", "PROTEIN", 163, 166], ["GP4", "PROTEIN", 172, 175], ["Virion production", "TEST", 94, 111], ["GP3", "TEST", 118, 121], ["GP3", "TEST", 158, 161], ["GP4", "TEST", 163, 166], ["protein functions", "OBSERVATION", 37, 54], ["proteinsVirion", "OBSERVATION", 86, 100], ["stability", "OBSERVATION", 183, 192]]]]}